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Age-related maculopathy (ARM) is a common cause of irreparable vision loss in industrialized
countries. The disease is characterized by progressive loss of central vision making everyday tasks
challenging. The etiology is complex and has both an environmental and a strong genetic compo-
nents. The public health relevance of the work is to improve the understanding genetic causes in
the disease etiology and ultimately to lead to better disease management and prevention. From my
ARM work, I present four papers covering range of statistical approaches. The first paper presents
fine-mapping efforts, using both linkage and association methods, under previously identified link-
age peaks on chromosomes 1q31 and 10q26. We replicate the discovery of the complement factor H
(CFH ) gene on 1q31 and identify a novel locus, harboring three closely linked genes (PLEKHA1,
LOC387715, and HTRA1 ), on 10q26. Both discoveries have been widely replicated. In the next
paper I present meta-analysis of 11 CFH and 5 LOC387715 data sets. We also replicate these
findings in two independent case-control cohorts, including one cohort, where ARM status was
not a factor in the ascertainment. In the third paper we replicate discoveries of new complement
related loci (C2 and CFB) on chromosome 19p13 as well as developing classification models based
on SNPs from CFH, LOC387715, and C2. The last paper focuses on applying statistical techniques
from the diagnostic medicine literature to ARM. We comment on the importance of understand-
ing the difference and similarities between different goals of genetic studies: improving etiological
understanding or finding variants that discriminate well between cases and controls. This work is
particularly relevant today when there has been explosion in the availability of direct-to-consumer
DNA tests.
In addition to carrying out linkage and association analysis, I also have extended the statistical
theory behind score-based linkage analyses for X chromosomal markers. This work has public health
relevance because many complex common diseases have sex-specific differences, such as prevalence
iv
and age of onset. Modeling those appropriately with powerful and robust methods will bring an
improved understanding of their genetic basis.
v
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1.0 BASICS IN GENETICS AND GENE MAPPING
The genetic material in humans is stored in 23 pairs of chromosomes: 22 pairs of autosomes, and 1
pair of sex chromosomes. Each chromosome is a double helix of deoxyribonucleic acid (DNA), which
is composed of a chain of nucleotides. Each nucleotide consists of three components, one of which
is the nitrogenous base. The bases that make up the DNA are adenine (A), cytosine (C), guanine
(G), and thymine (T). A sequence of three bases codes for an amino acid, the sub-components of
proteins (Thomas 2004).
Genetic differences between people arise from variant genes along the chromosomes. Specific
positions along the chromosomes are often referred to as loci and the variant genes are known as
alleles. Two alleles at the same locus constitute a specific genotype. A locus can span from a single
base pair to thousands of megabases. Single nucleotide polymorphisms (SNPs) are genetic variants
whose alleles consist of differences at a single specific base pair position. Opposed to genotype,
the term phenotype denotes an observable characteristic or trait. For a simple Mendelian diseases
it may be possible to infer the genotype underlying a specific observed phenotype but in complex
diseases this is not necessarily the case (Lange 2003). In genetics we generally distinguish between
simple Mendelian traits and complex traits. Mendelian traits exhibit a simple pattern of inheritance
of major genes (usually only one gene) that are both necessary and sufficient to infer the outcome.
Complex traits do not exhibit the same simple pattern of inheritance, and even genes with strong
effects on the complex trait are usually neither necessary nor sufficient to infer the phenotype.
Typically, more than one gene, and often many genes with small effects (so called polygenes), along
with environmental factors and gene-environmental interactions determine complex traits (Thomas
2004).
The old fashioned definition of a gene as a physical unit of heredity, given above, has been
expanded and the term is commonly used to refer to the part of the DNA (i.e., deoxyribonucleic
acid) that codes for protein. The term locus is, on the other hand, used for any physical unit of the
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DNA. For example if a chromosomal region is identified via linkage study, one often uses ‘locus’ to
refer to that region rather than ‘gene’ (Lange et al. 2001).
Mendel’s first law, or the law of segregation, states that each parent transmits one copy of
each of his/her chromosomes randomly to his/her offspring. The two parental chromosomes are
termed grandpaternal and grandmaternal chromosomes and are said to be homologous. Rarely
an entire chromosome is transmitted, usually the chromosome inherited through the gametes is
made up of recombined segments of the grandpaternal and grandmaternal chromosomes. Thus the
child’s chromosomes usually differ from both chromosomes of each parental homologous pair. The
transmitted chromosomes are formed during a process called meiosis, which is the cell division that
results in the production of gametes (Thomas 2004).
During meiosis, the chromosomes in the cell duplicate and homologous pairs of chromosomes
come together and genetic material is exchanged through a process process called chromosomal
crossover or recombination. Recombination is the process that ensures genetic diversity and linkage
analysis relies on it. The recombination fraction is the rate of recombination events (odd number of
crossovers) between two loci. θ traditionally denotes the recombination fraction. θ = 0.5 between
two loci means that the two loci segregate independently and the loci are said to be unlinked; the
two loci are considered linked if θ < 0.5 (Lange 2003; Thomas 2004).
The recombination fraction defines the genetic map of the genome. The genetic map is in
the unit centi-Morgan (cM) derived from the recombinations fractions through a specific mapping
function (θ 7→ cM). Numerous map functions have been proposed but the Haldane (Haldane
1919) and Kosambi (Kosambi 1944) map functions are the most commonly used ones. As opposed
to the genetic map, the physical map defines the base pair location and physical distance between
loci (Thomas 2004; Ott 1999).
Association analysis relies on the presence of linkage disequilibrium (LD). Statistically, two
loci are in linkage equilibrium if the genotypes at those two loci are independently distributed in the
population, otherwise they are said to be in LD; i.e., LD defines population associations between
the alleles at two loci. The closer two loci are together the less likely it is that recombination
between them occurs, and so they are transmitted together through many generations. Therefore,
LD typically occurs over small distances and significant associations should imply proximity to the
gene of interest. However, LD can occur for number of reasons, including random drift in allele
frequencies in finite populations, natural selection for or against a combination of alleles (which
2
may or may not be linked), nonrandom mating, mutations, and founder effects. Therefore, LD can
result in spurious associations (Thomas 2004).
The strategies for gene-mapping may be classified into two broad classes, linkage and asso-
ciation methods. Linkage methods attempt to localize disease genes by using the co-segregation in
families of the disease gene and a nearby genotyped marker. The farther away the marker is from
the disease locus the more likely recombination is to occur and so the likelihood of co-segregation
drops with distance. Association mapping on the other hand tries look for associations that could
reflect linkage disequilibrium between a causal disease allele and the marker allele. Association
mapping has the most power when the associated marker allele is the same allele in all affected
individuals. In contrast, linkage mapping only requires the marker loci to co-segregate (with high
probability) with the disease locus – the actual risk allele can be different in different lines of de-
scent. Since LD generally operates over small distances, association mapping may be perceived as
the more powerful approach for localizing disease genes. However, due to confounding factors, such
as admixture or founder effects, LD (or association) can occur between markers spaced far apart
and even on different chromosomes resulting in spurious associations. Presence of strong linkage,
on the other hand, is directly related to proximity with the disease locus (Bhattacharjee 2008).
Association and linkage are well-powered under different conditions. Linkage generally has
better power than association to detect rarer variants of larger effects, while association has more
power than linkage to detect common variants of smaller effects (Clerget-Darpoux and Elston
2007; Bourgain et al. 2007). Intuitively, it makes sense that linkage methods lose power as the
risk variant becomes more common, as then the risk variant is more likely to enter the pedigree
more than once.
The underlying principle of all statistical genetic mapping methods is that people who have
similar traits should have higher than expected levels of sharing of genetic material near the genes
that influence those traits. The genetic sharing among family members is referred to as identity
by descent (IBD). Sharing of two alleles are IBD occurs if one is a physical copy of the other (e.g.
parent-offspring sharing) or if they are both physical copies of the same ancestral allele (e.g. sibling
sharing). IBD is distinguished from two alleles being identical by state (IBS), which simply means
the alleles are the same but not necessarily IBD. Any two unrelated individuals share zero alleles
IBD. Siblings can share 0, 1, or 2 alleles IBD with probabilities 1/4, 1/2, and 1/4, respectively. A
child shares one allele IBD with each of its parents (Lange 2003; Szatkiewicz 2004).
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To do genetic mapping, the IBD sharing at each locus is estimated from marker data. In
two-point linkage analysis, the IBD sharing is estimated at a single marker and then the likelihood
that the trait locus is at the marker locus (or that there is no recombination between them) is
evaluated. Estimates of IBD sharing at each locus can be improved by incorporating marker
information from all the typed markers along the chromosome, which is called multipoint analysis.
Multipoint analysis is based on a probability model for recombination between markers along the
chromosome and require external information about the genetic map (Ott 1999).
When mapping complex traits, researchers face many challenges. Incomplete penetrance,
phenocopies, genetic heterogeneity, or polygenic inheritance may for example cause major difficul-
ties. Not only are those factors often present but each one is acting to an unknown and different
degree. The penetrance is the probability of disease given the mutant disease genotype. If the
penetrance is incomplete (i.e. < 1) then an individual who carries the risk genotype of interest
may be unaffected. On the other hand individuals who don’t carry the risk genotype but are nev-
ertheless affected by the disease are said to be phenocopies. Genetic heterogeneity in the context
of monogenic diseases arises from either allelic heterogeneity, when different mutations at the same
locus cause the same phenotype, or from locus heterogeneity when mutations at different loci cause
the same phenotype. Allelic heterogeneity is generally not of concern in linkage analysis but can
cause severe problems for association analysis. Locus heterogeneity complicates linkage analysis
and association analysis. Polygenic inheritance is typically defined by the phenotype requiring the
simultaneous presence of mutations in multiple genes. Isolating pieces of the polygenic inheritance
puzzle can be particularly challenging as each single gene may have only a very small effect on the
overall disease risk. Moreover, different non-overlapping subgroups may be involved in different
individuals (Strauch et al. 2003).
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2.0 BACKGROUND ON THE AGE-RELATED MACULOPATHY PROJECT
2.1 EPIDEMIOLOGY AND GENETICS OF AGE-RELATED MACULOPATHY
Age-related macular degeneration (AMD) is the leading cause of irreparable vision loss in the
elderly in industrialized countries and the third leading cause of blindness world-wide (Friedman
et al. 2004). Age-related maculopathy (ARM) refers to the full spectrum of the disease from mild
to the advanced forms (exudative and atrophic AMD) (Gorin 2007). The disease is a progressive,
chronic, and degenerative condition of the eye and primarily, but not exclusively, affects the central
macular region of the retina (Figure 2.1). Thus ARM results in blurred vision and loss of central
vision (Figure 2.2) making daily activities challenging and clearly affects quality of life.
ARM is a complex disease caused by a combination of genetic predisposition and environ-
mental factors (Seddon and Chen 2004). Old age and cigarette smoking are well-established
risk factors for ARM. Among other factors, exposure to sunlight, increased body mass index, and
hypertension have been found associated with increased risk of ARM. Dietary behaviors, such as
antioxidant, zinc, vitamin D and E, and omega-3 fatty acid consumption, have been found to be
associated with decreased risk of ARM (Haddad et al. 2006).
The genetic basis for ARM was established by twin and familial aggregation studies. In a
recent twin study, the roles of environment and heredity were investigated by comparing ARM
concordance rates between monozygotic and dyzygotic twins. Genetic factors explained 46% to
71% of the variation in the overall severity, unique environmental exposures (residuals) accounted
for 19% to 37%, but shared environmental exposures were not statistically significant and accounted
for 5% to 17% of the variation (Seddon et al. 2005). Familial aggregation studies have also found
that the prevalence of ARM among relatives of cases is higher than among relatives of controls.
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Figure 2.1: Anatomy of the eye. The retina is a multi-layered sensory tissue that lines the back of
the eye. The macula is a small area in the center of the retina at the back of the eye. The macula
is responsible for sharp, clear central vision and the ability to perceive color. Photo credit: The
National Eye Institute.
A number of linkage studies as well as candidate gene association studies have been done in
the search for ARM susceptibility loci and in 2005 the first genome-wide association (GWA) study
(Klein et al. 2005) for complex disease was done for ARM. The linkage studies consistently found
linkage signals at chromosomes 1q and 10q (Fisher et al. 2005). Other regions identified through
linkage studies are on chromosomes 2p, 3p, 4q, 12q and 16q (Fisher et al. 2005). The earlier (prior
to 2005) candidate gene association studies most consistently suggested that the APOE gene might
harbor protective and risk alleles for ARM. However, numerous studies have failed to demonstrate
an association between APOE variants and ARM. Other candidate genes with conflicting evidence
of association are ABCR, CX3CR1, HLA, VEGF, ELOVL4, and FBLN5 (Haddad et al. 2006).
In 2005, three studies, including the first GWA study, identified the complement factor H
(CFH ) gene, a susceptibility gene under the linkage peak on 1q (Edwards et al. 2005; Haines
et al. 2005; Klein et al. 2005) and two studies identified a cluster of three genes, PLEKHA1,
LOC387715, and HTRA1, under the linkage peak on 10q (Jakobsdottir et al. 2005; Rivera
et al. 2005). Note that the first part of my ARM project resulted in the publication of one of the
(and the first) 10q studies (Jakobsdottir et al. 2005). The association of the Y402H variant in
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Figure 2.2: Vision loss due to ARM. These pictures shows a central blind spot with the surrounding
area appearing fairly clear. Unfortunately this does not mean that if a person just moves the blind
spot out of the way, everything will be clear. The peripheral vision provides vision under low light
conditions and is not capable of the same sharp and clear vision as the macula. Photo credit: The
National Eye Institute.
CFH and S69A variant in LOC387715 have been widely replicated and negative results are rare.
In fact now ARMS1 and ARMS2 (for ARM susceptibility 1 and 2) are also the official names for
the CFH and LOC387715 genes, respectively.
The CFH gene is a regulator of the complement system and since its discovery, a number
of other complement genes (CFHR1, CFHR3, CFB, C2, and C3 ) have been found associated with
ARM. The function of LOC387715 is not yet understood and so its discovery has not yet resulted
in as fruitful studies as the CFH discovery has (Haddad et al. 2006).
The first component of my ARM project (chapter 3) presents our paper on the fine-mapping
efforts under previously identified linkage peak on chromosomes 1q31 and 10q26. We successfully
replicate the discovery of the CFH gene on 1q31 and identify a novel locus, harboring three closely
linked genes (PLEKHA1, LOC387715, and HTRA1 ), on 10q26. Both discoveries have now been
widely replicated and in the next part of the ARM project (chapter 4) I present our paper on
the meta-analysis of 11 CFH and 5 LOC387715 data sets. There we also replicate these findings
in two independent case-control cohorts, including the first cohort, where ARM status was not
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a factor in the ascertainment of study participants. In our third paper on ARM (chapter 5) we
replicate discoveries of new complement related loci (C2 and CFB) on chromosome 19p13 as well
as developing crude classification models based on SNPs from the three loci (CFH, LOC387715,
and C2 ). Finally, the last component on my ARM project (chapter 6) specifically focuses on
applying statistical techniques from the diagnostic medicine literature to our ARM data as well as
providing a review for the genetics community. We comment on the importance of understanding
the difference and similarities between different goals of genetic studies, namely improving the
etiological understanding or finding variants that discriminate well between cases and controls.
This work is quite timely and particularly relevant today when there has been explosion in the
availability of direct-to-consumer DNA tests.
2.2 STATISTICAL METHODS USED IN THE PROJECT
In this section I explain the basic principles behind most important statistical techniques used in
the ARM project component of this dissertation.
2.2.1 Linkage analysis
Linkage methods attempt to localize disease genes by using the co-segregation of the gene and a
nearby genotyped marker in families. The farther away the marker is from the disease locus the more
likely recombination is to occur between them and so the likelihood of co-segregation drops with
distance. Within the context of linkage analysis of qualitative traits there are two approaches to
gene mapping; parametric or model-based analysis and the non-parametric or model-free analysis,
which evaluate allele-sharing between affected relative pairs.
2.2.1.1 Parametric LOD scores and HLOD scores Parametric linkage analysis, also known
as LOD score analysis, dates back to Morton (1955) and originated from the idea of counting
recombinant and non-recombinant offsprings as systematically described by Ott (1999). The
parameters of the genetic model need be explicitly specified prior to analysis. The penetrances for
each genotype combination and the disease allele frequencies always need to be specified. If not
all founders are genotyped or some were not successfully typed, the population allele frequencies
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of the marker data may also be needed in the calculations of the pedigree likelihood. The LOD, or




where L(θ) is the likelihood of observing the marker genotypes and disease phenotypes in a family
given the disease model and θ is the recombination fraction between the unmeasured disease locus
and the marker locus. The LOD score for multiple families is simply the sum of individual family-
specific LOD scores. The LOD(θ) is maximized as function of θ (Ott 1999; Thomas 2004).
In complex disease it is not unrealistic for some proportion (α) of families to be linked and
some proportion unlinked; in the unlinked families the true recombination fraction is θ = 0.5 and
in the linked families the true recombination fraction is equal and < 0.5. Then the heterogeneity




[log10(αLi(θ) + 1− α)]
where Li(θ) is now the conditional likelihood of family i given that this is a linked family. HLOD(θ, α)
is maximized as function of θ and α (Ott 1983).
A single marker can be uninformative or partially uninformative for linkage if the observed
genotypes give no or limited information on the IBD sharing in the pedigree. However, there may
be other markers nearby that are either informative or partially informative. In multipoint linkage
analysis the underlying genetic map is used to infer the IBD status at locations along the whole
chromosome using information from all typed markers on that chromosome. The multipoint IBD
estimation is done via a sophisticated statistical technique called hidden Markov models (Siegmund
and Yakir 2007).
2.2.1.2 Model-free LOD scores Parametric linkage analysis can be sensitive to misspecifi-
cation of the inheritance model and so non-parametric linkage analysis is an important alternative
for all but the simplest of traits (Clerget-Darpoux et al. 1986). Non-parametric linkage method
are based on allele sharing and use of scoring function, S. A locus that is linked to a disease-
susceptibility gene is expected to show higher number of alleles IBD among the affecteds, relative
to null of no linkage. Testing for linkage becomes testing for excess sharing and S will put increased
weight on affected relative pairs who share alleles IBD (Shih and Whittemore 2001). A number
of scoring functions have been proposed, including Spairs and Sall. Spairs is simply the number of
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pairs of alleles that are IBD from distinct affected relatives combined in a pairwise manner. The
Sall score function considers all affected relatives simultaneously and more heavily weights three or
more affected relatives sharing an allele IBD (Whittemore and Halpern 1994). The NPL score
(Kruglyak et al. 1996) for n pedigrees, each equally weighted and with score Si, is
∑
Zi where
Zi = (Si − µi)/σi are the standardized scores.
Kong and Cox (1997) extended the model-free NPL score to a semi-parametric LOD score,
that is a function of one parameter δ and defines the likelihood, which is the basis of the Kong-Cox
Sall LOD score used in our analysis, as
`(δ) = C +
∑
ln(1 + δZi)
where C is a constant that depends on the data but not on δ and δ = 0 corresponds to the null
hypothesis and δ ≥ 0 corresponds to the alternative hypothesis of excess sharing.
2.2.2 Association analysis
Association mapping tries look for associations that could reflect linkage disequilibrium between
a causal disease allele and the marker allele. Association mapping has the most power when the
associated risk allele is the same in all individuals. Since LD generally operates over small distances,
association mapping may be perceived as a powerful approach to localize disease genes.
2.2.2.1 χ2 and Fisher’s exact tests and logistic regression Contingency tables, which are
composed of R × C rows and columns, are an appropriate way of displaying categorical data; for
example for a binary trait one may display the genotypic distribution among cases and controls in
a 2× 3 contingency table. In the contingency table approach, we fix the column and row total on
(R − 1) × (C − 1) degrees of freedom. Given the row, column, and grand totals we can calculate
the expected table and perform a χ2 test of the deviation of the observed vs. the expected table
and estimate odds ratios. The χ2 test, however, rests on the assumption of approximate normality
of binomial proportions and therefore may not always be appropriate especially when samples sizes
are small. For smaller contingency tables like those of allelic (2× 2) and genotypic tests (2× 3) the
Fisher’s exact test may be used instead where all tables possible for the observed row and column
sums need to be evaluated (Rosner 2000).
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In the logistic model the binary outcome (y) is modeled as
logit(p) = ln
p
1− p = α+ β1x1 + · · ·+ βnxn
where p is the probability of y being diseased (coded as 1), and the xi’s are the exposure variables,
which in our case are the genotypes and possible covariates; typically for ARM the covariates
are age, sex, cigarette smoking and possibly genotypes at other loci than the primary loci. The
advantage of using the logistic model over the contingency table approach is that it allows for easy
adjustment of continuous covariates and estimation of odds ratios adjusted for those covariates.
If x1 is our genotype variable then the odds ratio relating the genotype to the phenotype after
controlling for all the covariates in the model is estimated with eβˆ1 ; the logistic regression approach
can also be applied without the covariates and will then give the same results as the contingency
table approach and χ2 tests (Rosner 2000).
2.2.2.2 CCREL and MQLS When testing for association using related individuals the cor-
relation between individuals due to their relationships needs to be modeled appropriately to avoid
excess of false-positive findings. The CCREL and MQLS tests are both test statistics designed for
collection of related and unrelated individuals allowing families ascertained for linkage to be appro-
priately pooled with unrelated cases and controls ascertained for association studies (Browning
et al. 2005; Thornton and McPeek 2007). The CCREL methods, however, advises against using
familial controls, while the MQLS test is applicable to association testing in completely general com-
binations of family and case-control designs and allows cases to be related to controls. Furthermore,
MQLS distinguishes between unaffected controls and controls of unknown phenotype and makes use
of phenotype data about relatives who have missing genotype data at a given SNP. Those are the
reasons that, even though MQLS has only been developed for allelic tests while the CCREL method
has been developed for allelic, genotypic, and haplotypic tests, we now prefer the MQLS over the
CCREL test.
The CCREL tests accounts correlations between related individuals by calculating a weight
for each person. “The weights are used in constructing a composite likelihood, which is maximized
iteratively to form likelihood ratio tests for single-marker and haplotypic associations” (Browning
et al. 2005). On the other hand, the CCREL genotypic test is a standard 2 × 3 χ2 contingency
table test of weighted genotype counts (Browning et al. 2005).
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The MQLS is derived as a quasi-likelihood score test of a mean model for the expected allele
frequencies. The mean model of MQLS is an improvement over a mean model that puts similar
weights on individuals as the CCREL test by explicitly taking into account the fact that affected
individuals who have affected relatives (whether genotyped or not) have a higher expected frequency
of the susceptibility alleles for a genetic trait than do individuals with no affected relatives. The
mean model of MQLS is therefore a function of both the relationships and phenotypes (Thornton
and McPeek 2007).
2.2.3 Joint linkage and association
Linkage analysis tends to identify broad genomic susceptibility regions that often contain many
candidate genes. For many complex diseases, before the era of genome-wide association studies,
the study design of choice was linkage analysis followed by fine-mapping in identified regions of
linkage (Thomas 2004). There has been interest in the literature to identify polymorphisms that
may be responsible for an observed linkage peak.
2.2.3.1 GIST We used the genotype IBD sharing test (GIST) (Li et al. 2004) to explore which
alleles of some SNPs under our linkage peaks of chromosomes 1q31 and 10q26 for ARM accounts in
part the observed linkage signals. The GIST performs weighted analysis of nonparametric linkage
(NPL) scores, in which each family is weighted according to the genotype distribution of members
of the pedigree. The correlation between the family weight variable and the NPL score forms the
basis of the test statistic. The weights are unbiased under the null hypothesis of no disease-marker
association in sibship data. Therefore the GIST is currently applicable only to affected sib pair
families and we split our families into their component nuclear families before computing the NPL
scores and weights. Since the majority of our ARM families are sibships, this was unlikely to cause
problems with the analysis (Jakobsdottir et al. 2005).
2.2.4 Meta-analysis
Meta-analysis is powerful tool to pool summary data, such as odds ratios, from many studies into a
single estimate, which often has narrower confidence intervals than any single study. The methods
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for performing meta-analysis fall into two broad classes, fixed effects modeling and random effects
modeling (van Houwelingen et al. 2002; Brown 2006)
2.2.4.1 Fixed effects modeling When assuming the between-study variation is due to chance,
a fixed-effects model may be employed. Under the fixed-effect model, the maximum likelihood
estimator of the pooled OR is an average of individual estimates, weighted by the inverse of their
variances, and the variance of the pooled OR is estimated by the inverse of the sum of individual
weights (van Houwelingen et al. 2002).
2.2.4.2 Random effects modeling Rather then assuming the between-study variation is due
to chance, heterogeneity can be modeled by incorporating a label for the study variable as a random
covariate in the mixed model. The idea behind this approach is to assume that the studies at hand
are random sample of studies, and thus that the sample of studies cannot measure all the factors
contributing to the variance of the pooled OR (van Houwelingen et al. 2002; Brown 2006;
DerSimonian and Laird 1986).
2.2.5 Model building
I broadly split model building into two parts. First many different logistic regression models may
be fit to any particular data set in order to investigate which factors are important and how they
act together without asking whether the model can be used as a classification model. Secondly,
classification models or screening or diagnostic tests that assign individuals into categories of testing
affected or unaffected may be developed.
2.2.5.1 Logistic regression For ARM two very strongly associated variants were discovered
and it was of particular interest to shed some light on their joint contribution to the phenotype.
Various two-locus logistic regression models can be fit to find a most parsimonious model (which
for example may be a model of additive effects of both loci with or without interaction) (North
et al. 2005). Nested models can be compared statistically using a likelihood ratio test but non-
nested models can be compared using the Akaike’s information criterion (AIC), which penalizes
the models as number of parameters increases.
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2.2.5.2 GMDR The generalized multifactor dimensionality reduction (GMDR) method (Lou
et al. 2007) is an extension of the original MDR method (Ritchie et al. 2001). Both methods
attempt to classify multi-locus genotypes into “high” and “low” risk groups. The MDR methods
simply uses the ratio of the number of cases to the number of controls (within the multi-factor
genotype) as the basis for labeling each multi-factor genotype. Therefore the method is only
applicable to data with equal number of cases and controls. In the GMDR method individual-level







where yi is the phenotype of individual i, E[yi] = pi, and xij is the genotype of marker j for
individual i. Each multi-locus genotype is labeled “high–risk” or “low-risk” based on the average
score over individuals harboring the specific multi-locus genotype, and on the preassigned threshold,
which typically is set to zero as the scores are both standardized and normalized. Both methods
use cross-validation to guard against over-fitting.
2.2.5.3 ROC curves As is the case with multi-locus genotypes a screening test may provide
several categories or be reported as a continuous variable rather then simply “test positive” or “test-
negative”. When evaluating such a test it may be inadequate to only estimate the true positive
(TPF) and false positive fractions (FPF) corresponding to one threshold. The ROC curves (i.e., the
receiver operating characteristic curves) plot all pairs of TPF and FPF on single plot and estimate
the area under the curve (AUC). The larger the AUC the better the test is overall (Zhou et al.
2002).
2.2.6 Practical issues
2.2.6.1 Samples vs. individuals The most important practical issue in data analysis is the
data preparation. Even though I have worked with the ARM data for almost 5 years and we
now have a working database for the genotype data, it still takes considerable amount of time
and script writing to prepare the data for analysis. Once the data files are all set up then the
analysis are relatively easy to do. By preparation of the genotype data for analysis, as I am not
considering analysis quality checks such as running PedCheck to check for Mendelian inconsistencies
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and testing for Hardy-Weinberg equilibrium, I consider those steps part of the analysis. In the
laboratory, samples of DNA are the important unit, not the individual, and in a project like ARM,
which has been ongoing for over 15 years, many individuals have donated more than one sample of
DNA. Hence, for different genotypings those individuals may come back from the lab with different
identifiers (IDs). Therefore, merging the data with the phenotype data may become a huge issue
and actually we could not find a database that could handle multiple person IDs and non-numeric
IDs, so we built our own database.
2.2.6.2 Check your files, scripts, and results It is easy to make mistakes in any tiny step
along the way from the raw data files, to the formatted data files, to the script writing, both for
reformatting data files and for analysis, to pulling out the results, and so on. I cannot explain all
the mistakes that I have made in detail but will focus on a few and how they were discovered and
in some cases how I could have discovered them sooner.
Reformatting of files I once got SNP genotype data files where the SNP alleles were presented
using the codes for the nitrogenous bases (A, C, G, T) instead of numeric codes (1 and 2) used
before. Since our database only allows numeric allele labels and we had previously imported data
for those same SNPs using numeric allele labels, I had to recode the genotypes before importing
them into the database. I started by setting up a recode table that linked the A, C, G, and T to
1 and 2. I used arrays in the awk scripting language, using A, C, G, and T as keys and 1 and 2
as values. I forgot include the missing to missing (i.e. 0 to 0) link in the array. Since awk does
not give any warning if ones tries to look up the value for non-existing key, then missing genotypes
were set equal to the non-missing genotype of the marker in the two columns before the marker of
interest. This was discovered when doing Hardy-Weinberg checks on the final data files but could
have been discovered earlier, and before the data were imported into the database, by noting that
after running the awk script, all but the first marker had no missing genotypes.
Your scripts for analysis The genotypes are usually listed in two side-by-side columns for each
marker. I once had a file with number of markers and created a allele tables in R by looping through
the SNPs. However, I mistakenly set my starting column as the one in front of the first marker
(i.e. the column containing sex). This meant that the association tests performed on the allele
tables were wrong: the first marker’s first allele was the sex code and the second allele was the first
allele, the second marker’s first allele was the first marker’s second allele and so on. I noticed this
by noting that the allele tables showed an excess of half-typed individuals.
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Programs by others Even though a program is a published as a part of a peer-reviewed paper,
it can still contain errors. We once used programs by others to look at various two locus models.
This program, however, mixed up the names of the loci in the output. The only reason I noticed
the mix-up was that we had already done single-locus analysis and those suggested that one marker
was much more strongly associated with ARM than the other. We then wrote our own R script to
double check our suspicion.
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3.0 SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY ON
CHROMOSOME 10Q26
This chapter has been published in American Journal of Human Genetics, volume 77, issue 3,
pages 389 - 407 (Jakobsdottir et al. 2005). The journal grants the authors rights to include the
article in full in a thesis or a dissertation. No changes have been made to the published version of
the paper, except that tables and figures have been renumbered and the supporting information
published online is in Appendix A. My contribution to this paper was in writing all components of
the paper, data analysis and script writing for method implementation.
3.1 ABSTRACT
On the basis of genomewide linkage studies of families affected with age-related maculopathy
(ARM), we previously identified a significant linkage peak on 10q26, which has been indepen-
dently replicated by several groups. We performed a focused SNP genotyping study of our families
and an additional control cohort. We identified a strong association signal overlying three genes,
PLEKHA1, LOC387715, and PRSS11. All nonsynonymous SNPs in this critical region were geno-
typed, yielding a highly significant association (P < 0.00001) between PLEKHA1/LOC387715 and
ARM. Although it is difficult to determine statistically which of these two genes is most important,
SNPs in PLEKHA1 are more likely to account for the linkage signal in this region than are SNPs
in LOC387715 ; thus, this gene and its alleles are implicated as an important risk factor for ARM.
We also found weaker evidence supporting the possible involvement of the GRK5/RGS10 locus in
ARM. These associations appear to be independent of the association of ARM with the Y402H
allele of complement factor H, which has previously been reported as a major susceptibility factor
for ARM. The combination of our analyses strongly implicates PLEKHA1/LOC387715 as primar-
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ily responsible for the evidence of linkage of ARM to the 10q26 locus and as a major contributor
to ARM susceptibility. The association of either a single or a double copy of the high-risk allele
within the PLEKHA1/LOC387715 locus accounts for an odds ratio of 5.0 (95% confidence interval
3.27.9) for ARM and a population attributable risk as high as 57%.
3.2 INTRODUCTION
Age-related maculopathy (ARM), or age-related macular degeneration (ARMD-1 [MIM 603075]), is
a leading cause of central blindness in the elderly population, and numerous studies support a strong
underlying genetic component to this complex disorder. Genomewide linkage scans performed using
large pedigrees, affected sib pairs, and, more recently, discordant sib pairs have identified a number
of potential susceptibility loci (Klein et al. 1998; Weeks et al. 2000; Majewski et al. 2003;
Schick et al. 2003; Seddon et al. 2003; Abecasis et al. 2004; Iyengar et al. 2004; Kenealy
et al. 2004; Schmidt et al. 2004; Weeks et al. 2004; Santangelo et al. 2005). Our genomewide
linkage screen strongly implicated the 10q26 region as likely to contain an ARM gene (Weeks et al.
2004); this region has also been supported by many other studies and was the top-ranked region
in a recent meta-analysis (Fisher et al. 2005). Recently, three studies (Edwards et al. 2005;
Haines et al. 2005; Klein et al. 2005) identified an allelic variant in the complement factor H gene
(CFH [MIM 134370]) as responsible for the linkage signal seen on chromosome 1 and as the variant
accounting for a significant attributable risk (AR) of ARM in both familial and sporadic cases. We
and others have confirmed these findings (Conley et al. 2005; Hageman et al. 2005; Zareparsi
et al. 2005). CFH has previously been suspected of playing a role in ARM, as a result of the work
of Hageman and Anderson (Hageman and Mullins 1999; Johnson et al. 2000; Johnson et al.
2001; Mullins et al. 2000; Hageman et al. 2001), who have shown that the subretinal deposits
(drusen) that are observed in many patients with ARM contain complement factors. However, until
other genes that contribute to ARM are identified, CFH remains an isolated piece of the puzzle,
implicating the alternative pathway and inflammation as part of the ARM pathogenesis but failing
to fully account for the unique pathology that is observed in the eye.
We have expanded our family linkage studies and have also undertaken a case-control asso-
ciation study, using a high-density SNP panel in two regions of linkage on 1q31 and 10q26 that
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we had previously reported. Our SNP linkage and association results for chromosome 1q31 yielded
the same findings as others, confirming that the peak of linkage and the strongest associations
with ARM were localized over the CFH gene. We have analyzed both our family data and the
case-control data on chromosome 10q26 to identify the next major ARM susceptibility-related gene.
3.3 MATERIAL AND METHODS
3.3.1 Families and Case-Control Cohort
A total of 612 ARM-affected families and 184 unrelated controls were sent to the Center for Inherited
Disease Research (CIDR) for genotyping. Because of possible population substructure, we restricted
our analysis to the subset of data from white subjects; we were not able to analyze the set of data
from nonwhites separately, because it was too small. The white subset had 594 ARM-affected
families, containing 1,443 genotyped individuals, and 179 unrelated controls. The white families
contained 430 genotyped affected sib pairs, 38 genotyped affected avuncular pairs, and 52 genotyped
affected first-cousin pairs.
A total of 323 white families, 117 unrelated controls, and 196 unrelated cases were also
genotyped locally for additional SNPs. The local subset contained 824 genotyped individuals, 298
genotyped affected sib pairs, 23 genotyped affected avuncular pairs, and 38 genotyped affected
first-cousin pairs. We used PedStats from the Merlin package (Abecasis et al. 2002) to easily get
summary counts on the family data.
3.3.2 Affection-Status Models
We have defined three classification models (types A, B, and C) for the severity of ARM status
(Weeks et al. 2004). For simplicity, we have restricted our attention here to individuals affected
with “type A” ARM, our most stringent and conservative diagnosis. We used only unrelated
controls who were unaffected under all three diagnostic models. Unaffected individuals were those
for whom eye-care records and/or fundus photographs indicated either no evidence of any macular
changes (including drusen) or a small number (< 10) of hard drusen (≤ 50µm in diameter) without
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Table 3.1: Distribution of Subphenotypes in Patients with Advanced ARM
No. of Patients from No. of Patients from No. of Local
CIDR Familiesa Local familiesa Unrelated Patients
Subphenotype With GA Without GA With GA Without GA With GA Without GA
With CNV 220 (76) 187 130 (45) 106 71 (17) 59
Without CNV 108 62 57 28 40 26
Note.—The numbers in parentheses are the numbers of individuals with both CNV and GA who were also included
in GA group (see section 3.3.2 for selection criteria) for OR and AR estimation and association tests.
a Counts are based on the set of unrelated cases generated by selecting one type A–affected person from each family
(see section 3.3.13.1).
any other retinal pigment epithelial (RPE) changes. Individuals with evidence of large numbers of
extramacular drusen were not coded as unaffected.
In our efforts to examine specific ARM subphenotypes, we chose to look at only patients
with end-stage disease, either those with evidence of choroidal neovascular membrane (CNV) in
either eye or those with geographic atrophy (GA) in either eye. There are a significant number of
individuals who have been described as having both GA and CNV, though this is problematic, since,
in these cases, it is often difficult to determine whether the GA is secondary to the damage from the
CNV or is from the treatment given to limit the CNV growth (i.e., laser, surgery, or photodynamic
therapy). Because it is often difficult to discern from photographs or records whether a person had
GA in an eye prior to the development of CNV, we included the patients who had both pathologies
in the CNV group. However, we allowed only a subset of this overlapping group to be included in
the GA group, specifically those who reportedly had GA in one eye that did not have evidence of
CNV. Table 3.1 shows the numbers of individuals in each of our three sets. This approach may
have excluded a small proportion of individuals from the GA group who had asymmetric GA prior
to the development of CNV in the same eye or who may have had bilateral GA but developed CNV
in both eyes.
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3.3.3 Pedigree and Genotyping Errors and Data Handling
We used the program PedCheck (O’Connell and Weeks 1998) to check for Mendelian inconsis-
tencies. Since it can be extremely difficult to determine which genotypes within small families are
erroneous (Mukhopadhyay et al. 2004), we set all genotypes at each problematic marker to missing
within each family containing a Mendelian inconsistency. Mega2 (Mukhopadhyay et al. 2005)
was used to set up files for linkage analysis and for allele-frequency estimation by gene counting.
3.3.4 Allele Frequencies and Hardy-Weinberg Equilibrium
The allele frequencies used in the linkage analyses were estimated, by direct counting, from the
unrelated and unaffected controls. All controls were unaffected under all three affection status
models. Genotyped spouses who had no children or who had children who were not yet part of the
study were combined with the controls for this study. The exact test of Hardy-Weinberg equilibrium
(HWE), implemented in Mega2 (Mukhopadhyay et al. 2005), was performed on our SNPs.
We also used Mendel (version 5) (Lange et al. 2001) to estimate allele frequencies directly
from the family data, because Mendel properly accounts for relatedness of the subjects while
estimating the allele frequencies. Since the majority of the genotyped family members were affected,
these estimates were quite close to estimates obtained using our unrelated affected cases.
3.3.5 Genetic Map
We used linear interpolation on the Rutgers combined linkage-physical map (version 2.0) (Kong
et al. 2004) to predict the genetic position of the SNPs that were not already present in the Rutgers
map. Since the distribution of our SNPs was very dense in the regions of interest, the estimated
recombination between several SNPs was zero; for these, we set the recombination to 0.000001.
We obtained the physical positions for all our SNPs from the National Center for Biotechnology
Information (NCBI) dbSNP database (human build 35).
3.3.6 LD Structure
Ignoring high linkage disequilibrium (LD) between SNPs when performing linkage analysis can
result in false-positive findings (Schaid et al. 2002; Huang et al. 2004). Our efforts to take high
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SNP-SNP LD into account included the following measures. (1) We used the H-clust method
(Rinaldo et al. 2005), which is implemented in R (R Development Core Team 2004; see R Project
for Statistical Computing Web site), to determine haplotype-tagging SNPs (htSNPs) for linkage
analysis. The method uses hierarchical clustering to cluster highly correlated SNPs. After the
clustering, the H-clust method chooses a htSNP from each cluster; the htSNP chosen is the SNP
that is most correlated with all other SNPs in the cluster. We chose to cluster the SNPs so that
each SNP had a correlation coefficient (r2) > 0.5 with at least one htSNP; we used HaploView
(Barrett et al. 2005) to get a graphical view of SNP-SNP LD along both chromosomes, and we
compared LD estimates of htSNPs with SNPs omitted by H-clust. (2) We performed haplotype-
based association analyses using two- and three-SNP moving windows (see Association Analysis
section).
3.3.7 Linkage Analysis
3.3.7.1 Two-point analysis As in our previous study (Weeks et al. 2004), we computed LOD
scores under a single simple dominant model (with disease-allele frequency of 0.0001 and penetrance
vector of [0.01, 0.90, 0.90]). Because of the complexities and late onset of the ARM phenotype,
only two disease phenotypes were used: “affected under model A” (i.e., “type A–affected”) and
“unknown”. Parametric LOD scores were computed under heterogeneity (HLOD), whereas model-
free LOD scores were computed with the linear Sall statistic. Both scores were computed using
Allegro (Gudbjartsson et al. 2000).
3.3.7.2 Multipoint analysis ignoring LD Since intermarker distances are often very small,
LD between SNPs can be high and thus violate the assumption of no LD made by most linkage
analysis programs. Multipoint analyses ignoring LD were performed using Allegro (Gudbjartsson
et al. 2000). Both HLOD scores and Sall statistics were computed. Our main goal in estimating
the multipoint linkage curve without properly accounting for LD was not to predict the position of
ARM-associated loci but to compare the results with those from analyses in which LD was taken
into account.
3.3.7.3 Multipoint analysis using htSNPs When only htSNPs were used for LOD score
calculation, the number of SNPs decreased from 679 to 533 on chromosome 1 and from 196 to
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159 on chromosome 10. Multipoint linkage analyses were done as described elsewhere (Weeks
et al. 2004). The SNPs that were omitted fit well into the SNP-SNP LD structure estimated by
HaploView (Barrett et al. 2005).
3.3.8 Association Analysis
To incorporate all cases from the families, we used the new CCREL program (Browning et al.
2005), which permits testing for association with the use of related cases and unrelated controls
simultaneously. CCREL was used to analyze SNPs under the linkage peak on chromosomes 1 and
10, to test for association. The CCREL test accounts for biologically related subjects by calculating
the effective number of cases and controls. For these analyses, type A–affected family members were
assigned the phenotype “affected”, unrelated controls were assigned the phenotype “normal”, and
family members that were not affected with type A ARM were assigned the phenotype “unknown”.
(The CCREL approach has not yet been extended to permit the simultaneous use of both related
cases and related controls.) The effective number of controls for each SNP used for association
testing is therefore the number of controls genotyped for that SNP. An allelic test, a haplotype test
with a two-SNP sliding window, a haplotype test with a three-SNP sliding window, and a genotype
test were performed. We used the CCREL R package for analysis, as provided by (Browning
et al. 2005).
3.3.9 GIST Analysis
To explore which allele/SNP contributes the most to the linkage signal, we performed the genotype-
identity by descent (IBD) sharing test (GIST) using our locally genotyped SNPs and significant
SNPs from the CCREL test that are located around the linkage peaks on chromosomes 1 and 10.
GIST determines whether an allele, or another allele in LD with it, accounts in part for the observed
linkage signal (Li et al. 2004). Weights were computed for each affected sibship under three differ-
ent disease models (recessive, dominant, and additive); these weights are unbiased under the null
hypothesis of no disease-marker association. The correlation between the family weight variable
and the nonparametric linkage (NPL) score is the basis of the test statistic. Since the GIST method
is currently applicable only to affected sib pair families, we split our families into their component
nuclear families before computing the NPL scores. Since we do not know the underlying disease
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model, we performed tests using three different disease models (recessive, dominant, and additive)
and then took the maximum result, using a P value that was adjusted for multiple testing over the
three models.
3.3.10 Tripartite Analyses
Our analyses were performed in three sequential steps. First, we analyzed the set of data that
had been genotyped at CIDR. Second, after locally genotyping eight additional SNPs in the
PLEKHA1/LOC387715/PRSS11 region on chromosome 10, we then analyzed the locally geno-
typed data set. Note that all of the known nonsynonymous SNPs in the region from PLEKHA1
(MIM 607772) through PRSS11 (MIM 602194) were investigated. Because these two data sets
differ in size and composition, it is most straightforward to analyze them separately (table 3.2).
Allele-frequency estimation, CCREL association testing, and GIST analysis were performed on
both of these (overlapping) data sets, as described above. Third, we tested for interaction between
the chromosome 1 and chromosome 10 regions and examined whether or not the risk differed as a
function of the presence of either GA or CNV.
3.3.11 Part I: Analysis of CIDR SNPs
To identify the responsible gene on chromosome 10q26, the CIDR performed high-density custom
SNP genotyping of 612 ARM-affected families and 184 unrelated controls with the use of 199 SNPs
spanning 13.4 Mbp (26.7 cM), from rs7080289 through rs6597818 (nucleotide position: 115094788–
128517320 bp), which spans our region of interest. For our analysis, we used 196 SNPs; 3 were
skipped because of a lack of polymorphism in the controls (when this was checked within the family
data, the less common allele was extremely rare and was only present in heterozygotes). In addition,
684 SNPs spanning 45.7 Mbp (47.1 cM) on chromosome 1q31, from rs723858 through rs653734
(nucleotide position: 169749920–215409007 bp), were also genotyped; 5 SNPs were skipped because
of a lack of polymorphism in the controls—the less common allele was either not present or very rare
and, in the family data, was only present in heterozygotes. Table A1 shows the correspondence
between our allele labels and the actual alleles, and, for nonsynonymous SNPs, the amino acid
change.
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Table 3.2: Summary of Statistical Analyses and Sample Sizes in Parts I–III
Part and Analysis Set of SNPs, Method, and Sample Used Results Shown in
I:
htSNP selection CIDR SNPs, 179 controls
SNP-SNP LD CIDR SNPs, 179 controls Figs. A1 and A2
Linkage CIDR SNPs and htSNPs, 594 ARM-affected families Figs. 3.3 and 3.4
Allele frequencies Mendel v5 for 594 ARM-affected families; Table 3.3
counting for 179 controls
CCREL CIDR SNPs, 594 ARM-affected families and 179 controls Table 3.3
GIST 594 ARM-affected families split into 734 typed nuclear families Table 3.3
II:
Allele frequencies All SNPs (CIDR and local); Mendel v5 for 323 Table 3.4
ARM-affected families; counting for 117 controls
CCREL CIDR SNPs and local SNPs, 323 families and 117 controls Table 3.4
GIST 323 ARM-affected families split into 407 typed nuclear families Table 3.4
SNP-SNP LD CIDR and local SNPs, 117 unrelated controls Fig. 3.2
III:
Interaction by GIST See GIST in I and II above Tables 3.3 and 3.4
Logistic regression CIDR SNPs, 577 cases and 179 controls Table A3
OR and AR CIDR SNPs, 577 cases and 179 controls; Table 3.5
local SNPs, 517 cases (321 familial, 196 sporadic)
and 117 controls
OR and AR of subtypes:
CIDR SNPs For CNV, 407 cases and 179 controls; Table A4
for GA, 184 cases and 179 controls
Local SNPs For CNV, 366 cases and 117 controls; Table A4
for GA, 159 and 117 controls
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3.3.12 Part II: Analysis of Locally Genotyped SNPs
We genotyped eight additional SNPs on chromosome 10 that overlie three susceptibility genes,
PLEKHA1 (rs12258692, rs4405249, and rs1045216 ), LOC387715 (rs10490923, rs2736911, and
rs10490924 ), and PRSS11 (rs11538141 and rs1803403 ). This genotyping effort included all of
the nonsynonymous SNPs that have been reported for these genes in the NCBI databases (see fig.
3.1). As part of another study (Conley et al. 2005), we genotyped two CFH variants (rs10922093
and rs1061170 ), which we have used here as well. Genotyping of additional SNPs under the
GRK5/RGS10 (MIM 600870/MIM 602856) locus is in process. Genotype data for rs12258692,
rs1803403, and the newly characterized SNP rs4405249 (which is 1 base 3′ of rs12258692 ) were
collected by sequencing (Rexagen) and were analyzed using Sequencher software (Gene Codes).
Genotype data for rs11538141, rs2736911, rs10490923, and rs10490924 were collected using RFLP.
The primers, amplification conditions, and restriction endonucleases, where appropriate, for SNPs
that were genotyped by sequencing or RFLP can be found in table A2. Genotype data for rs1045216
were collected using a 5′ exonuclease Assay-on-Demand TaqMan assay (Applied Biosystems). Am-
plification and genotype assignments were conducted using the ABI 7000 and SDS 2.0 software
(Applied Biosystems). Two unrelated CEPH samples were genotyped for each variant and were
included on each gel and in each TaqMan tray, to assure internal consistency in genotype calls.
Additionally, double-masked genotyping assignments were made for each variant and were com-
pared, and each discrepancy was addressed using raw data or regenotyping. Table A1 shows the
correspondence between our allele labels and the actual alleles and, for nonsynonymous SNPs, the
amino acid change.
3.3.13 Part III: Interaction and OR Analysis
3.3.13.1 Unrelated cases No unrelated cases were genotyped by CIDR, but 196 unrelated
cases were genotyped locally for our additional SNPs. For computation of odds ratios (ORs) and
for interaction analyses (see below), we chose to generate a set of unrelated cases by drawing
one type A–affected person from each family. A total of 321 locally genotyped families had at
least one type A–affected person. If a family had more than one type A–affected person, we
chose the person who had the most complete genotyping at the Y402H variant (rs1061170 ) and
three CIDR SNPs representative of CFH, GRK5, and PLEKHA1 : rs800292 (CFH ), rs1537576
26
Figure 3.1: Location of CIDR SNPs and locally genotyped SNPs with respect to candidate genes.
Positions, distances, and nucleotide positions along chromosome 10 are derived from NCBI Entrez
Gene and dSNP databases.
(GRK5 ), and rs4146894 (PLEKHA1 ; rs4146894 also represents LOC387715, because of high LD
with rs10490924 ) (see fig. 3.2). If they could not be distinguished by the number of genotyped
SNPs, we chose the person who developed the disease at the youngest age, or, if more than one
shared the earliest age at onset, we selected one type A–affected individual at random from those
with the most SNPs genotyped and the earliest age at onset. A total of 577 CIDR families had
at least one type A–affected person; 321 of these families were also genotyped locally, and the
type A–affected person was the same one chosen for the local set. For the remaining 256 families,
we based our selection on the same criteria described above, except that only rs800292 (CFH ),
rs1537576 (GRK5 ), and rs4146894 (PLEKHA1 ) were used to identify the person with the most
complete genotyping.
27
Figure 3.2: A, LD patterns in GRK5 (Block 1), RGS10 (SNP 6), PLEKHA1 (Block 2), LOC387715
(Block 3), and PRSS11 (Block 4). B, LD patterns in CFH (Block 1). Squares shaded pink or red
indicate significant LD between SNP pairs (bright red indicates pairwise D′ = 1), white squares
indicate no evidence of significant LD, and blue squares indicate pairwise D′ = 1 without statistical
significance. Significant SNPs from the CCREL allele test are highlighted in green (see table 3.4).
Three SNPs (rs6428352, rs12258692, and rs11538141 ) were not included, because of very low
heterozygosity, and one SNP (rs2736911 ) was not included, because it was uninformative. Note
that the blocks were drawn to show clearly the position of the genes and do not represent haplotype
blocks.
28
3.3.13.2 Analysis of interaction with CFH We investigated possible interaction between
CFH on chromosome 1 and the genes on chromosome 10 by using GIST to test whether SNPs in
CFH are associated with the linkage signal on chromosome 10 and whether SNPs on chromosome
10 are associated with the linkage signal on chromosome 1. We did this by using weights from
SNPs on one chromosome and family-based NPLs from the other.
We also used logistic regression to evaluate different interaction models and to test for inter-
action by use of the approach described by North et al. (2005). In this approach, many different
possible models of the interactions, allowing simultaneously for additive and dominant effects at
both of the loci, are fit, and relative likelihoods of the different models are compared to draw
inferences about the most likely and parsimonious model. As described elsewhere (North et al.
2005), the fitted models include a MEAN model, in which only the mean term is estimated; ADD1,
ADD2, and ADD models, which assume an additive effect at one or both loci; DOM1, DOM2,
and DOM models, which additionally incorporate dominance effects; and three further models,
ADDINT, ADDDOM, and DOMINT, which allow for interactive effects (for more details, see the
work of (North et al. 2005)). Since some pairs of these models are not nested, we compared them
by using the Akaike information criteria (AIC); in this approach, the model with the lowest AIC is
considered to be the best fitting and the most parsimonious. For these analyses, we used the pro-
gram provided by North and colleagues (2005), after some bugs that we discovered had been fixed;
we double-checked our results with our own R program. To maximize the sample size, we chose
CIDR SNPs in high LD with a highly significant nonsynonymous SNP within each gene. The CIDR
SNP rs800292 was chosen to represent rs10611710 (the Y402H variant of CFH ), and the CIDR
SNP rs4146894 represented rs1045216 in PLEKHA1. Similarly, we also selected a representative
CIDR SNP in GRK5, RGS10, and PRSS11.
3.3.13.3 Magnitude of association We calculated crude ORs and estimated ARs for SNPs
in each gene. The allele that was least frequent in the controls was considered to be the risk allele.
AR was estimated using the formula AR = 100 × P × (OR − 1)/[1 + P × (OR − 1)], where OR
is the OR and P is the frequency of the risk factor (genotype) in the population, as estimated
from the controls. We did this by comparing type A–affected subjects with controls, comparing
subjects who had CNV with controls, and comparing subjects who had GA with controls. To have
the maximum possible sample size, we used different but overlapping samples for CIDR and locally
typed SNPs. A total of 577 cases selected from the families and 179 unrelated cases were used for
29
calculating OR and AR of CIDR SNPs, but 517 cases (of those, 321 are within the 577 CIDR SNP
cases) and 117 controls (all within the 179 CIDR SNP controls) were used for calculating the OR
and AR on the locally genotyped SNPs.
3.3.13.4 Multiple-testing issues Since we have very strong evidence from previous studies
that there is an ARM–susceptibility locus in the chromosome 10q26 region, the analyses performed
here were aimed at estimating the location of the susceptibility gene, rather than testing a hypoth-
esis. Multiple-testing issues are most crucial and relevant in the context of hypothesis testing. In
estimation, we are simply interested in determining where the signal is strongest. In any event,
any correction for multiple testing would not alter the rank order of the results. A Bonferroni
correction, which does not account for any correlation between tests due to LD, for 196 tests at
the 0.05 level would lead to a significance threshold of 0.05/196=0.00026; correlations due to LD
would lead to a larger threshold.
3.4 RESULTS
Our analyses were performed in three sequential steps. First, we analyzed the set of data that
had been genotyped at CIDR. Second, after locally genotyping eight additional SNPs in the
PLEKHA1/LOC387715/PRSS11 region on chromosome 10, we then analyzed the locally geno-
typed data set. Allele-frequency estimation, testing for HWE (table A1), CCREL association
testing, and GIST testing were performed on both of these (overlapping) data sets, as described
above. Third, we tested for interaction between the chromosome 1 and chromosome 10 regions and
examined whether or not the risk differed as a function of the presence of GA or CNV.
3.4.1 Part I: Analysis of CIDR SNPs
3.4.1.1 CIDR linkage results The narrow peak of our Sall linkage curve obtained using the
159 htSNPs on chromosome 10 suggests that there might be an ARM gene in the GRK5 region
(marked ‘G’ in fig. 3.3, right panel); rs1537576 in GRK5 had a two-point Sall of 1.87, whereas the
largest (across our whole region) two-point Sall of 3.86 occurred at rs555938, 206 kb centromeric
of GRK5. Several elevated two-point nonparametric Sall LOD scores and our highest HLOD score
30
drew attention to the PLEKHA1/LOC387715/PRSS1 1 region (marked ‘P’ in fig. 3.3). In this
region, SNP rs4146894 in PLEKHA1 had a two-point Sall of 3.34 and the highest two-point
HLOD of 2.66, whereas SNPs rs760336 and rs763720 in PRSS11 had two-point Sall values of 2.69
and 2.23, respectively. However, the 1–unit support interval is large (10.06 cM) (fig. 3.3), and so
localization from the linkage analyses alone is rather imprecise.
We also explored the effect of failing to take SNP-SNP LD into account, by comparing the
multipoint scores computed using all SNPs (fig. 3.3, left panel) with those computed using only the
htSNPs (fig. 3.3, right panel). Two of the peaks found using all SNPs (referred to as “false peaks”;
marked ‘F’ in fig. 3.3, left panel) almost vanish completely when using only htSNPs; interestingly,
these two peaks lie within haplotype blocks (Figure 4 and Figure 4), whereas the LD around our
highest multi- and two-point LOD scores is low (fig. 4C), indicating the importance of taking LD
into account when performing linkage analysis.
Our linkage results on chromosome 1 gave three peaks with Sall > 2, and only one of those
peaks was observed when we restricted our analysis to htSNPs (fig. 3.4). This remaining peak
overlies CFH and includes two SNPs with very high two-point Sall and HLOD scores: rs800292, a
nonsynonymous SNP in CFH, had an Sall of 1.53 and an HLOD of 2.11, whereas SNP rs1853883,
165 kb telomeric of CFH, had an Sall of 4.06 and an HLOD of 3.49. These results strongly
support earlier findings of CFH s involvement in ARM (Conley et al. 2005; Edwards et al. 2005;
Hageman et al. 2005; Haines et al. 2005; Klein et al. 2005; Zareparsi et al. 2005). The vanishing
peaks (marked ‘F’ in fig. 3.4, left panel) that we saw when we used all of our SNPs in the linkage
analysis are located within strong haplotype blocks (figs. A2A and A2B), whereas the LD under
the CFH peak is relatively low (fig. A2C).
3.4.1.2 CIDR association results For finer localization than can be obtained by linkage,
we turned to association analyses (which were very successful in discovering CFH on chromo-
some 1). Here, we performed association analyses using the CCREL approach (Browning et al.
2005), which permitted the simultaneous use of our unrelated controls and all of our related fa-
milial cases by appropriately adjusting for the relatedness of the cases. In the CIDR sample
on chromosome 10, within our linkage peak, we found a cluster of four adjacent SNPs with
very small P values (rs4146894, rs1882907, rs760336, and rs763720 ) that overlies three genes:
PLEKHA1, LOC387715, and PRSS11. Our strongest CCREL results on chromosome 10 were for
31
















   
 
   
 
   
 
   
 
   
 
   
 







   
 
   
 
   
 






   
 







   
 
   
 
   
 







   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 






   
 
   
 
   
 







   
 







   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 







   
 
   
 
   
 












   
 
   
 
   
 
   
 













   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 






   
 







   
 
   
 
   
 







   
 
   
 






   
 
   
 
   
 
   
 
   
 
   
 
   
 






   
 
   
 
   
 
   
 







   
 
   
 
   
 







   
 
   
 
   
 
   
 
   
 







   
 
   
 
   
 







   
 
   
 
   
 
   
 
   
 







   
 







   
 
   
 
   
 
   
 






   
 
   
 







   
 







   
 







   
 
   
 






   
 







   
 
   
 






   
 
   
 
   
 
   
 
   
 
   
 













   
 
   
 

























   
 
   
 
   
 
   
 
   
 







   
 
   
 
   
 













   
 
   
 







   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 






   
 
   
 







   
 
   
 
   
 
   
 
   
 
   
 






   
 












   
 














   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 







   
 







   
 
   
 







   
 
   
 
   
 
   
 
   
 







   
 
   
 
   
 
   
 







   
 
   
 







   
 
   
 
   
 
   
 
   
 







   
 
   
 







   
 
   
 
   
 
   
 
   
 







   
 







   
 
   
 
   
 
   
 






   
 
   
 







   
 














   
 







   
 







   
 






   
 
   
 
   
 
   
 
   
 













   
 
   
 











Figure 3.3: Two-point (2pt) and multipoint (mpt) linkage results on chromosome 10. The panel
on the left summarizes the results when all SNPs were used for analysis. The panel on the right
summarizes the results when only htSNPs were used. The peaks marked ‘F’ represent likely false
peaks due to high SNP-SNP LD, whereas the peaks marked ‘G’ and ‘P’ correspond to the loci
containing GRK5 and PLEKHA1, respectively. The horizontal lines indicate the 1–unit support
interval of multipoint Sall (i.e., maximum Sall − 1).
SNP rs4146894 in PLEKHA1 (table 3.3). The moving-window haplotype analyses using three
SNPs at a time resulted in very small P values across the whole PLEKHA1 to PRSS11 region
(table 3.3). The association testing also generated some moderately small P values in the GRK5
region, which is where our highest evidence of linkage occurred.
32
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Figure 3.4: Two-point (2pt) and multipoint (mpt) linkage results on chromosome 1. The panel
on the left summarizes the results when all SNPs were used for analysis. The panel on the right
summarizes the results when only htSNPs were used. The peaks marked ‘F’ represent likely false
peaks due to high SNP-SNP LD, whereas the peak marked ‘C’ corresponds to the CFH gene. The
horizontal lines indicate the 1–unit support interval of multipoint Sall (i.e., maximum Sall over
CFH -1).
We performed the CCREL on 56 SNPs spanning the linkage peak on chromosome 1 and
found two highly significant SNPs (rs800292 and rs1853883 ) that overlie CFH (table 3.3). The
moving-window haplotype analyses, performed using two and three SNPs at a time, resulted in
33
Table 3.3: CCREL, GIST, and Allele-Frequency Estimation for Families and Controls Typed at
CIDR
P value for Test
Moving-Window
Frequency in Haplotype Test GIST
Families Controls Allele With With Genotype
SNP Gene (n = 594) (n = 179) Test 2 SNPs 3 SNPs Test NPL 10 NPL1
rs6658788 0.460 0.489 0.37312 0.01616 0.00778 0.44415 0.106 0.055
rs1538687 0.234 0.307 0.00178 0.00206 0.00674 0.0054 0.781 0.129
rs1416962 0.321 0.352 0.16378 0.39256 0.4157 0.38009 0.566 0.019
rs946755 0.317 0.344 0.20073 0.20147 <0.00001 0.37434 0.513 0.012
rs6428352 0.001 0.003 . . . <0.00001 <0.00001 . . . . . . . . .
rs800292 CFH 0.132 0.232 <0.00001 <0.00001 <0.00001 <0.00001 0.437 0.001
rs70620 CFH 0.147 0.173 0.15602 <0.00001 <0.00001 0.33122 0.893 0.333
rs1853883 0.630 0.489 <0.00001 <0.00001 <0.00001 <0.00001 0.521 <0.001
rs1360558 0.425 0.397 0.34842 0.60377 0.01118 0.63012 0.183 0.296
rs955927 0.416 0.391 0.36201 0.00833 . . . 0.65613 0.065 0.145
rs4350226 0.055 0.095 0.00182 . . . . . . 0.00183 0.171 0.242
rs4752266 GRK5 0.220 0.223 0.84131 0.23223 0.28973 0.03802 0.088 0.475
rs915394 GRK5 0.214 0.187 0.15214 0.19235 0.00309 0.35594 0.028 0.643
rs1268947 GRK5 0.112 0.117 0.97426 0.00969 0.01031 0.97976 0.052 0.345
rs1537576 GRK5 0.507 0.433 0.01881 0.01354 0.03257 0.0295 0.006 0.251
rs2039488 0.078 0.115 0.01339 0.07877 . . . 0.05075 0.004 0.609
rs1467813 RGS10 0.286 0.293 0.63177 . . . . . . 0.71857 0.539 0.582
rs927427 0.514 0.464 0.06936 0.00003 0.00002 0.05976 0.198 0.577
rs4146894 PLEKHA1 0.598 0.466 <0.00001 <0.00001 0.00001 <0.00001 0.008 0.802
rs1882907 0.127 0.187 0.00261 0.00013 0.00006 0.00521 0.169 0.172
rs760336 PRSS11 0.395 0.480 0.00469 0.00126 . . . 0.02036 0.232 0.581
rs763720 PRSS11 0.295 0.212 0.00053 . . . . . . 0.00290 0.198 0.021
Note.—The minor-allele frequency is reported for controls (estimated by counting) and families (estimated by Mendel, version
5). The moving-window haplotype P values correspond to the SNPs in the same row as the P value and the next one or two SNPs
for the two- and three-SNP moving window, respectively. For GIST, with the use of NPL scores from chromosome 1 (NPL 1)
and chromosome 10 (NPL 10), P values ≤0.05 are in bold italics and P values ≤0.001 are underlined. Blank spaces separate the
three chromosomal regions corresponding to SNPs in and around CFH, GRK5/RGS10, and PLEKHA1/LOC687715/PRSS1.
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extremely low P values across the whole CFH gene (table 3.3), which supports earlier findings of
strong association between CFH and ARM.
3.4.1.3 CIDR GIST results When GIST was performed on the CIDR data set, the two
smallest P values in chromosome 10q26 (0.006 and 0.004) occurred in the GRK5/RGS10 region,
whereas the third smallest P value (0.008) occurred in PLEKHA1 (table 3.3). All four SNPs in the
GRK5 gene have small GIST P values. The GIST results suggest that both GRK5 and PLEKHA1
contribute significantly to the linkage signal on chromosome 10 and that CFH contributes to the
linkage signal on chromosome 1. Neither of the two SNPs in PRSS11 contributes significantly to
the linkage signal on chromosome 10. There was no evidence that the genes on chromosome 10
were related to the linkage signal seen on chromosome 1.
3.4.2 PART II: Analysis of Locally Genotyped SNPs
3.4.2.1 Local association results After additional SNPs were typed locally, the allele and
genotype test generated extremely small P values for each of the three genes PLEKHA1, LOC387715,
and PRSS11 (table 3.4). The moving-window haplotype analyses with three SNPs resulted in very
small P values across the entire PLEKHA1/LOC387715/PRSS11 region (table 3.4). Thus, al-
though association implicates the PLEKHA1/LOC387715/ PRSS11 region, it does not distinguish
between these genes.
3.4.2.2 Local GIST results Of the three genes PLEKHA1, LOC387715, and PRSS11, GIST
most strongly implicated PLEKHA1 (table 3.4). It also generated a small P value for rs10490924
in LOC387715, but this SNP is in high LD with the PLEKHA1 SNPs (see fig. 3.2A). When the
locally typed data set was used, GIST did not generate any significant results for PRSS11, similar
to the nonsignificant results observed in the larger CIDR sample. This implies that PLEKHA1 (or
a locus in strong LD with it) is the most likely to be involved in ARM, and therefore LOC387715
remains a possible candidate locus.
For a fair assessment of which SNP accounts for the linkage signal across the region, the
NPLs were computed using only the locally genotyped families. This permitted us to compare the
PLEKHA1/LOC387715/PRSS11 results (table 3.4) directly with the GRK5/RGS10 results. For
the locally typed data set, the GIST results for GRK5 are also interesting, with modest P values
35
Table 3.4: CCREL, GIST, and Allele-Frequency Estimation for Locally Typed Families and Con-
trols
P value for Test
Moving-Window
Frequency in Haplotype Test GIST
Families Controls Allele With With Genotype
SNP Gene (n = 323) (n = 117) Test 2 SNPs 3 SNPs Test NPL 10 NPL 1
rs6658788 0.563 0.483 0.02200 0.00052 0.00162 0.04920 0.319 0.244
rs1538687 0.213 0.342 0.00004 0.00043 0.00066 0.00014 0.652 0.302
rs1416962 0.299 0.393 0.00597 0.02623 0.02051 0.01819 0.442 0.041
rs946755 0.295 0.380 0.01234 0.01243 <0.00001 0.04531 0.409 0.040
rs6428352 0.001 0.004 . . . <0.00001 <0.00001 . . . . . . . . .
rs800292 CFH 0.120 0.269 <0.00001 <0.00001 <0.00001 <0.00001 0.315 0.014
rs1061170 CFH 0.609 0.310 <0.00001 <0.00001 <0.00001 <0.00001 0.895 0.132
rs10922093 CFH 0.210 0.295 0.00693 0.00175 <0.00001 0.01723 0.360 0.327
rs70620 CFH 0.148 0.150 0.91163 <0.00001 <0.00001 0.56770 0.737 0.356
rs1853883 0.633 0.432 <0.00001 <0.00001 <0.00001 <0.00001 0.776 0.011
rs1360558 0.437 0.389 0.18014 0.43576 0.02079 0.37993 0.975 0.488
rs955927 0.433 0.385 0.15343 0.01037 . . . 0.36087 0.017 0.585
rs4350226 0.050 0.103 0.00312 . . . . . . 0.00373 0.228 0.174
rs4752266 GRK5 0.223 0.226 0.81772 0.27748 0.64917 0.08279 0.107 0.453
rs915394 GRK5 0.228 0.209 0.34489 0.83219 0.05560 0.62183 0.049 0.320
rs1268947 GRK5 0.117 0.115 0.81975 0.02748 0.02192 0.78965 0.049 0.689
rs1537576 GRK5 0.497 0.419 0.02604 0.02232 0.05636 0.06334 0.012 0.023
rs2039488 0.083 0.115 0.11177 0.42428 . . . 0.42399 0.025 0.358
rs1467813 RGS10 0.293 0.295 0.86608 . . . . . . 0.85954 0.506 0.492
rs927427 0.506 0.487 0.56710 0.00056 0.00083 0.42264 0.306 0.625
rs4146894 PLEKHA1 0.611 0.474 0.00004 0.00012 0.00053 0.00024 0.006 0.737
rs12258692 PLEKHA1 0.008 0.000 . . . 0.54750 0.00018 . . . . . . . . .
rs4405249 PLEKHA1 0.139 0.158 0.39378 0.00026 0.00280 0.33118 0.003 0.345
rs1045216 PLEKHA1 0.289 0.427 0.00004 0.00036 0.00001 0.00026 0.068 0.825
rs1882907 0.131 0.184 0.01761 0.00140 0.01099 0.04401 0.017 0.372
rs10490923 LOC387715 0.089 0.141 0.02112 0.05024 <0.00001 0.03415 0.086 0.251
rs2736911 LOC387715 0.121 0.119 0.71668 <0.00001 <0.00001 0.64230 0.312 0.968
rs10490924 LOC387715 0.475 0.193 <0.00001 <0.00001 <0.00001 <0.00001 0.018 0.327
rs11538141 PRSS11 0.004 0.005 . . . 0.00726 0.01676 . . . . . . . . .
rs760336 PRSS11 0.373 0.474 0.00527 0.01386 0.00036 0.01396 0.479 0.683
rs763720 PRSS11 0.296 0.226 0.01645 0.00016 . . . 0.03899 0.305 0.451
rs1803403 PRSS11 0.118 0.030 0.00009 . . . . . . 0.00022 0.714 0.778
Note.—The minor-allele frequency is reported for controls (estimated by counting) and families (estimated by Mendel, version
5). The moving-window haplotype P values correspond to the SNPs in the same row as the P value and the next one or two SNPs
for the two- and three-SNP moving window, respectively. For GIST, with the use of NPL scores from chromosome 1 (NPL 1)
and chromosome 10 (NPL 10), P values ≤0.05 are in bold italics and P values ≤0.001 are underlined. Blank spaces separate the
three chromosomal regions corresponding to SNPs in and around CFH, GRK5/RGS10, and PLEKHA1/LOC687715/PRSS1.
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of the same magnitude as the P values we got from applying GIST to CFH (table 3.4). However,
note that the P values are not as small as those seen when the CIDR data set was analyzed. Since
all of the SNPs in the GRK5 region are CIDR SNPs, this difference is solely a function of sample
size, because the locally typed data set is smaller than the CIDR data set (see table 3.2).
3.4.3 Part III: Interaction and OR Analyses
3.4.3.1 GIST results We did not see any strong evidence of an interaction between the chro-
mosome 1 and chromosome 10 regions, by use of GIST. When the CIDR data set was used to test
whether SNPs on chromosome 10 contribute to the linkage signal on chromosome 1 (see GIST,
NPL 1, in table 3.3), only rs763720 in PRSS1 gave a P value < 0.05; however, rs763720 does
not contribute significantly to the linkage signal on chromosome 10, which makes this P value less
convincing. When we used the local data set, one GRK5 variant (rs1537576 ), which was not sig-
nificant in the larger CIDR data set, gave a P value < 0.05. Similarly, we did not see evidence that
SNPs within CFH contribute to the linkage signal on chromosome 10; only one SNP (rs955927 )
gave a P value < 0.05—this SNP, however, is not in the CFH gene and is not in strong LD (see
fig. 3.2B) with any SNPs in CFH.
3.4.3.2 Logistic regression results The logistic regression results (table A3) suggest that an
additive model including the variants from CFH and PLEKHA1 is the best model for predicting
case-control status; this indicates that both genes are important to the ARM phenotype. The
AIC criteria also suggest that an additive model including an additive interaction term is the next
best model (table A3); however, the interaction term is not significant (P = 0.71). We obtain
similar results for interaction between CFH and PRSS11, where the additive model including both
variants appears to be the best model. Within the GRK5/RGS10 region, a model with the CFH
SNP alone is the best-fitting model, which suggests that the prediction of case-control status with
CFH genotype does not improve by the addition of either the GRK5 or RGS10 variant to the
model.
3.4.3.3 OR and AR We estimated the magnitude of association by calculating OR and AR
values; the significant associations we saw (table 3.5) are, not surprisingly, consistent with the results
from the CCREL tests in parts I and II. Our two most significant SNPs in the PLEKHA1/LOC387715
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region are SNPs rs4146894 (PLEKHA1 ) and rs10490924 (LOC387715 ); the two tests are highly
correlated because the LD between those SNPs is very high (D′ = 0.93) (see fig. 3.2A). The
third most significant SNP (rs1045216 ) in the chromosome 10 region is a nonsynonymous SNP in
PLEKHA1 and in high LD with both rs4146894 (D′ = 0.97) and rs10490924 (D′ = 0.91).
We obtained results and OR and AR values (table 3.5) similar to those that others have
reported for the CFH gene. The three most significant SNPs were rs1061170 (Y402H variant),
rs800292 (in CFH ), and rs1853883 (in strong LD with rs1061170 ; D′ = 0.91).
The magnitude of the association we saw within PLEKHA1/LOC387715 is very similar to
the level of association seen between CFH and ARM; both loci result in extremely low P values
(P < 0.0001). The OR and AR values were also similarthe dominant OR was 5.29 (95% CI 3.358.35)
within CFH and 5.03 (95% CI 3.27.91) within PLEKHA1/LOC387715, and the dominant AR for
CFH and PLEKHA1/LOC387715 was 68% and 57%, respectively.
3.4.3.4 Subphenotype analyses We estimated ORs and ARs for patients with exudative
disease versus controls and for patients with GA versus controls (table A4). ORs and corresponding
P values yielded similar findings to those of the allele test of CCREL (tables 3.3 and 3.4). We found
no major differences between the ORs for the presence of either GA or CNV.
3.5 DISCUSSION
Our linkage studies of families with ARM have consistently identified the chromosome 1q31 and
chromosome 10q26 loci, in addition to several other loci. Multiple linkage studies have replicated
this finding; thus, we undertook a focused SNP analysis of both regions, using ARM-affected
families as well as unrelated affected individuals and controls. We confirmed the strong association
of chromosome 1q31 with CFH that has been reported by others (see also (Conley et al. 2005)),
and we have shown, for the first time, that SNPs in CFH significantly account for the linkage
signal. Interestingly, our smallest GIST P value (< 0.001) was for rs1853883 (which has a high
D′ of 0.91 with the Y402H variant) and not for the presumed “disease-associated” Y402H variant
itself. This raises the possibility that we may still have to consider other possible ARM-related
variants within the CFH gene and that these may be in high LD with Y402H.
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Table 3.5: ORs, ARs, and Simulated P Values from χ2 Test with 10,000 Replicates
Dominant Heterozygotes Recessive Homzygotes
([RR+RN] vs. NN) (RN vs. NN) (RR vs [RN+NN]) RR vs. NN
SNP (allele) Gene OR 95% CI AR P OR AR OR 95% CI AR P OR AR
rs6658788 (2) 0.83 0.57-1.22 -14.04 0.3909 1.09 2.69 1.01 0.68-1.5 0.21 1.0 0.88 -5.92
rs1538687 (2) 0.68 0.49-0.95 -19.38 0.023 0.5 -11.74 0.42 0.23-0.78 -6.52 0.0068 0.38 -12.42
rs1416962 (2) 0.84 0.6-1.18 -10.02 0.3418 0.89 -2.57 0.82 0.49-1.38 -2.31 0.5002 0.77 -5.74
rs946755 (2) 0.8 0.57-1.13 -12.52 0.232 1.0 0.04 0.9 0.53-1.52 -1.24 0.7816 0.8 -4.34
rs6428352 (2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs800292 (1) CFH 0.43 0.3-0.62 -30.01 <0.0001 0.48 -23.85 0.15 0.05-0.45 -4.98 0.0001 0.12 -8.19
rs1061170 (2) CFH 5.29 3.35-8.35 68.2 <0.0001 2.66 28.55 4.57 2.48-8.42 30.06 <0.0001 10.05 63.72
rs10922093 (1) CFH 0.59 0.39-0.88 -25.61 0.0111 0.63 -19.65 0.5 0.24-1.04 -4.98 0.0736 0.41 -10.14
rs70620 (1) CFH 0.83 0.57-1.19 5.64 0.3366 0.85 -4.29 0.67 0.27-1.68 -1.3 0.4525 0.64 -1.93
rs1853883 (2) 2.67 1.78-4.01 54.41 <0.0001 1.65 19.21 2.08 1.43-3.02 22.06 0.0003 3.55 55.04
rs1360558 (1) 1.16 0.82-1.65 9.12 0.414 1.1 5.39 1.25 0.8-1.96 3.94 0.3774 1.32 9.01
rs955927 (2) 1.13 0.79-1.6 7.5 0.5303 1.28 6.35 1.31 0.83-2.08 4.53 0.2588 1.36 9.38
rs4350226 (2) 0.51 0.32-0.81 -9.68 0.0038 0.27 -4.76 0.16 0.01-1.74 -0.95 0.142 0.14 -1.16
rs4752266 (2) GRK5 0.88 0.62-1.23 -5.57 0.4325 3.27 10.68 2.81 0.98-8.04 3.89 0.0457 2.56 5.51
rs915394 (2) GRK5 1.28 0.9-1.82 8.91 0.1543 1.35 2.73 1.56 0.58-4.14 1.53 0.3892 1.68 2.72
rs1268947 (2) GRK5 1.05 0.7-1.57 1.06 0.841 1.24 1.82 1.27 0.35-4.55 0.45 0.7761 1.28 0.58
rs1537576 (2) GRK5 1.59 1.11-2.29 27.95 0.0109 0.89 -3.74 1.08 0.71-1.62 1.59 0.7579 1.47 15.14
rs2039488 (2) 0.7 0.45-1.07 -6.5 0.1067 0.23 -11.98 0.19 0.04-0.79 -2.33 0.0242 0.18 -2.85
rs1467813 (1) RGS10 0.96 0.69-1.35 -1.84 0.8645 1.01 0.42 0.77 0.42-1.38 -2.27 0.4265 0.77 -3.76
rs927427 (1) 1.09 0.74-1.62 6.57 0.6172 0.94 -4.66 1.67 1.09-2.56 10.73 0.0201 1.6 19.91
rs4146894 (1) PLEKHA1 2.22 1.49-3.31 46.78 0.0002 1.77 33.08 2.21 1.49-3.29 20.46 <0.0001 3.31 49.88
rs12258692 (2) PLEKHA1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs4405249 (1) PLEKHA1 0.62 0.33-1.15 -12.96 0.1692 0.61 -12.69 0.87 0.1-7.56 -0.23 1.0 0.77 -0.57
rs1045216 (2) PLEKHA1 0.48 0.32-0.74 -51.23 0.0005 0.49 -18.27 0.37 0.21-0.65 -14.3 0.0003 0.28 -35.68
rs1882907 (2) 0.58 0.4-0.84 -16.73 0.0026 0.44 -5.79 0.31 0.1-0.97 -2.37 0.0438 0.27 -3.65
rs10490923 (2) LOC387715 0.53 0.31-0.9 -13.27 0.0239 0.34 -9.01 0.22 0.04-1.09 2.51 0.0809 0.2 -3.32
rs2736911 (2) LOC387715 0.72 0.42-1.21 -6.92 0.2552 1.47 1.99 1.1 0.13-9.53 0.1 1.0 1.03 0.04
rs10490924 (2) LOC387715 5.03 3.2-7.91 57.11 <0.0001 2.72 22.76 5.75 2.46-13.46 21.2 <0.0001 10.57 42.71
rs11538141 (2) PRSS11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs760336 (2) PRSS11 0.64 0.44-0.93 -35.37 0.013 0.8 -6.95 0.69 0.46-1.03 -7.95 0.0773 0.55 -26.43
rs763720 (1) PRSS11 1.69 1.2-2.38 21.24 0.0018 1.55 16.95 2.63 1.1-6.25 5.17 0.0277 3.16 10.14
rs1803403 (1) PRSS11 2.98 1.25-7.06 10.51 0.0093 2.98 10.51 . . . . . . . . . . . . . . . . . .
Note.—Type A-affected individuals are compared with controls. Allele denotes the risk allele (minor allele in controls). RR = homozygotes for the risk allele; RN = heterozygotes
for the risk allele; NN = homozygotes for the normal allele. Locally typed SNPs are in bold italics. Blank spaces separate the three chromosomal regions corresponding to SNPs
in and around CFH, GRK5/RGS10, and PLEKHA1/LOC687715/PRSS11.
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Our studies of chromosome 10q26 have implicated two potential loci: (1) a very strongly
implicated locus that includes three tightly linked genes, PLEKHA1, LOC387715, and PRSS11,
and (2) a less strongly implicated locus comprising two genes, GRK5 and RGS10 (fig. 3.1). The
GIST analysis does not support PRSS11 as the ARM-related gene, but it does not completely
exclude it as a potential candidate. PLEKHA1 has the lowest GIST-derived P values, whereas
LOC387715 harbors the SNP with the strongest association signal and the highest ORs. With
the high LD between SNPs in LOC387715 and PLEKHA1, one cannot clearly distinguish between
these genes by statistical analyses alone. However, it is clear that the magnitude of the impact
of the PLEKHA1/LOC387715 locus on ARM is comparable to that which has been observed for
the CFH locus. As in recent studies (Edwards et al. 2005; Haines et al. 2005; Klein et al.
2005), we have found, in our case-control population, that the CFH allele (either heterozygous or
homozygous) accounts for an OR of 5.3 (95% CI 3.48.4) and a significant population AR of 68%.
In the same fashion, the high-risk allele within the PLEKHA1/LOC387715 locus accounts for an
OR of 5.0 (95% CI 3.27.9) and an AR of 57% when both heterozygous and homozygous individuals
are considered. As noted by Klein et al. (2005), unless the disease is very rare, the OR determined
from a case-control study will usually overestimate the equivalent relative risk. Estimates of AR
based on ORs for common genetic disorders can misrepresent the extent to which a variant accounts
for the population AR. However, if this caution is kept in mind, it is still useful for us to present
AR values to allow for relative comparisons and to allow the reader to appreciate that the potential
impact of the CFH Y402H variant on ARM is comparable to that of the variants observed in the
PLEKHA1/LOC387715 locus.
In the case of CFH on chromosome 1, the association data were extremely compelling for a
single gene, even though CFH is within a region of related genes. In addition to the association
data found by multiple independent groups, there is additional biological data to implicate CFH,
including localization of the protein within drusen deposits of patients with ARM. Thus, we also
must consider the biological relevance of the potential ARM-susceptibility genes identified by our
studies of chromosome 10q26.
As noted above, the GIST analysis most strongly implicated PLEKHA1, particularly when
we included the additional nonsynonymous SNPs that we genotyped locally. PLEKHA1 encodes the
protein TAPP1, which is a 404-aa protein with a putative phosphatidylinositol 3,4,5-trisphosphate-
binding motif (PPBM), as well as two plectstrin homology (PH) domains. The last three C-
terminal amino acids have been predicted to interact with one or more of the 13 PDZ domains
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of MUPP1 (similar to the PDZ domain within PRSS11). Dowler and colleagues (Dowler et al.
2000) have shown that the entire TAPP1 protein, as well as the C-terminal PH domain, interacts
specifically with phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) but not with any other
phosphoinositides. TAPP1, which has 58% identity with the first 300 aa of TAPP2, shows a
fivefold higher affinity for PtdIns(3,4)P2 than does TAPP2, and this binding is nearly eliminated
by mutation of the conserved arginine 212 to leucine within the PPBM region (which is part of
the second PH domain). The most well-defined role for TAPP1 (and its relatives, Bam32 and
TAPP2) has been as an activator of lymphocytes. PtdIns(3,4)P2 is preferentially recruited to cell
membranes when lipid phosphatase (SHIP) is activated along with PI3K (phosphatidyl inositol
3-kinase). SHIP is responsible for the dephosphorylation of PIP3 to PtdIns(3,4)P2. SHIP is a
negative regulator of lymphocyte activation, and thus TAPP1 and TAPP2 may be crucial negative
regulators of mitogenic signaling and of the PI3K signaling pathway. Thus, one can envision a
role in the eye for PLEKHA1 and its protein, TAPP1, in modifying local lymphocyte activation,
consistent with the hypothesis that ARM is closely linked to an inflammatory process.
However, we need to still consider the biological plausibility of the other two candidate genes
within this locus, LOC387715 and PRSS11. Little is known regarding the biology of LOC387715,
except that its expression appears to be limited to the placenta. Our own reverse transcription
experiments with human retinal RNA have confirmed the expression of PLEKHA1 and PRSS11,
but we have not detected LOC387715 transcripts in the retina under standard conditions, even
though we confirmed its expression with placental RNA (data not shown). However, we cannot
exclude the possibility that LOC387715 is expressed at very low levels in the retina or retinal
pigment epithelium or that its expression in nonocular tissues, such as dendritic cells or migrating
macrophages, could be a factor in the pathogenesis of ARM.
PRSS11 is one of the genes of the mammalian high temperature requirement A (HtrA) serine
protease family, which has a highly conserved C-terminal PDZ domain (Oka et al. 2004). These
secretory proteases were initially identified because of their homologies to bacterial forms that are
required for survival at high temperatures and molecular chaperone activity at low temperatures.
The ATP-independent serine protease activity is thought to degrade misfolded proteins at high
temperatures. The mammalian form, HtrA1, has been shown to be selectively stimulated by type
III collagen alpha 1 C propeptide, in contrast to HtrA2 (Murwantoko et al. 2004). Type III
collagen is a major constituent (35%–39% of the total collagen) in Bruch membrane and is also
present in small amounts in the retinal microvascular basement membranes. Developmental studies
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have reported ubiquitous expression of HtrA1, but with temporal and spatial specificities that
coincide with those regions in which Tgfβ proteins play a regulatory role (De Luca et al. 2004).
Oka and colleagues (Oka et al. 2004) have shown that HtrA1 is capable of inhibiting the signaling
of a number of Tgfβ family proteins, including Bmp4, Bmp2, and Tgfβ1, presumably by preventing
receptor activation with a requirement for protease activity of the HtrA1 molecule. One clue as
to the potential importance of these relationships for ARM comes from the studies of Hollborn
et al. (2004), who found that human RPE cells in vitro experienced reduced proliferation in the
presence of Tgfβ1 and Tgfβ2 and an increase in levels of collagen III and collagen IV transcripts.
Normally, a rise in collagen III would activate HtrA1 and would lead to secondary inhibition of
the effects of Tgfβ1. However, if the serine protease is less effective (because of either reduced
synthesis or a nonfunctional mutation), then this regulatory pathway would be disrupted, leading
to an overall reduction in the proliferation potential of the RPE cells, perhaps contributing to RPE
atrophy or further changes that could lead to the development of ARM. The gradual reduction in
solubility of type III collagen in Bruch membrane that has been observed with aging could also, in
part, account for a general reduction in HtrA1 activity as an individual ages.
Both PRSS11 and PLEKHA1 are expressed in the retina, and a SAGE analysis of central
and peripheral retina (Gene Expression Omnibus [GEO] expression data) indicates higher levels of
transcripts of both genes in the central macula (more so for PLEKHA1 than for PRSS11 ). Multiple
studies (reported in GEO profiles) have shown that PLEKHA1 expression is significantly induced
in a variety of cell types in response to exposure to specific inflammatory cytokines. PRSS11 has
also been investigated as part of a microarray expression analysis of dermal fibroblasts that have
been oxidatively challenged, in a comparison between normal individuals and patients with ARM.
In that study, half of the ARM samples (9 of 18) had lower Htra1 expression levels than any of
the normal samples. The lower levels of Htra1 in nonocular tissues of patients with ARM would
suggest that this is an intrinsic difference in the biology of these patients, compared with that of
normal individuals, and is not a consequence of degenerative changes in the eye.
Several lines of evidence support the GRK5/RGS10 locus. The peak of our Sall multipoint
curve is directly over GRK5, and our largest two-point Sall=3.86 (rs555938 ) is only 206 kb cen-
tromeric of GRK5. The P values for the GIST analysis of the GRK5/RGS10 CIDR data were 0.004
and 0.006, which are even smaller than the P value for the SNP within PLEKHA1 (P = 0.008).
By use of our locally genotyped sample, the GIST P value for the GRK5 locus was 0.012, which is
comparable to the P value that we found for the Y402H variant in CFH (P = 0.011). However,
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the CCREL analyses were not very significant for the GRK5 SNPs, and the ORs were mostly
nonsignificant.
On the basis of biological evidence, GRK5 is a reasonable ARM candidate gene, given its role
in modulating neutrophil responsiveness to chemoattractants and its interactions with the Toll 4
receptor (Haribabu and Snyderman 1993; Fan and Malik 2003), which has also been implicated
in ARM (Zareparsi et al. 2005). The retinal or RPE expression of GRK5 is not especially relevant
to the argument of causality, because it would be the expression and function of GRK5 in migrating
lymphocytes and macrophages that would be crucial to its role in the immune and/or inflammatory
pathways that may be pathogenic in ARM. The strongest GIST results occur at rs2039488, which
is located between GRK5 and RGS10, 3′ of the ends of both genes. Several other SNPs within
GRK5 also have small GIST P values, whereas the RGS10 SNP has a nonsignificant GIST P value.
However, we cannot completely exclude the possibility that there is a SNP within RGS10 that is
in strong LD with rs2039488.
RGS10 is one of a family of G protein–coupled receptors that has been implicated in
chemokine-induced lymphocyte migration (Moratz et al. 2004) and whose expression in den-
dritic cells (which have been identified in ARM-related drusen deposits) is modified by the Toll-like
signaling pathway (Shi et al. 2004). RGS10 and GRK5 expression in the same microarray study
of oxidatively stressed dermal fibroblasts in patients with ARM and control subjects showed minor
fluctuations among the samples but no clear differences between the controls and affected individu-
als. This does not necessarily lower the potential for these genes being involved in ARM, since the
dermal fibroblasts lack the cell populations that would be expected to have modulation of RGS10 -
and/or GRK5 -related proteins.
We have attempted to look at potential interactions between the high-risk alleles within the
PLEKHA1/LOC387715 and GRK5/RGS10 loci with respect to CFH on chromosome 1. This
is perhaps the first report to use GIST to examine these interactions, and we found no evidence
that the NPL data on chromosome 1 could be accounted for by the SNP data on chromosome 10.
Conversely, we found no such associations between the NPL data on chromosome 10 and the SNP
data from the CFH alleles. Logistic regression analysis also failed to identify an interaction, and
it appears that a simple additive risk model is the most parsimonious. We have performed some
initial logistic analyses that include exposure to smoking. These analyses were initiated because of
the previous suggestion of an interaction between smoking and the biology of complement factor
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H (Esparza-Gordillo et al. 2004) and because of our prior studies, which found an interaction
between smoking and the locus on chromosome 10q26 (Weeks et al. 2004). To date, we have found
no strong interaction between smoking and either CFH or PLEKHA1/LOC387715, but we are still
exploring a possible interaction with the GRK5/RGS10 locus and different modeling strategies.
We also examined the associations of ARM subphenotypes with the SNPs on chromosomes
1 and 10 (table A4). We found no major differences in the ORs for the presence of either GA or
CNV, which suggests that these ARM loci contribute to a common pathogenic pathway that can
give rise to either end-stage form of the disease. This does not exclude the possibility that there
are other as-yet-undescribed genetic loci that may confer specific risk of GA or CNV development
separately.
In summary, these SNP–based linkage and association studies illustrate both the power and
the limitation of such methods to identify the causative alleles and genes underlying ARM suscep-
tibility. These genetic approaches allow us to consider genes and their variants that may contribute
to disease, whether or not there is tissue-specific expression. Through high-density SNP genotyping,
we have narrowed the list of candidate genes within the linkage peak found on chromosome 10q26,
from hundreds of genes to primarily GRK5 and PLEKHA1, but we cannot completely exclude pos-
sible roles for RGS10 and/or PRSS11 and LOC387715. Additional genotyping of nonsynonymous
3 SNPs within the GRK5 gene may help to further discriminate between GRK5 and RGS10, but
it may not establish a definitive assignment of causality. Replication by other studies (as done
in the case of CFH ) may allow the attention to be focused on a single gene in future studies of
ARM pathology, but there is also the distinct possibility that we will be unable to achieve further
resolution with association studies or to clearly establish whether there are more than two genes
responsible for ARM susceptibility on chromosome 10q26. However, it is now well within the capa-
bilities of molecular biologists to investigate the potential role of each of these candidate genes in
mouse models of ARM and to address the issue of a causal role in disease pathogenesis. Association
studies are an incredibly powerful means of testing hypotheses of genetic contributions to disease,
but, except in the most extreme cases, they cannot provide definitive answers, even when there are
impressive P values.
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4.0 CFH, ELOVL4, PLEKHA1 AND LOC387715 GENES AND
SUSCEPTIBILITY TO AGE-RELATED MACULOPATHY: AREDS AND CHS
COHORTS AND META-ANALYSES
This section has been published in Human Molecular Genetics volume 15, issue 21, pages 3206-
3218(Conley et al. 2006). The authors retain the rights to include the article in full or in part
in a thesis or dissertation, provided that this not published commercially. No changes have been
made to the published version of the paper, except that tables and figures have been renumbered,
the citations are of different style and some minor formatting has been made to keep this chapter
coherent to the reminder of the thesis. The supporting information published online is in Appendix
B. My contribution to this paper was in writing all components of the paper, data analysis, script
writing for method implementation.
4.1 ABSTRACT
Age-related maculopathy (ARM) is an important cause of visual impairment in the elderly popula-
tion. It is of crucial importance to identify genetic factors and their interactions with environmental
exposures for this disorder. This study was aimed at investigating the CFH, ELOVL4, PLEKHA1
and LOC387715 genes in independent cohorts collected using different ascertainment schemes. The
study used a casecontrol design with subjects originally recruited through the Cardiovascular Health
Study (CHS) and the Age-Related Eye Disease Study (AREDS). CFH was significantly associated
with ARM in both cohorts (P ≤ 0.00001). A meta-analysis confirmed that the risk allele in the
heterozygous or homozygous state (OR, 2.4 and 6.2; 95% CI, 2.2–2.7 and 5.4–7.2, respectively)
confers susceptibility. LOC387715 was also significantly associated with ARM in both cohorts
(P ≤ 0.00001) and a meta-analysis confirmed that the risk allele in the heterozygous and homozy-
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gous state (OR, 2.5 and 7.3; 95% CI, 2.2–2.9 and 5.7–9.4, respectively) confers susceptibility. Both
CFH and LOC387715 showed an allele-dose effect on the ARM risk, individuals homozygous at
either locus were at more than two-fold risk compared to those heterozygous. PLEKHA1, which is
closely linked to LOC387715, was significantly associated with ARM status in the AREDS cohort,
but not the CHS cohort and ELOVL4 was not significantly associated with ARM in either cohort.
Joint action of CFH and LOC387715 was best described by independent multiplicative effect with-
out significant interaction in both cohorts. Interaction of both genes with cigarette smoking was
insignificant in both cohorts. This study provides additional support for the CFH and LOC387715
genes in ARM susceptibility via the evaluation of cohorts that had different ascertainment schemes
regarding ARM status and through the meta-analyses.
4.2 INTRODUCTION
Age-related maculopathy (ARM) is a leading cause of central blindness in the elderly of indus-
trialized nations. The prevalence of ARM is expected to increase because of the aging of these
populations (1). The etiology of ARM is complex, with environmental as well as genetic suscep-
tibility playing a role. Association-based analyses are generally more sensitive to small genetic
effects than linkage-based analyses and are extremely valuable for fine mapping of disease-related
genes (Cordell and Clayton 2005). Case–control association studies with the use of unrelated
individuals may have advantages over family-based studies, especially when a multilocus genetic
model is anticipated (Howson et al. 2005; Risch 2001), however, such studies are potentially
sensitive to the ascertainment scheme for the case and control cohorts. For this reason, there is
value in assessing candidate genes in populations from projects with different study designs. This
current study investigates the complement factor H (CFH ) gene, the elongation of very long chain
fatty acid-like 4 (ELOVL4 ) gene, the pleckstrin homology domain-containing protein (PLEKHA1 )
gene, and the hypothetical LOC387715 gene in two such distinct cohorts.
The association of the CFH gene with ARM susceptibility has been established in samples
of European American descent (Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005;
Hageman et al. 2005; Conley et al. 2005; Zareparsi et al. 2005) as well as in samples from the
United Kingdom (Sepp et al. 2006), Germany (Rivera et al. 2005), France (Souied et al. 2005),
Iceland (Magnusson et al. 2006) and Japan (Okamoto et al. 2006).
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Three studies support the PLEKHA1/LOC387715 locus on chromosome 10q26 (Jakob-
sdottir et al. 2005; Rivera et al. 2005; Schmidt et al. 2006). The study by Jakobsdottir
etal. (Jakobsdottir et al. 2005) reported that the PLEKHA1/LOC387715 locus was signifi-
cantly associated with ARM status, however, strong linkage disequilibrium between PLEKHA1
and LOC387715 in the independent family-based and casecontrol populations utilized for the
study meant that a role for one gene over the other could not be determined (Jakobsdottir
et al. 2005). Evidence that the hypothetical LOC387715 gene was more likely to be the gene ac-
counting for susceptibility to ARM came from a study by Rivera et al. (2005) that utilized two
independent casecontrol samples and a study by Schmidt et al. that utilized both family–based and
case–control studies (Schmidt et al. 2006). All three studies indicated that the association of this
region on chromosome 10q26 with ARM status was independent of the association with CFH that
had been previously reported in all three populations (Haines et al. 2005; Conley et al. 2005;
Rivera et al. 2005). In addition, based on the Schmidt et. al. study, the effect of the LOC387715
locus appears to be modified by smoking history (Schmidt et al. 2006).
Two studies have evaluated a potential role for ELOVL4 in ARM in humans. Ayyagari
et al. (2001) evaluated the gene and found no significant association with ARM status in their
sporadic case–control analysis. However, Conley et al. found a significant association of ELOVL4
and ARM status in familial and sporadic case–control analyses (Conley et al. 2005). The difference
in findings between these studies may be related to the proportion of cases with exudative ARM
in each population, since Conley et al. found that ELOVL4 was especially associated with the
exudative sub-phenotype (Conley et al. 2005). These results indicate that additional studies are
needed to establish or refute a relationship between ELOVL4 and ARM.
The two cohorts utilized for this study were the Cardiovascular Health Study (CHS), a
population-based cohort of individuals 65 years and older at baseline for which ARM status was not
a factor for ascertainment (Fried et al. 1991), and the Age-Related Eye Disease Study (AREDS), a
cohort of individuals aged 5580 years participating in a randomized controlled clinical trial of anti-
oxidant and zinc intervention for which ARM status was a factor for ascertainment (Age Related
Eye Disease Study Group 1999). These cohorts have been previously described (Klein et al.
2003; Age Related Eye Disease Study Group 2000).
This study was designed to evaluate the CFH, ELOVL4, PLEKHA1 and LOC387715 genes
in two independent cohorts with very different ascertainment schemes in relation to ARM status
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and then to incorporate the findings into meta-analyses. Association of a gene with susceptibility to
ARM regardless of ascertainment scheme would further increase the evidence that the association
is real and would enhance the likelihood that evaluation of the gene(s) would accurately identify
at risk individuals.
4.3 RESULTS
To further evaluate CFH, ELOVL4, PLEKHA1 and LOC387715 in ARM, we genotyped previously
reported SNPs within all four genes in samples from the AREDS and CHS studies. Separate
analyses were performed on each data set, using a total of 701 non-Hispanic white ARM patients
and 175 controls from the AREDS study, and a total of 126 non-Hispanic white ARM patients
and 1051 controls from the CHS study (see Table 4.1 for sample sizes and other characteristics
of the data, and Table 4.2 for genotype frequencies). The disease status of subjects at their last
follow-up visit was the primary endpoint evaluated for AREDS subjects. The AREDS subjects
include controls of grade 1 and cases (grades 3–5) with moderate ARM and advanced ARM in
one or both eyes. The ARM disease status of CHS subjects was evaluated by Dr. Gorin, using
monocular, non-mydriatic fundus photographs taken at the 8-year follow-up visit. The majority
of CHS cases had moderate ARM including multiple drusen with and without pigment epithelial
changes (equivalent to AREDS grade 3) with a small number of cases having geographic atrophy
(GA) or choroidal neovascular membranes (CNV) and the CHS controls are of AREDS grade 1
with the exclusion of those cases with significant extramacular drusen.
4.3.1 Association analyses
For each gene, CFH, ELOVL4, PLEKHA1 and LOC387715, association of one non-synonymous
SNP with ARM was assessed by a 2 statistic. The magnitude of the effect of each variant was
estimated by odds ratios (ORs) and population attributable risks (PARs). To evaluate whether
the variants confer risk similarly to mild/moderate and advanced ARM, ORs were calculated for
each grade and subtype (GA and CNV) separately using the AREDS data.
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Table 4.1: Characteristics of the study populations
Clinical subtypes
Mean age (SD) Neither GA only CNV only Both Total No. Males (%)
AREDS data
Controls (1) 76.53 (4.44) 175 . . . . . . . . . 175 86 (49)
Cases (345) 79.46 (5.23) 123 147 278 153 701 293 (42)
Cases (45) 79.54 (5.23) 27 147 278 153 605 253 (42)
Cases (3) 78.93 (5.22) 96 0 0 0 96 40 (42)
Cases (4) 78.83 (5.23) 24 59 149 34 266 124 (47)
Cases (5) 80.10 (5.17) 3 88 129 119 339 129 (38)
CHS data
Controls 70.27 (3.92) 1051 . . . . . . . . . 1051 455 (43)
Cases 73.22 (4.84) 100 15 9 2 126 55 (44)
Note.—In the AREDS cohort, mean age and phenotypic classification is based on age at last fundus photography.
The number in the parentheses denotes the disease severity according the AREDS grading method. In the CHS
cohort mean age is based on age at baseline visit, but retinal evaluation was done at 8-year follow-up visit.
4.3.1.1 CFH The association of the Y402H variant in CFH with ARM is extremely significant
(P ≤ 0.00001) in both the AREDS and CHS cohorts (Table 4.3), confirming earlier findings by
ourselves (Conley et al. 2005; Jakobsdottir et al. 2005) and others (Edwards et al. 2005;
Haines et al. 2005; Klein et al. 2005; Rivera et al. 2005). The estimated ORs for Y402H in CFH
suggest that the variant confers similar risk to all stages of ARM and both forms of advanced ARM,
GA and CNV (Fig. 4.1 and Table B1). An allele–dose effect appears to be present, with carriers of
two C alleles at higher risk of ARM than carriers of one C allele (Table 4.4) and ??fig:garm2-s1).
Despite the increased risk in carriers of two C alleles, the PAR is similar for the two risk genotypes,
owing to relatively high frequency of the CT genotype compared to the CC genotype in the general
population. PAR estimates derived from the CHS data set suggest that the CT and CC genotypes
explain 27% and 25% of ARM in the non-Hispanic white population, respectively.
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Table 4.2: Genotype distributions by ARM status
Genotype frequencies in
AREDS CHS AREDS CHS HapMap
Gene (Variant) cases cases controls controls (CEU)
and genotypes (n = 701) (n = 126) (n = 175) (n = 1051)
CFH (Y402H)
TT 0.170 0.264 0.434 0.448 . . .
CT 0.435 0.482 0.416 0.450 . . .
CC 0.395 0.255 0.150 0.103 . . .
ELOVL4 (M299V)
AA 0.781 0.742 0.711 0.802 0.717
AG 0.195 0.250 0.259 0.174 0.233
GG 0.024 0.008 0.030 0.024 0.050
PLEKHA1 (A320T)
GG 0.474 0.411 0.339 0.346 0.317
AG 0.443 0.460 0.464 0.476 0.467
AA 0.084 0.129 0.196 0.178
LOC387715 (S69A)
GG 0.313 0.442 0.645 0.604 0.583
GT 0.492 0.408 0.331 0.353 0.400
TT 0.195 0.150 0.023 0.043 0.017
Note.—AREDS cases are of grades 3–5 and AREDS controls of grade 1. Genotype counts are available by each
grade and subphenotype in Table S1 of the Supplementary Material. Description of the HapMap CEU populations
is given in the Supplementary Material.
Table 4.3: Results of allele- and genotype-association tests
CFH ELOVL4 PLEKHA1 LOC387715
Evaluated contrast in P -value for test P -value for test P -value for test P -value for test
AREDS or CHS Allele Genotype Allele Genotypea Allele Genotype Allele Genotype
AREDS
1 vs 345 ≤ 0.00001 ≤ 0.00001 0.06775 0.13963 0.00004 0.00004 ≤ 0.00001 ≤ 0.00001
1 vs 5 ≤ 0.00001 ≤ 0.00001 0.20518 0.32438 ≤ 0.00001 ≤ 0.00001 ≤ 0.00001 ≤ 0.00001
1 vs 5 (GA)b ≤ 0.00001 ≤ 0.00001 0.10465 0.21869 0.04131 0.03862 ≤ 0.00001 ≤ 0.00001
1 vs 5 (CNV)c ≤ 0.00001 ≤ 0.00001 0.03445 0.04851 ≤ 0.00001 ≤ 0.00001 ≤ 0.00001 ≤ 0.00001
CHS ≤ 0.00001 ≤ 0.00001 0.33832 0.07819 0.07626 0.22544 ≤ 0.00001 ≤ 0.00001
Note.—a Two-sided P-values from Fishers exact test.
b ARM cases have GA in both eyes.
c ARM cases have CNV in both eyes.
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Table 4.4: ORs and PAR% for subjects who are hetero- and homozygous for Y402H in CFH and S69A in LOC387715
Y402H in CFH S69A in LOC387715
Evaluated contrast in Heterozygotes (CT vs TT) Homozygotes (CC vs TT) Heterozygotes (GT vs GG) Homozygotes (TT vs GG)
AREDS or CHS ORhet PAR% ORhom PAR% ORhet PAR% ORhom PAR%
AREDS
1 vs 345 2.66 (1.81,3.92) 43 (29,54) 6.69 (4.08,10.98) 37 (24,48) 3.06 (2.13,4.39) 42 (33,50) 17.26 (6.22,47.89) 41 (36,46)
1 vs 45 2.82 (1.89,4.19) 45 (31,56) 7.06 (4.27,11.70) 38 (24,50) 3.18 (2.20,4.60) 43 (34,52) 18.30 (6.57,50.93) 43 (37,48)
1 vs 3 1.93 (1.04,3.60) 30 (-3,52) 4.95 (2.46,9.95) 29 (-2,50) 2.45 (1.42,4.23) 34 (13,49) 11.89 (3.70,38.19) 32 (18,43)
1 vs 4 2.67 (1.67,4.27) 43 (24,57) 6.33 (3.60,11.16) 35 (16,50) 2.34 (1.55,3.53) 32 (19,43) 8.19 (2.80,24.00) 24 (16,31)
1 vs 5 2.94 (1.87,4.63) 47 (29,60) 7.71 (4.46,13.34) 41 (23,54) 4.32 (2.85,6.57) 54 (43,63) 32.07 (11.30,91.01) 57 (50,64)
1 vs 45 (GA) 2.54 (1.44,4.48) 41 (15,59) 7.04 (3.69,13.41) 38 (12,56) 2.81 (1.74,4.52) 39 (23,52) 10.14 (3.28,31.31) 28 (17,38)
1 vs 4 (GA) 1.68 (0.78,3.61) 23 (-21,51) 5.55 (2.48,12.41) 32 (-8,57) 2.74 (1.46,5.17) 38 (13,56) 7.57 (1.97,29.06) 22 (5,36)
1 vs 5 (GA) 3.47 (1.69,7.14) 53 (20,72) 8.65 (3.92,19.09) 44 (7,66) 2.86 (1.63,5.02) 40 (19,55) 12.02 (3.65,39.57) 32 (17,45)
1 vs 45 (CNV) 2.48 (1.57,3.93) 40 (21,55) 5.60 (3.21,9.78) 32 (13,47) 3.30 (2.17,5.01) 45 (33,55) 15.34 (5.32,44.25) 38 (30,46)
1 vs 4 (CNV) 2.78 (1.61,4.80) 44 (20,61) 5.24 (2.74,10.01) 30 (4,50) 2.44 (1.53,3.90) 34 (17,47) 6.58 (2.07,20.90) 19 (9,28)
1 vs 5 (CNV) 2.17 (1.22,3.86) 34 (6,54) 6.00 (3.12,11.53) 34 (7,53) 5.24 (3.02,9.10) 60 (43,72) 35.22 (11.47,108.17) 60 (46,70)
CHS 1.82 (1.13,2.92) 27 (1,46) 4.22 (2.39,7.42) 25 (3,42) 1.58 (1.05,2.39) 17 (21,32) 4.75 (2.56,8.80) 14 (1,25)
Note.—95% CIs are given in the parentheses. Results for the ELOVL4 and PLEKHA1 genes are given in table B2. Results for evaluations of dominance and
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ORdom and 95% CI for PLEKHA1
Figure 4.1: Estimated crude ORs and 95% CIs for CFH, ELOVL4, PLEKHA1 and LOC387715
genes. Carriers of one or two risk alleles (RR+RN) are compared with those subjects homozygous
for the non-risk allele (NN). The solid lines denote the 95% CI corresponding to an OR (open
circle). The dotted vertical line marks the null value of an OR of 1. The contrasts that were
evaluated in AREDS and CHS cohorts are given on the vertical axis.
4.3.1.2 ELOVL4 The M299V variant in ELOVL4 is significantly associated (P = 0.034)
with exudative ARM in the AREDS sample (Table 4.3), in agreement with our previous findings
(Conley et al. 2005). However, no ORs are statistically significant at 95% significance level (Fig.
4.1 and Table B2 and Fig. B2). These results do not exclude the potential role of ELOVL4 in
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ARM, but do not strongly support it. The small number of individuals with exudative ARM did
not allow for subphenotype analysis in the CHS cohort.
4.3.1.3 PLEKHA1 and LOC387715 The association of the S69A variant in LOC387715
with all presentations of ARM is extremely significant (P ≤ 0.00001) in both the AREDS and
CHS data sets (Table 4.3), confirming earlier findings by ourselves (Jakobsdottir et al. 2005)
and others (Rivera et al. 2005; Schmidt et al. 2006). The A320T variant in PLEKHA1, which
is located on the same haplotype block as LOC387715, is highly significant (P = 0.00004) in the
AREDS sample but only borderline significant (P = 0.08) in the CHS sample. The degree of linkage
disequilibrium between A320T and S69A is statistically significant in both AREDS (D′ = 0.66)
and CHS (D′ = 0.65) controls. In order to identify which gene, PLEKHA1 or LOC387715, more
likely harbors the true ARM-predisposing variant, we applied the haplotype method (Valdes and
Thomson 1997). According to the haplotype method, the relative frequency of alleles at neutral
variants is expected to be the same in cases and controls for a haplotype containing all the predis-
posing variants. The results based on applying the method suggest that S69A in LOC387715, and
not A320T in PLEKHA1, is an ARM–predisposing variant (Appendix B., Distinguishing between
PLEKHA1 and LOC387715 –Results). Further, by permutation testing, the null hypothesis: H0 :
the S69A variant in LOC387715 fully accounts for the ARM predisposition to the PLEKHA1–
LOC387715 haplotype block, is not rejected (P = 0.92 in the AREDS data, P = 0.45 in the
CHS data), while a similar hypothesis for A320T is rejected (P ≤ 0.0001 in the AREDS data,
P = 0.0002 in the CHS data).
The S69A variant in LOC387715 shows different risk patterns than Y402H in CFH. The
variant appears to increase the risk of severe ARM substantially more than the risk of mild ARM
(fig. 4.1, table B2 and fig. B4) in the AREDS data where severity of disease is differentiated.
For example, the OR for AREDS cases of grade 3, who carry one or two T alleles, is 3.07 (95%
CI 1.82–5.17), while the OR for AREDS cases, with CNV in both eyes, who carry one or two T
alleles, is 7.21 (95% CI 4.24–12.27). Similar to CFH, S69A shows an allele-dose effect without
dramatic differences in the PAR of the GT and TT genotypes (table 4.4 and fig. B4). Since only
four AREDS controls are TT homozygous at S69A, point estimates and CIs, for recessive and
homozygote contrasts, derived from regular logistic regression were compared with estimates from
exact regression [models fitted in SAS software release 8.2 (SAS Institute Inc., Cary, NC, USA)].
These quality checks revealed no major differences in point estimates (which is the basis of the
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PAR estimates) and lower confidence limits (which is the basis of comparison with the ORs), but
the upper confidence limits were higher (results not shown).
4.3.2 Interaction analyses
We used logistic regression modeling to build a model of the joint contribution of CFH and
LOC387715, CFH and cigarette smoking and LOC387715 and cigarette smoking. A series of mod-
els were fitted in order to draw inferences about the most likely and most parsimonious model(s).
As described by North et al. (2005), models were compared using the Akaike information criterion
(AIC). When the most parsimonious model had been identified we estimated joint ORs of the risk
factors. Separate estimates were calculated from each cohort. In order to maximize the AREDS
sample size, no subphenotype or subgrade analyses were performed; AREDS cases of grade 3–5
were compared with AREDS controls of grade 1.
In a previous article (Jakobsdottir et al. 2005), we found no evidence of interacting effects
of the CFH and PLEKHA1/LOC387715 loci; the joint action of the two loci was best described
by independent multiplicative effects (additive on a log–scale). Rivera et al. (2005) reported that
S69A in LOC387715 acted independently of Y402H in CFH. Schmidt et al. (2006) also arrived
at the same most parsimonious model. The AREDS and CHS data also suggest that the two
genes contribute independently to disease risk. The best fitting model (the model with the smallest
AIC) derived from the AREDS data is an additive model with an interaction term. This model,
with AIC of 721.4, does however not provide a significantly better fit (AIC difference < 2) than
a simpler additive model with AIC of 723.0. The additive model is the most parsimonious model
(AIC=635.1) derived from the CHS data and is also the best fitting model (Table 4.5). Joint ORs
for combinations of risk genotypes at Y402H and S69A were computed to further understand the
joint action of the two loci (Table B4). Using all cases regardless of severity, the AREDS data
suggest that individuals heterozygous for the risk allele at one of the loci and homozygous for the
non-risk allele at the other are more susceptible to ARM than individuals with no-risk allele at
both loci (for the CT–GG joint genotype, OR 2.8, 95% CI 1.6–5.0; for the TT–GT joint genotype,
OR 3.2, 95% CI 1.7–6.0). The ARM risk more than doubles if a person is heterozygous at both
loci (for the CT–GT joint genotype, OR 7.2, 95% CI 3.8–13.5) and being homozygous for the risk
allele for at least one of the loci further increases the risk. The joint ORs estimated from the CHS
data show a similar pattern, but having only one risk allele is not sufficient to increase the risk (for
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the CT–GG joint genotype, OR 1.3, 95% CI 0.6–2.7; for the TT–GT joint genotype, OR 1.2, 95%
CI 0.5–2.8).
A recent study (Schmidt et al. 2006) reported a strong statistical interaction between geno-
types at S69A and smoking, both on binary (ever versus never smoked) and continuous scale
(pack-years of smoking). We fail to replicate this finding in both the AREDS and CHS data
sets (table 4.5). Results from the AREDS sample suggests that the joint effects of Y402H and
smoking are best described by independent multiplicative effects, without significant dominance or
interacting effects. On the other hand, the model that best describes the CHS data includes only
additive effects of Y402H. Results from the AREDS data suggest that the joint effects of S69A and
smoking are best described by independent multiplicative effects, without significant dominance or
interacting effects. The CHS data implicate a model with only S69A. When smoking exposure is a
continuous variable (pack-years of smoking) and the S69A genotypes are coded in additive fashion,
the interaction term is not significant (P = 0.40) in the CHS data. Pack-years of cigarette smoking
were not available for participants in the AREDS study. To further understand the combined effect
of the genes and cigarette smoking, joint ORs of risk genotypes at each gene and smoking were
estimated from the AREDS data (table B7). The results suggest that, while the risk of ARM
due to any of the risk genotypes (at Y402H and S69A) is elevated in smokers, both genes have
substantially more influence on ARM risk than cigarette smoking. Both the model fitting approach
and a simple 2 test (P = 0.71) show that the main effects of cigarette smoking are insignificant (on
binary scale) in the CHS data.
4.3.3 APOE results
Main effects of the APOE gene in ARM were tested using the CHS data. Neither the distribution
of APOE − 4 carriers (P = 0.41) nor APOE − 2 (P = 0.42) carriers was significantly different
between cases and controls, when compared to APOE − 3/3.
4.3.4 Meta-analyses
4.3.4.1 Meta-analysis of CFH We used a meta-analysis approach to pool estimated ORs for
Y402H from 11 independent data sets [including the CHS and AREDS cohorts reported here (Table
B10)]. This resulted in the analysis of 5451 cases and 3540 controls all of European or European
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Table 4.5: Results of fitting two-factor models by logistic regression
AREDS data CHS data
AIC AIC AIC AIC
Two-Factor Model difference difference
Y402H (Factor 1) and
S69A (Factor 2)
ADD1 799.3 77.9 652.7 17.6
ADD2 786.1 64.7 656.0 21.0
ADD-BOTH 723.0 1.7 635.1 0.0
DOM1 801.2 79.8 654.4 19.3
DOM2 786.9 65.5 656.0 21.0
DOM-BOTH 726.5 5.1 636.3 1.3
ADD-INT 721.4 0.0 635.8 0.8
ADD-DOM 724.3 3.0 638.8 3.8
DOM-INT . . . . . . 637.8 2.8
Y402H (Factor 1) and
Smoking (ever vs. never)
ADD1 787.3 6.0 677.3 0.0
SMOKE 848.3 67.0 700.6 23.3
ADD1-SMOKE 781.3 0.0 679.1 1.8
DOM1 789.3 8.0 679.0 1.7
ADD1-SMOKE-INT 783.2 1.8 678.3 1.0
DOM1-SMOKE-INT 786.6 5.3 681.9 4.6
S69A (Factor 2) and
Smoking (ever vs. never)
ADD2 774.0 6.1 745.6 0.1
SMOKE 842.9 75.0 765.2 19.8
ADD2-SMOKE 767.9 0.0 747.3 1.8
DOM2 774.7 6.7 745.5 0.0
ADD2-SMOKE-INT 769.7 1.8 749.1 3.7
DOM2-SMOKE-INT 772.4 4.4 748.9 3.4
Note.—95% CIs are given in the parentheses. Results for the ELOVL4 and PLEKHA1 genes are given in table B2.
Results for evaluations of dominance and recessive effects are given table B2.
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American descent. The results confirm the increased ARM risk due to the C allele in the non-
Hispanic white population (fig. 4.2 and table B11). The pooled estimates have narrower CI than
any individual study, and non-overlapping CI for hetero- and homozygote ORs: ORhet=2.43 (95%
CI 2.17–2.72) and ORhom=6.22 (95% CI 5.38–7.19), when assuming homogeneity across studies.
When the analysis is performed under heterogeneity, the point estimates are essentially the same and
the CIs are slightly wider. Leave-one-out sensitivity analyses, under a fixed effect model, show that
no study has dramatic influence on the pooled estimates (table B11). The study by Rivera et al.
(2005) changes the estimates more than any other study; when the study is excluded, the ORdom
and ORhet are approximately 0.2 higher, while the ORrec and ORhom are lowered by approximately
0.2. The Rivera et al. study is the only study where the genotype distribution, in the control
group, deviates from Hardy–Weinberg equilibrium [HWE (P = 0.03)]. The allele and genotype
distributions, in cases and controls, are strikingly similar across studies. However, the genotype
distribution in CHS cases differs from the other studies and the frequency of the CC risk genotype
is lower compared to other cohorts (fig. B5).
4.3.4.2 Meta-analysis of LOC387715 Meta-analysis of the risk associated with S69A in
ARM included five independent data sets [including the CHS and AREDS cohorts reported here
(Table B12)]. This resulted in the analysis of 3147 cases and 2381 controls all of European or
European American descent. The studies of LOC387715 are more heterogeneous than the studies
of CFH ; ORdom and ORhet differ significantly across studies (P < 0.01 and 0.02, respectively). The
results support earlier findings of the association of the T allele with increased ARM risk (table
B13). Carriers of two T alleles are at substantially higher risk than are carriers of one T allele;
when accounting for between-study variation, the ORhet and ORhom are 2.48 (95% CI 1.67–3.70)
and 7.33 (95% CI 4.33–12.42), respectively. The genotype distribution is similar across all control
populations and across all ARM populations, except the CHS ARM population (fig. B6).
4.4 DISCUSSION
During the past year, major discoveries of associations of the CFH and PLEKHA1/LOC387715
genes with ARM were published. A number of reports established a strong association of the Y402H
coding change in CFH with ARM and three reports found an association, of similar magnitude as
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the association of Y402H, of the S69A coding change in LOC387715 with ARM. Both of those genes
lie within chromosomal regions, CFH on 1q31 and LOC387715 on 10q26, consistently identified
by family-based linkage studies (Seddon et al. 2003; Majewski et al. 2003; Iyengar et al. 2004;
Weeks et al. 2001; Weeks et al. 2004; Klein et al. 1998; Kenealy et al. 2004).
Because the majority of the studies of Y402H and all three studies of S69A were specially
designed to search for (and find) genes involved in ARM complex etiology, it is possible that
they overestimate the effect size of the risk alleles at Y402H and S69A. Therefore, we analyzed
two independent case–control cohorts with varying inclusion and exclusion criteria based on ARM
status, the AREDS and CHS cohorts. The AREDS cohort did have inclusion and exclusion criteria
relevant to severity of ARM and both affected and non-affected individuals were enrolled (Age
Related Eye Disease Study Group 1999). In contrast, the CHS cohort is a population-based
cohort that utilized community-based recruitment of individuals 65 years and older with no inclusion
and exclusion criteria relevant to ARM status (Fried et al. 1991). Retinal assessments in the CHS
cohort were not conducted until the 8-year follow-up visit. Given the difference in ascertainment of
subjects into the two studies, replication of association of a candidate gene in both cohorts greatly
strengthens the support for its causal involvement in ARM pathogenesis.
We evaluated previously reported associations of four genes, CFH (1q31), ELOVL4 (6q14),
PLEKAH1 (10q26) and LOC387715 (10q26). Variants in both CFH and LOC387715 are extremely
significantly (P ≤ 0.00001) associated with ARM in both AREDS and CHS cohorts. Both variants
show an allele-dose effect on the ARM risk and a model of independent multiplicative contribution
of the two genes is most parsimonious in both AREDS and CHS cohorts. The A320T coding
change in the PLEKHA1 gene, adjacent to and in linkage disequilibrium with LOC387715 on
10q26, is significantly associated with ARM in the AREDS cohort (P = 0.00004), but not in
the CHS cohort (P = 0.08). Because of extensive linkage disequilibrium between PLEKHA1 and
LOC387715 in our initial study population we could not, with reasonable certainty, distinguish
between their association signals. Our results based on applying the haplotype method to both
the AREDS and CHS cohorts, combined with the findings of Rivera et al. (2005), who used
conditional haplotype analysis and detected, for the first time, a weak expression of LOC387715 in
the retina, and Schmidt et al. (2006), who detected only a weak association signal at PLEKHA1,
indicate that S69A in LOC387715 is most likely the major ARM-predisposing variant on 10q26.
The results of the haplotype method show that PLEKHA1 is not sufficient to account for the ARM-
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predisposition at 10q26; however, we cannot exclude the possibility that A320T in PLEKHA1 may
be on a causative haplotype with S69A and other unknown variants.
The replication of associations of CFH and LOC387715 genes with ARM in AREDS and
CHS cohorts, two cohorts with different study designs, continues to provide strong support for their
involvement in ARM. Variable findings for PLEKHA1 in AREDS and CHS cohorts do however need
to be considered in the light of differences between the two cohorts. In addition to differences in
ascertainment of the case and control populations, the evaluation of retinal changes, documentation
of retinal findings and prevalence of advanced ARM differed between the two cohorts. In the CHS
study, fundus photography was only available for one randomly selected eye and the photography
was performed with non-dilated pupils and these limitations could certainly influence the sensitivity
to detect disease pathology, although this is more likely to influence the detection of early retinal
changes. The proportion of advanced ARM in the entire CHS cohort that was evaluated at the
8-year follow-up evaluation was 1.3% (Klein et al. 2003) compared to 17% in the AREDS (Age
Related Eye Disease Study Group 2000) and the variation in the proportion of advanced
ARM disease pathology between the two cohorts could lead to variation in findings, especially if
a gene is more likely to influence progression of the disease. In addition, one important difference
between these two cohorts is the timing of the retinal evaluations. AREDS participants had retinal
evaluations conducted at baseline as well as during follow-up evaluations, whereas CHS participants
had retinal evaluations done eight or more years after enrollment, when they would have been at
least 73 years old. It is possible that survival to the retinal evaluation for the CHS participants could
bias the population available for this particular type of study. Potential confounding issues related
to the use of the AREDS cohort are that subjects in categories other than the unaffected group
were randomized into a clinical trial using vitamin and mineral supplements to evaluate the impact
of these on ARM progression and there is some evidence indicating that unaffected subjects in
category 1 have different demographic characteristics than affected subjects in the other categories
(Age Related Eye Disease Study Group 2000). It is not clear whether these could impact
the results of our study, but it should be considered when findings are interpreted.
As mentioned previously, most studies that have investigated the genetic etiology of ARM
were designed to optimize identification of regions of the genome housing susceptibility genes for
ARM and for ARM candidate gene testing. Published attributable risks range from 43 to 68%
(Edwards et al. 2005; Haines et al. 2005; Jakobsdottir et al. 2005; Schmidt et al. 2006)
for the Y402H variant in CFH and from 36 to 57% (Jakobsdottir et al. 2005; Schmidt et al.
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2006) for the S69A variant in LOC387715. Interestingly, the PARs for the CHS population are
lower than those previously published: 41% for the Y402H variant in CFH and 27% for the S69A
variant in LOC387715 (table B2). Because the majority of the CHS cases have moderate ARM
the PAR estimates derived from the CHS data are not completely comparable with estimates from
previous studies in which the proportion of patients with advanced ARM was considerably higher.
However, they are comparable to estimates derived from using AREDS cases of grade 3. Those
estimates are within the previously published range of PARs: 49% for Y402H in CFH and 45%
for S69A in LOC387715. These findings may indicate that the ARM attributed to these two
susceptibility variants may be lower than previously thought, given that the CHS cohort was not
ascertained based on ARM status. A prospective design is needed to more precisely estimate the
relative risks, which are approximated by ORs estimated from retrospective case–control designs,
and corresponding PARs.
We were not able to replicate the association of ELOVL4 with overall ARM (Conley et al.
2005). The number of individuals with exudative ARM allowed us to perform subphenotype anal-
ysis in the AREDS, but not the CHS cohort. Subphenotype analysis was especially important with
regard to ELOVL4, where our previous findings indicated a role for ELOVL4 in exudative ARM;
this is trending towards significance in the AREDS cohort. Given the lack of strong association
and significant ORs for ELOVL4 in ARM susceptibility in both cohorts and the lack of association
reported by Ayyagari et al., it is very unlikely that ELOVL4 plays a substantial role in ARM
susceptibility. The power to detect an OR of 0.6 for overall ARM is reasonable, with type I error
rate 5%, minor allele frequency 0.15 and population prevalence 6% the power is ∼81% in AREDS
and ∼69% in CHS. The power to detect the same effect in exudative ARM is only 53% in AREDS
data, under the same conditions. Therefore, the possibility that ELOVL4 plays a role in overall
ARM is unlikely but mild effect in exudative ARM cannot be refuted. These power estimates were
performed using Quanto (32).
We also used the CHS cohort to test whether the ε4 or ε2 alleles of the APOE gene are
associated with ARM. In several studies, the ε2 allele is suggested to contribute to disease risk and
the ε4 allele has been found to protect from ARM. Our results do not reach statistical significance
and do not support the hypothesized role of the gene in ARM pathogenesis.
The AREDS and CHS data support the independent contribution of Y402H in CFH and
S69A in LOC387715 to ARM susceptibility. A multiplicative risk model for these two variants is
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the most parsimonious based on evaluation of the AREDS and CHS cohorts; this model was also
supported by our previous paper (Jakobsdottir et al. 2005) as well as data presented byRivera
et al. (2005) and Schmidt et al. (2006). The ARM risk appears to increase as the total number of
risk alleles at Y402H and S69A increases (table B4).
Prior to the discovery of CFH and LOC387715 cigarette smoking was one of the more
important known ARM-related risk factors. Cigarette smoking is generally accepted as a modifiable
risk factor for ARM; van Leeuwen et al. provide a review of the epidemiology of ARM and discuss
the support of smoking as ARM risk factor (van Leeuwen et al. 2003). Schmidt et al. (2006)
recently reported statistically significant interaction between LOC387715 and cigarette smoking in
ARM. Their data suggested that the association of LOC387715 with ARM was primarily driven
by the gene effect in heavy smokers. Our own analyses of interaction do not support this finding
and the AREDS data suggest that the joint action of S69A and smoking is multiplicative.
A role for CFH and LOC387715 in ARM susceptibility is further supported via the results of
our meta-analysis. The meta-analysis, which include the CHS and AREDS cohorts reported in this
article, indicates that having one or two copies of the risk allele at CFH or LOC387715 increases
the risk of ARM, and those who have two copies are at higher risk. The combined results from
all studies as well as the results from each independent study were remarkably tight (figs. 4.2 and
4.3). One known limitation of meta-analysis is the susceptibility to publication bias. Generally,
such bias is a result of non-publication of negative findings (Normand 1999). In the case of CFH
and LOC387715, all published studies have reported strong association with ARM in the same
direction, with the risk allele for CFH being the allele that codes for histidine and the risk allele
for LOC387715 being the allele that codes for serine. We expect the preferential publication of
statistically significant associations to show random directionality if the significant association is a
false-positive result (Lohmueller et al. 2003). It is therefore unlikely that the consistency of the
association of CFH and LOC387715 with ARM is a result of publication bias.
While the results of our statistical analyses are in agreement with LOC387715 being the
major ARM–related gene on 10q26, they do not prove causality. The possible causal role of CFH
in ARM pathogenesis has been further supported by the localization of its protein within drusen
deposits of ARM patients and involvement in activation of the complement pathway. Regarding
LOC387715, little is currently known about the biology of the gene and nothing about how its
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protein may affect ARM susceptibility. Until recently the expression of LOC387715 appeared
limited to the placenta, but recently weak expression was reported in the retina (Rivera et al.
2005), which opens up the possibility of a tissue-specific role of the gene.
In summary, our results continue to support a role of both CFH and LOC387715 in etiology
of ARM, given that both genes harbor variants highly associated with ARM, regardless of how the
subjects were ascertained. Evaluation of PLEKHA1 and ELOVL4 in the AREDS and CHS cohorts
demonstrates that these genes are much less likely to play role in ARM susceptibility. The CFH
and LOC387715 genes appear to act independently in a multiplicative way in ARM pathogenesis
and individuals homozygous for the risk alleles at either locus are at highest risk. The continued
support for these genes in ARM susceptibility will hopefully bring us closer to being able to utilize
the information in these genes to identify at risk individuals and provide a rational basis for future
clinical trials to test preventive therapies in high-risk cohorts as well as to provide insights into the
basic pathogenesis of this condition.
4.5 MATERIALS AND METHODS
4.5.1 Cardiovascular health study (CHS) participantssampling and phenotyping
CHS is a population–based, longitudinal study primarily designed to identify factors related to
cardiovascular disease in those aged 65 and older. Retinal assessments were performed at the 8-
year follow–up visit. Community–based recruitment took place in Forsyth County, NC; Sacramento
County, CA; Washington County, MD; and Pittsburgh, PA. Medicare eligibility lists of the Health
Care Financing Administration were utilized to identify individuals who were aged 65 and older.
Individuals aged 65 years and older living in the households of list members were also eligible.
Inclusion criteria were minimal and included being non-institutionalized, expected to remain in the
area for at least 3 years, able to give informed consent, not wheelchair-bound, not receiving hospice
care and not receiving radiation or chemotherapy for cancer (Fried et al. 1991). DNA samples
from the CHS from participants who consented for genetic studies were used for this research. Only
DNA samples from subjects who had a retinal examination where the findings fit our criteria of a
case or control were included in this study.
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CHS subjects usually had the retina of one randomly selected eye photographed and the
photographs were graded by Dr. Gorin using the same classification model that was described in
prior publications (Weeks et al. 2004). Only Caucasian individuals are included in the analysis,
as the sample size of other groups with ARM is too small for reasonable results: there were 180
black controls but only three cases, and five controls of other races. All CHS cases (n=126)
used for analyses are “Type A” which falls into our most stringent model for clinical classification
(Weeks et al. 2004). Individuals in this category are clearly affected with ARM based on extensive
and/or coalescent drusen, pigmentary changes (including pigment epithelial detachments) and/or
the presence of end-stage disease (GA and/or CNV membranes). Very few CHS cases had end-stage
ARM, GA or CNV (Table 4.1); therefore, analyses of specific subtypes of ARM were not conducted.
All CHS controls (n=1051) were of AREDS grade 1. A few potential controls (n=22) had unclear
signs of GA or CNV and were excluded from analyses.
4.5.2 Age-related eye disease study (AREDS) participantssampling and phenotyping
AREDS is a prospective, multicenter study of the natural history of ARM and age-related cataract
with a clinical trial of high-dose vitamin and mineral supplementation embedded within the study.
Individuals recruited into the AREDS study were men and women aged 55–80 years at enrollment;
these individuals were required to be free of any condition or illness that would hinder long-term
follow-up. Inclusion criteria were minimal and included having ocular media clear enough to allow
for fundus photography and either no evidence of ARM in either eye or having ARM in one eye
while the other maintained good vision (20/30 or better) (Age Related Eye Disease Study
Group 1999). DNA samples from subjects who consented for genetic studies from the NEI-AREDS
Genetic Repository were used for this research.
ARM status was assigned using the AREDS ARM grading system and based on phenotypes
assigned at the most recent follow-up visit. Again, only Caucasian individuals are included in
the analysis, as the sample size of other groups is too small for reasonable results: there are only
15 African American, two Hispanic and three individuals of other races. AREDS cases (n=701)
consisted of grade 3, 4 and 5. AREDS subjects of grade 3 (n=96) have ARM but do not suffer
from end-stage ARM, subjects of grade 4 (n=266) have end-stage ARM in one eye and subjects of
grade 5 (n=339) have end-stage ARM in both eyes. AREDS controls (n=175) have AREDS grade
1 (grade 2 individuals were excluded prior to analyses).
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4.5.3 Genotyping
The M299V variant in ELOVL4 (rs3812153 ), the Y402H variant in CFH (rs1061170 ) and the
S69A variant in LOC387715 (rs10490924 ) were genotyped using RFLP techniques. The primers,
annealing temperatures and restriction endonuclease for each assay were: 5′–AGATGCCGATG
TTGTTAAAAG–3′ (F), 5′–CATCTGGGTATGGTATTAAC–3′ (R), 50 ◦C and BspH I for ELOVL4 ;
5′–TCTTTTTGTGCAAACCTTTGTTAG–3′ (F), 5′–CCATTGGTAAAACAAGGTGACA–3′ (R),
52 ◦C and NlaIII for CFH ; 5′–GCACCTTTGTCACCACATTA–3′ (F), 5′–GCCTGATCATCTGCA
TTTCT–3′ (R), 54 ◦C and PvuII for LOC387715.
The A320T variant in PLEKHA1 (rs1045216 ) was genotyped using 5’ exonuclease Assay-on-
Demand TaqMan assays (Applied Biosystems Incorporated). Amplification and genotype assign-
ments were conducted using the ABI7000 and SDS 2.0 software (Applied Biosystems Incorporated).
For all genotyping conducted for this research, double-masked genotyping assignments were made
for each variant, compared and each discrepancy addressed using raw data or by re-genotyping.
4.5.4 Association analyses
SNP-disease association was measured with allele- and genotype χ2 tests, and P-values were simu-
lated using 100,000 replicates; in cases with one or more expected cell numbers less than five, the
Fisher’s exact test was used. The strength of the association was estimated by crude OR and PAR.
A general formula was used to calculate the PAR: PAR=Pr(OR−1)/(1+Pr(OR−1)), where Pr is
the prevalence of the risk factor in the general population. Estimates of Pr were derived from the
CHS controls; this is reasonable, because the CHS subjects were not selected on the basis of ARM
disease status, and the number of CHS controls is large (n=1,051). Confidence intervals for the
PARs were derived using asymptotic normal distribution of log(1−PAR) and transforming to an
interval for the PAR. The CIs derived in this way are likely to be too narrow when the risk factor is
rare (Pr< 0.1) and sample sizes are small (Walter 1975). For comparison purposes, ORs adjusted
(ORadj) for age and gender were estimated. Logistic regression models were used to calculate both
crude and adjusted ORs, using R (37). The less frequent allele in the control group was considered
the risk allele, and the OR and ORadj were calculated by comparing those homozygous for the risk
allele (RR) to the baseline group [those homozygous for the normal allele (NN)] and comparing
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those heterozygous for the risk allele (RN) to the baseline group. The contrasts for dominance (RR
and RN versus NN) and recessive (RR versus RN and NN) effects were also evaluated.
4.5.5 Distinguishing between PLEKHA1 and LOC387715
We employed the haplotype method (Valdes and Thomson 1997) to identify which one of the two
loci, A320T in PLEKHA1 or S69A in LOC387715, is more likely the actual disease predisposing
variant in the 10q26 region. The basis of the haplotype method is simple and elegant [for a
mathematical proof, see Valdes and Thomson (1997)]. If all predisposing variants are included
on a haplotype, then the neutral variants are expected to be in the same ratio in cases and controls
on a particular disease-predisposing haplotype, although the actual frequencies may differ. On the
other hand, if not all predisposing variants have been identified, equality in the ratios of haplotype
frequencies of non-predisposing variants is not expected. The expected ratios for the A320T–S69A
haplotype are formulated in Appendix B.. Two null hypotheses were tested: one that A320T
fully accounts for the ARM predisposition to the PLEKHA1–LOC387715 haplotype block, and
the other that S69A fully accounts for the ARM predisposition to the PLEKHA1–LOC387715
haplotype block (for details on the hypotheses and permutation procedure to generate P values, see
the Appendix B.). The program SNPHAP (Clayton ) was used to estimate haplotype frequencies
and individual haplotypes. SNPHAP uses the EM algorithm to calculate a maximum likelihood
estimate of haplotype frequencies given the unphased genotype data. The posterior probabilities of
individual haplotype assignments exceed 87% for every individual typed at both A320T and S69A.
For 80% of the haplotype assignments the underlying genotype at one or both loci is homozygous
and hence the posterior probability is 100%.
4.5.6 Interaction analyses
The analyses of interaction were three-fold: first, we tested for interacting genetic effects of Y402H
in CFH and S69A in LOC387715 in both CHS and AREDS samples, then we tested for interaction
of both Y402H and S69A with smoking history in both CHS and AREDS samples and finally we
calculated joint ORs of the three risk factors.
We followed a modeling strategy proposed by North et al. (2005). Series of logistic regression
models are fitted to the AREDS and CHS data sets in order to find the model that best describes
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the joint effects of CFH and LOC387715. For each genotype, models allowing for additive effects
(ADD1, ADD2 and ADD-BOTH), and models which incorporate dominance effects (DOM1, DOM2
and DOM-BOTH) are fitted. The ADD1 model includes only the term x1 for additive effects of
CFH, coded as −1 for genotype TT at Y402H, as 0 for genotype CT and as 1 for genotype CC. The
ADD2 includes only model term x2 for additive effects of LOC387715, coded as −1 for genotype
GG at S69A, as 0 for genotype GT and as 1 for genotype TT. The ADD-BOTH models the joint
additive effects of CFH and LOC387715. The DOM1 incorporates dominance effects to ADD1, and
includes x1 and z1, coded as 0.5 for genotype CT and −0.5 for genotypes TT and CC at Y402H.
The DOM2 model similarly incorporates dominance effects to ADD2, and includes x2 and z2, coded
as 0.5 for genotype GT and −0.5 for genotypes GG and TT at S69A. DOM-BOTH models the
joint dominance effects of CFH and LOC387715. Three further models, that model the interaction
between CFH and LOC387715 are fitted: ADD-INT includes the product term x1∗x2, ADD-DOM
includes x1 ∗ x2, x1 ∗ z2 and z1 ∗ x2 and DOM-INT includes x1 ∗ x2, x1 ∗ z2, z1 ∗ x2 and z1 ∗ z2.
The above modeling strategy was modified to investigate the joint effects of CFH and smok-
ing, and the joint effects of LOC387715 and smoking. The modified approach is the same as used by
Schmidt et al. (2006) to test for interaction between LOC387715 and smoking. The coding scheme
is the same, as above, except that smoking is coded as 0 for never smokers and 1 for ever smok-
ers. The models fitted for the effects of CFH and smoking are: ADD1, SMOKE, ADD1-SMOKE,
DOM1, ADD1-SMOKE-INT and DOM1-SMOKE-INT, and the models fitted for the effects of
LOC387715 and smoking are: ADD2, SMOKE, ADD2-SMOKE, DOM2, ADD2-SMOKE-INT and
DOM2-SMOKE-INT.
All models were compared by the AIC. Models for which the AIC differed by < 2 are
considered indistinguishable (North et al. 2005), and the model with fewer parameters was chosen
as the most parsimonious model. Since adjusting for age and gender did not affect the estimates
of ORs for Y402H nor S69A (table B3), and to keep number of parameters as small as possible,
no adjustment was made for these covariates when modeling interaction. Based on the results of
the above interaction analyses, joint ORs were calculated.
4.5.7 APOE analyses
Previous studies have reported possible protective and harmful effects of the apolipoprotein E
(APOE ) gene in ARM. The ε4 allele may have protective effects (Klaver et al. 1998; Schmidt
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et al. 2000; Schmidt et al. 2002; Baird et al. 2004; Zareparsi et al. 2004), whereas the least
frequent allele, ε2, may increase the risk of ARM (Klaver et al. 1998; Zareparsi et al. 2004). The
APOE variant was genotyped by CHS and its association with ARM was assessed in this study.
Individuals were classified by APOE genotype into individuals with APOE -ε3/ε3 genotype, and
APOE -ε2 and APOE -ε4 carriers (denoted APOE -ε2/* and APOE -ε4/*, respectively); individuals
with APOE -ε2/ε4 genotype were included in both the APOE -ε2/* and APOE -ε4/* groups. χ2
tests were used to test for differences in distributions of APOE -ε3/ε3 and APOE -ε2/*, and APOE -
ε3/ε3 and APOE -ε4/*, genotypes in controls and cases.
4.5.8 Meta-analyses
We undertook a meta-analysis approach to pool estimated OR from previously published reports on
CFH and LOC387715 and the two reports presented here. Initially data were analyzed, assuming
the between-study variation is due to chance, and fixed-effects model was employed. Under the
fixed-effect model, the maximum likelihood estimator of the pooled OR is an average of individual
estimates, weighted by the inverse of their variances, and the variance of the pooled OR is estimated
by the inverse of the sum of individual weights. Meta-analyses under homogeneity were performed
in R (R Development Core Team 2005). The assumption of homogeneity was checked using a
χ2 test. However, tests of homogeneity tend to have low power, and therefore, for comparison, we
also pooled the OR in a random effects setting. Meta-analyses under heterogeneity were performed
using the method of restricted maximum likelihood (REML), as implemented in SAS Proc Mixed
[SAS software release 8.2 (SAS Institute Inc.)]. The pooled REML estimator is identical to the
DerSimonian-Laird estimator (DerSimonian and Laird 1986; van Houwelingen et al. 2002).
The SAS codes by van Houwelingen et al. (van Houwelingen et al. 2002) were modified to
perform the analyses under heterogeneity. A literature search was performed in PubMed in May
2006 and was limited to the English language. CFH studies were found by entering the search
phrase: (CFH or ‘Complement Factor H) and (‘Age-related macular degeneration’ or ‘Age-related
maculopathy or AMD or ARM). Similarly, LOC387715 studies were found using the search phrase:
LOC387715 and ‘Age-related macular degeneration or ‘Age-related maculopathy or AMD or ARM.
The only inclusion criterion was that the research participants were Caucasian.
The Y402H variant within CFH has been found strongly associated with ARM in 11 studies
(Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005; Hageman et al. 2005; Conley et al.
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2005; Zareparsi et al. 2005; Sepp et al. 2006; Rivera et al. 2005; Souied et al. 2005; Magnusson
et al. 2006; Jakobsdottir et al. 2005; Schmidt et al. 2006); two of these 11 studies are ours,
so only the results from our Jakobsdottir et al. (2005) paper, that evaluated all contrasts, were
used in meta-analysis. The Klein et al. (2005) study used a small subset of the AREDS sample,
and the Magnusson et al. (2006) paper only reported allele-based ORs and no genotype counts.
Therefore, these two studies were not included. Results from the Haines et al. (2005) study
were included in pooled estimates of ORs for hetero- and homozygotes; genotype counts were not
available to evaluate contrasts for dominance and recessive effects. Three studies have reported
highly associated variant, S69A, within the hypothetical LOC387715 (Jakobsdottir et al. 2005;
Rivera et al. 2005; Schmidt et al. 2006). All three reports on LOC387715 were included in
the meta-analysis. Research participants in all studies of CFH and LOC387715 are non-Hispanic
whites of European and European American descent. Tables B10 and B12 summarize the studies






















































































ORhom and 95% CI
Figure 4.2: Estimated ORs and 95% CIs, derived from data sets included in meta–analysis of
Y402H in CFH, and pooled estimates from fixed and random effect models. The top figure shows
ORhet (OR for CT heterozygotes compared to TT) and the bottom figure shows ORhom (OR
for CC homozygotes compared to TT). ‘Hage–C’ and ‘Hage–I denote estimates derived from the
Columbia and Iowa cohorts of Hageman et al., respectively, and Jakobs denotes estimates from the
Jakobsdottir et al. paper. ‘Fixed denotes pooled estimates derived from all the studies assuming
the between-study variability is due to chance. ‘Random denotes pooled estimates derived from
all the studies allowing for heterogeneity across studies. ‘nARM is the total number of ARM cases
included in the estimates and ‘ncon is the total number of controls without ARM included in the
estimates. For the Haines et al. study ‘nARM and ‘ncon refer to the whole sample (individuals of all


















































ORhom and 95% CI
Figure 4.3: Estimated ORs and 95% CIs, derived from data sets included in meta–analysis of
S69A in LOC387715, and pooled estimates from fixed and random effect models. The top figure
shows ORhet (OR for GT heterozygotes compared to GG) and the bottom figure shows ORhom
(OR for TT homozygotes compared to GG). ‘Jakobs denote estimates from the Jakobsdottir et al.
paper. ‘Fixed denotes pooled estimates derived from all the studies assuming the between-study
variability is due to chance. ‘Random denotes pooled estimates derived from all the studies allowing
for heterogeneity across studies. ‘nARM is the total number of ARM cases included in the estimates
and ‘ncon is the total number of controls without ARM included in the estimates. For the Haines
et al. study, ‘nARM and ‘ncon refer to the whole sample (individuals of all genotypes). The dotted
vertical line marks the point estimate of the pooled OR under homogeneity (‘Fixed).
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5.0 C2 AND CFB GENES IN AGE-RELATED MACULOPATHY AND JOINT
ACTION WITH CFH AND LOC387715 GENES
This section has been published in PLoS ONE volume 3, issue 5, pages e2199 (Jakobsdottir
et al. 2008). The copyright of the article belongs to the authors and the article is an open-
access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited. No changes have been made to the published version of the paper,
except that tables and figures have been renumbered, the citations are of different style and some
minor formatting has been made to keep this chapter coherent to the reminder of the thesis. My
contribution to this paper was in writing all components of the paper, data analysis and script
writing for method implementation.
5.1 ABSTRACT
Background Age-related maculopathy (ARM) is a common cause of visual impairment in the
elderly populations of industrialized countries and significantly affects the quality of life of those
suffering from the disease. Variants within two genes, the complement factor H (CFH) and the
poorly characterized LOC387715 (ARMS2), are widely recognized as ARM risk factors. CFH is
important in regulation of the alternative complement pathway suggesting this pathway is involved
in ARM pathogenesis. Two other complement pathway genes, the closely linked complement com-
ponent receptor (C2) and complement factor B (CFB), were recently shown to harbor variants
associated with ARM. Methods/Principal Findings We investigated two SNPs in C2 and two
in CFB in independent case-control and family cohorts of white subjects and found rs547154, an
intronic SNP in C2, to be significantly associated with ARM in both our case-control (P-value
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0.00007) and family data (P-value 0.00001). Logistic regression analysis suggested that accounting
for the effect at this locus significantly (P-value 0.002) improves the fit of a genetic risk model
of CFH and LOC387715 effects only. Modeling with the generalized multifactor dimensionality
reduction method showed that adding C2 to the two-factor model of CFH and LOC387715 in-
creases the sensitivity (from 63% to 73%). However, the balanced accuracy increases only from
71% to 72%, and the specificity decreases from 80% to 72%. Conclusions/Significance C2/CFB
significantly influences AMD susceptibility and although accounting for effects at this locus does
not dramatically increase the overall accuracy of the genetic risk model, the improvement over the
CFH-LOC387715 model is statistically significant.
5.2 INTRODUCTION
Age-related maculopathy (ARM), also known as age-related macular degeneration (AMD), is a
devastating disorder and a major public health issue. ARM poses one of the greatest threats to
vision in the elderly of developed countries and an estimated 1.75 million individuals over 40 years
old in the United States suffer vision loss from the disease with an estimated increase to 2.95 million
individuals by 2020 (Friedman et al. 2004). ARM is a degenerative disorder primarily, but not
exclusively, affecting the central macular region of the retina. It is characterized by formation
of drusen, pigment epithelial changes, atrophic degenerative changes, and formation of choroidal
neovascularization.
The etiology of ARM is complex and the disease susceptibility is influenced by both en-
vironmental and genetic components (Seddon and Chen 2004; van Leeuwen et al. 2003). Of
modifiable risk factors, the most recognized one is cigarette smoking (Thornton et al. 2005). In
the past couple of years, a light has been shed on our understanding of the genetic susceptibility of
the disease (Gorin 2007). A genome-wide association scan (Klein et al. 2005) and two targeted
searches (Haines et al. 2005; Edwards et al. 2005) identified variants in the complement factor
H (CFH, Entrez GeneID 3075) gene on chromosome 1q32 and two targeted searches (Jakobsdot-
tir et al. 2005; Rivera et al. 2005) identified variants in the poorly characterized LOC387715
(also known as ARMS2, GeneID 387715) gene, as well as in the closely linked PLEKHA1 (GeneID
59338) and HTRA1 (GeneID 5654) genes, on chromosome 10q26. Both findings have proven to be
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robust and the associations of CFH and LOC387715 variants and haplotypes, especially Y402H
and S69A, respectively, have been replicated in multiple cohorts of various nationalities and ethnic
backgrounds. This includes mostly samples of white European (Baird et al. 2006; Despriet et al.
2006; Ennis et al. 2007; Hughes et al. 2006; Magnusson et al. 2006; Seitsonen et al. 2006; Sepp
et al. 2006; Simonelli et al. 2006; Souied et al. 2005; Wegscheider et al. 2007; Wang et al.
2007) and white European American (Conley et al. 2006; Conley et al. 2005; Francis et al.
2007; Hageman et al. 2005; Li et al. 2006; Maller et al. 2006; Ross et al. 2007; Schaumberg
et al. 2006; Schmidt et al. 2006; Seddon et al. 2007; Thompson et al. 2007; Tuo et al. 2006;
Zareparsi et al. 2005; DeAngelis et al. 2007; Narayanan et al. 2007; Schaumberg et al. 2007)
descent, but also samples of Hispanic origin (Tedeschi-Blok et al. 2007) and samples from Russia
(Fisher et al. 2007), India (Kaur et al. 2006), China (Lau et al. 2006; Chen et al. 2006), and
Japan (Okamoto et al. 2006; Tanimoto et al. 2007; Mori et al. 2007). Negative findings have,
however, been reported for the role of CFH in Japanese ARM cohorts (Fuse et al. 2006; Gotoh
et al. 2006; Uka et al. 2006). Two more recent studies (DeWan et al. 2006; Yang et al. 2006)
identified an additional variant (rs1120638 ) in the promoter region of HTRA1. This variant is in
extremely strong linkage disequilibrium (LD) with the S69A variant in LOC387715, keeping the
debate on the true susceptibility gene in the 10q26 region ongoing (Cameron et al. 2007; Mori
et al. 2007; Yoshida et al. 2007; Kanda et al. 2007). In the present study, we do not try to
distinguish between the genes and variants in this region but use S69A as a tagging SNP; given
the extensive LD in the region, especially between S69A and the HTRA1 promoter variant, S69A
can serve as a reasonable proxy for the genetic risk contributed by this region. In fact, a recent
fine-mapping effort in this region does suggest that S69A is more likely, than the HTRA1 promoter
variant, to be causally responsible for the impact of this locus on ARM (Kanda et al. 2007).
CFH is now widely accepted as an important ARM susceptibility gene, harboring variants
and haplotypes associated with increased and reduced disease risk. Functional studies suggest
that CFH inhibits the activation of the alternative complement cascade and complements have
been found in the drusen of ARM patients (Hageman et al. 2001; Hageman and Mullins 1999;
Johnson et al. 2001; Johnson et al. 2000; Mullins et al. 2000). It is therefore logical to ask
whether other genes involved in the alternative complement pathway may influence the risk. This
task was partly tackled by Gold et al. (Gold et al. 2006) who found ARM-associated variants
in the complement component receptor B (CFB, GeneID 629) gene and the adjacent complement
component 2 (C2, GeneID 717) gene on chromosome 6p21. Both genes play a role in complement
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pathways: CFB in the alternative pathway and C2 in the classical pathway. As was the case
for CFH and LOC387715, this finding also seems robust and has been replicated in two case-
control cohorts (Maller et al. 2006; Spencer et al. 2007) and one family cohort (Spencer et al.
2007). However, because of the strong LD across the C2/CFB region, distinguishing between the
genes and identifying true functional variants has proven challenging. Recently two studies (Yates
et al. 2007; Maller et al. 2007) reported significant associations between ARM and variants
in the complement component 3 (C3, GeneID 718) gene on chromosome 19p13. C3 plays an
important role in activation of both the classical and the alternative complement pathways and
the plasma complement C3a des Arg levels are significantly elevated in ARM cases compared to
controls (Sivaprasad et al. 2007). A fourth recent study (Dinu et al. 2007) also found ARM
associated variants in the C7 (GeneID 730) and MBL2 (GeneID 4153) complement pathway genes
by complement pathway focused analysis of an earlier genome-wide association scan (Klein et al.
2005).
In the present study, we investigated four SNPs in the C2/CFB region, rs9332739 and
rs547154 in C2 and rs4151667 and rs2072633 in CFB, in case-control and family cohorts of white
subjects. Only rs547154, an intronic SNP in C2, was significantly associated with ARM in our
data. Subsequently, rs547154 was used as a tag for this region in multifactor analyses of the joint
effect of the three genomic regions (CFH, LOC387715, and C2/CFB) on ARM susceptibility.
5.3 MATERIALS AND METHODS
5.3.1 Phenotyping, study participants and quality control
Because of the complexity and ambiguity in the ARM phenotype, we have previously defined three
affection status models (types A, B, and C) (Weeks et al. 2000; Weeks et al. 2004). For clarity we
restrict our analyses here to unaffected (or normal) individuals and type A affected individuals. The
type A model is our most stringent and conservative diagnostic model and individuals classified as
type A ARM affected are clearly affected with ARM based on extensive and/or coalescent drusen,
pigmentary changes (including pigment epithelial detachments) and/or the presence of end-stage
disease (geographic atrophy [GA] and/or choroidal neovascular [CNV] membranes). Unaffected
individuals were those for whom eye-care records and/or fundus photographs indicated either no
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evidence of any macular changes (including drusen) or a small number (< 10) of hard drusen
(50 m in diameter) without any other retinal pigment epithelial (RPE) changes. Individuals with
evidence of large numbers of extramacular drusen were not classified as unaffected and therefore
not included in the analyses. No family member was considered unaffected but was considered of
unknown phenotype if not affected with type A ARM.
Using only the subset of white participants, our data include 611 ARM families, 187 unre-
lated cases and 168 unrelated controls. The ARM families consist of 1,524 genotyped individuals
(569 males and 955 females) and, in terms of genotyped affected relative pairs, the families include
total of 501 sib pairs, 7 half sib pairs, 60 cousin pairs, 13 parent-child pairs, and 38 avuncular pairs;
Pedstats (version 0.6.8) (Wigginton and Abecasis 2005) was used to get summary counts of
the family data. See Table 5.1 for other characteristics of the subjects. Before analyzing the fam-
ily data, PedCheck (version 1.1) (O’Connell and Weeks 1998) was used to check for Mendelian
inconsistencies. Since it can be extremely difficult to determine who exactly has the erroneous geno-
type within small families (Mukhopadhyay et al. 2004), we set genotypes of problematic markers
to missing for every individual within each family containing a Mendelian inconsistency. Informed
consent was obtained from all participants under research protocols that have been reviewed and
approved in accordance with the Declaration of Helsinki and the Guidelines for Human Subjects
Protection issued by the Office of Human Subjects Research (National Institutes of Health) by
the University of Pittsburgh IRB (#9506133) and the University of CaliforniaLos Angeles IRB
(#10-06-096-01).
5.3.2 Genotyping
The variants: rs9332739 (E318D) and rs547154 (IVS10 ) in C2, and rs4151667 (L9H ) and
rs2072633 (IVS17 ) in CFB, were genotyped using 5? exonuclease Assay-on-Demand TaqMan as-
says (Applied Biosystems Incorporated). Amplification and genotype assignments were conducted
using the ABI7000 and SDS 2.0 software (Applied Biosystems Incorporated, Foster City, CA). The
variant rs1061170 (Y402H ) in CFH and the variant rs10490924 (S69A) in LOC387715 were geno-
typed using RFLP techniques. The primers, annealing temperatures and restriction endonuclease
for each assay were: 5′–TCTTTTTGTGCAAACCTTTGTTAG–3′ (F), 5′–CCATTGGTAAAACAA
GGTGACA–3′ (R), 52 ◦C, NlaIII for Y402H in CFH ; 5′–GCACCTTTGTCACCACATTA–3′ (F),
5′-GCCTGATCATCTGCATTTCT-3′ (R), 54 ◦C, PvuII for S69A in LOC387715. For all genotyp-
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Table 5.1: Samples sizes and other characteristics of the data.
Family data Case-control data
Type A not Type A Cases (Type A) Controls
Number of genotyped individuals
Females 690 265 113 87
Males 405 164 74 81
Total 1095 429 187 168
Mean age (SD)
Females 77.7 (7.3) 73.4 (12.9) 78.6 (7.0) 71.3 (10.2)
Males 77.0 (7.1) 73.3 (11.5) 79.8 (6.0) 74.6 (9.4)
Total 77.4 (7.2) 73.4 (12.4) 79.1 (6.6) 72.9 (9.9)
Cigarette smokers (%)
Females 37 35 43 34
Males 61 50 55 42
Total 46 41 48 38
GA (%)
Females 56 . . . 55 . . .
Males 52 . . . 58 . . .
Total 54 . . . 56 . . .
CNV (%)
Females 70 . . . 64 . . .
Males 71 . . . 69 . . .





ing conducted for this research, double-masked genotyping assignments were made for each variant
and compared; each discrepancy was addressed using raw data or by re-genotyping. Genotype
efficiency for the C2/CFB SNPs ranged from 93% to 96% and 88% to 90% for the two previously
published CFH and LOC387715 SNPs.
5.3.3 Association analyses and LD estimation
5.3.3.1 Case-Control data Using the set of unrelated cases and controls, SNP-disease allelic
and genotypic associations were tested using the Fisher’s exact test as implemented in R (version
2.2.1) (R Development Core Team 2005). For significantly associated SNPs the strength of the
association was estimated by crude odds ratios (ORs) and population attributable risks (PARs). To
calculate the PARs we used the general formula: PAR = Pf (OR− 1)/(1 +Pf (OR− 1)), where Pf
is the prevalence of the risk or protective factor (genotype) in the general population as estimated
from the controls. The ORs were calculated using logistic regression models in R. Confidence inter-
vals (CIs) for the ORs and PARs were derived using the asymptotic normal distribution of ln(OR)
and ln(1-PAR), respectively. Haplotypic associations of 2- and 3-SNP moving window haplotypes
in the C2/CFB locus were evaluated using the haplo.cc function of the haplo.stats package (version
1.2.2) (Schaid et al. 2002) of R. This function implements a score test for global test of association
between binary traits and haplotypes and accounts for ambiguous linkage phase by the EM algo-
rithm; empirical P-values were generated using 10,000 replicates. Allele and genotype frequencies
were estimated by direct counting and deviations from Hardy-Weinberg equilibrium (HWE) were
tested, in cases and controls separately, using the exact test as implemented in R Genetics package
(version 1.2.1) (Warnes and Friedrich 2006). Haploview (version 3.32) (Barrett et al. 2005)
was used to estimate the LD across the C2/CFB region, both D′ and r2 were calculated separately
in cases and controls.
5.3.3.2 Family data When incorporating cases from the families into the analyses, the CCREL
method (version 0.3) (Browning et al. 2005) was used to test SNP-disease allelic, genotypic and 2-
and 3-SNP haplotypic associations. The CCREL method permits testing for association with the
use of related cases and unrelated controls simultaneously and, briefly, it accounts for biologically
related subjects by calculating an effective number of cases such that individuals are assigned
weights that are used to construct a composite likelihood, which is then maximized iteratively to
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form likelihood ratio tests. For the CCREL analyses, type A-affected family members were assigned
the phenotype affected, unrelated controls the phenotype normal and family members not affected
with type A ARM the phenotype unknown.
5.3.4 Multifactor and gene-gene interaction analyses
To build predictive models of the genetic risk of ARM contributed by the CFH, LOC387715, and
C2/CFB loci, we applied both logistic regression and the new generalized multifactor dimensionality
reduction (GMDR) method (version 0.7) (Lou et al. 2007). The GMDR method, unlike the original
MDR method (Ritchie et al. 2001), permits adjustment for covariates and better handles data
with unequal numbers of cases and controls, and can be used to analyze both qualitative (e.g.
binary) and quantitative traits via different link functions. Both methods only handle unrelated
individuals. Therefore, to make use of more of our data, we combined one type A affected person
picked at random from each of the 611 ARM families with the data of unrelated cases and controls.
We consider this to be appropriate to do since the association results suggest the effects of the
genes to be similar in both groups.
5.3.4.1 Logistic regression For each pair of loci, we first followed the modeling strategy
proposed by North et al. (North et al. 2005) for two-factor genetic risk models. A series of
logistic regression models were fitted to the data in order to find a parsimonious model for the joint
effects of each pair of loci. Models allowing for additive effects (ADD1, ADD2, and ADD-BOTH),
models incorporating dominance effects (DOM1, DOM2, and DOM-BOTH), and three interaction
models (ADD-INT, ADD-DOM, and DOM-INT) were fitted. We fit three-factor models of the
joint effect of all three loci and test, using a likelihood ratio test (LRT), whether accounting for the
protective effects at C2/CFB significantly improves the fit of a model with CFH and LOC387715
effects only. Since, for each pair of loci, the two-factor analyses implicated additive models as
the most parsimonious and to keep the number of parameters as small as possible we only fit
three-factor additive models without interaction (ADD1, ADD2, ADD3, ADD12, ADD13, ADD23,
and ADD123). The models are compared by the Akaike information criterion (AIC); the most
parsimonious model has the lowest AIC and a model is considered to provide a significantly better
fit to the data if it has AIC more than 2 units lower than the comparison model (North et al.
2005). Details regarding coding of genotypes in the models are available in appendix C.
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5.3.4.2 GMDR Just as in the case of logistic regression, when using the GMDR method, one
needs to be aware of the risk of overfitting, especially in the case of small sample sizes. The GMDR
method, however, uses cross-validation to guard against overfitting. We applied the method to
our data in order to identify three-locus genotypes associated with increased and decreased disease
risk. For comparison we also present and discuss the CFH and LOC387715 two-factor model. We
performed both crude analysis and analyzed the data while adjusting for age, gender, and cigarette
smoking. We used 5-fold leave-one-out cross-validation and exhaustive search of all possible one-
to three-locus models in the GMDR analyses. In the adjusted analysis age (in years) was the age
at the time blood was drawn (i.e. DNA donated), and cigarette smoking was a binary variable
(ever vs. never smoked). The smokers smoked on averaged 40.45 (standard deviation [SD] 32.96;
range 0.23207.00) pack-years (years?packs/day smoked) of cigarettes. The sample in the adjusted
analysis includes fewer observations (557 cases and 118 controls fully typed at all three SNPs)
than the sample in the unadjusted analysis (640 cases and 142 controls fully typed at all three
SNPs) because of missing information. We compared both the sensitivity=TP/(TP+FN) and
the specificity=TN/(TN+FP) of the models, where TP=number of true positives, TN=number
of true negatives, FP=number of false positives, and FN=number of false negatives. As a single
measure of the accuracy of the models we used the balanced accuracy=(sensitivity+specificity)/2
rather than the accuracy=(TP+TN)/(TP+TN+FP+FN) because number of cases and controls is
unequal. The average sensitivity, specificity, and balanced accuracy over the testing sets of all five
cross-validations are reported. As a measure for the appropriateness of the models, the sensitivity,
specificity, balanced accuracy, and P-value are reported for all models when applied to the whole
dataset.
5.3.5 Interaction with cigarette smoking
In a logistic regression framework we tested, using a LRT and the combined data of unrelateds and
one type A affected from each family, whether cigarette smoking interacts with the SNPs at the
three genes. The genotypes were coded in additive way, as in the logistic regression analysis above,
and cigarette smoking as ever vs. never smoked.
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5.4 RESULTS
5.4.1 Results of association analyses
The genotype distributions of the 4 SNPs typed in C2 and CFB and the Y402H variant in CFH
and the S69A variant in LOC387715 are in HWE in both our cases and controls (Table 5.2). Of
the 4 SNPs typed in the C2/CFB region, only rs547154, an intronic SNP in C2, is significantly
associated with ARM (Table 5.2) in both our case-control (P-value of genotypic test 0.00007) and
family data (P-value of genotypic test 0.00001), which is also significant after adjusting for multiple
testing of 4 tests (Bonferroni corrected 0.05 significance level is 0.0125). The haplotypic association
tests show that haplotypes spanning the entire C2/CFB locus are significantly associated with
ARM (Table 5.2). Although LD between rs547154 and the SNPs in CFB (Figure 5.1) is not
strong, in neither cases nor controls, these results are not sufficient to rule out either C2 or CFB as
an ARM candidate gene, because of limited number of SNPs investigated. Individuals carrying the
protective allele at C2 are at 0.22 (95% CI 0.10 to 0.48) times less risk of having ARM compared
to controls as estimated with a crude OR. The corresponding PAR is 18% (95% CI 28% to 8%).
Detailed results of marginal association of Y402H in CFH and S69A in LOC387715 are in Table
5.2 and the supporting information (Text S2).
5.4.2 Results of multifactor analyses
5.4.2.1 Logistic regression First we fitted two-factor genetic risk models for each pair of loci
and found that an additive model without interaction was the most parsimonious in all cases (Table
5.3). Three-factor additive model was then fitted in order to test whether the three-factor model
provided better fit to the data than any two-factor models (Table 5.4). The three-factor model of
CFH, LOC387715, and C2 SNPs coded in additive fashion was the most parsimonious and fitted
significantly better (P-value of LRT 0.002) than the next-best model (which modeled CFH and
LOC387715 additive effects only).
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Table 5.2: Association results for C2/CFB variants, Y402H in CFH, and S69A in LOC387715.
P-value for test
Single SNP in Moving window haplotypic test
Global test
MAF in HWE in CCREL Exact test in unrelateds CCREL in unrelateds
With With With With
SNP (Location) Gene MA Cases Controls Cases Controls Allelic Genotypic Allelic Genotypic 2 SNPs 3 SNPs 2 SNPs 3 SNPs
rs9332739 (E318D) C2 C 0.027 0.033 1.000 0.157 0.26542 0.37187 0.66583 0.90278 0.00088 0.00076 0.00020 0.00000
rs547154 (IVS10) C2 T 0.025 0.096 1.000 0.365 0.00010 0.00001 0.00011 0.00007 0.00071 0.00131 0.00020 0.00030
rs4151667 (L9H) CFB A 0.028 0.036 1.000 0.185 0.19863 0.27610 0.66609 0.81796 0.38067 . . . 0.27480 . . .
rs2072633 (IVS17) CFB A 0.330 0.393 0.499 0.104 0.64767 0.07003 0.09299 0.05780 . . . . . . . . . . . .
rs1061170 (Y402H) CFH C 0.621 0.348 0.615 0.288 <0.00001 <0.00001 6.3× 10−12 7.7× 10−11 . . . . . . . . . . . .
rs10490924 (S69A) LOC387715 T 0.470 0.200 0.272 0.075 <0.00001 <0.00001 4.2× 10−13 8.2× 10−11 . . . . . . . . . . . .
MA = minor allele
MAF = minor allele frequency
HWE = Hardy-Weinberg equilibrium
The haplotypic P-values correspond to the haplotypes of the SNP in the same row as the P-value and the next one or two SNPs for the ’With 2 SNPs’ and ’With 3 SNPs’
P-values, respectively




































































































Figure 5.1: Linkage disequilibrium (LD) across the C2/CFB region in unrelated cases and controls.
The darker the boxes the higher the r2. The top number in each box is r2 and the bottom number
is D′. Locations of the SNPs within the genes are shown. Red lines/boxes show the locations of
exons in C2 and green lines/boxes the locations of exons in CFB.
5.4.2.2 GMDR The two-factor GMDR unadjusted and adjusted models (Figure 5.2A and B)
classify everyone with a homozygous (TT ) LOC387715 risk genotype as cases and everyone with
the homozygous (GG) LOC387715 non-risk genotype as controls. On the other hand, individuals
heterozygous (GT ) at LOC387715 need to have at least one CFH risk allele (C ) to be classified as
cases. When comparing the unadjusted two-factor model (Figure 5.2A) to the unadjusted three-
factor model (Figure 5.2C), the most dramatic change is in the upper left most cell (CC-GG
CFH-LOC387715 joint genotype): 76 cases in that cell that were wrongly classified as controls by
the two-factor model while 71 are correctly (5 wrongly) classified in the three-factor model. This
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Table 5.3: Results of fitting two-factor logistic regression models.
Two-factor model AIC AIC difference






























Detailed model definitions are given in the Materials and Methods - Multifactor and interaction analyses section.
AIC difference is the difference from the AIC of the best fitting model. Most parsimonious model is in bold. Model
with best fit (lowest AIC) has AIC difference = 0.
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Table 5.4: Results of fitting three-factor logistic regression models.








Factor 1 is Y402H in CFH, Factor 2 is S69A in LOC387715, and Factor 3 is rs547154 in C2. Detailed model
definitions are given in the Materials and Methods - Multifactor and interaction analyses section. AIC difference
is the difference from the AIC of the best fitting model. Most parsimonious model is in bold. Model with best fit
(lowest AIC) has AIC difference = 0.
increases the sensitivity from 63% to 73%, but comes at a cost of decreased specificity (80% to
72%).
Now looking more closely at the three-factor models (Figures 2C and D), the results of the
GMDR analyses suggest that having at least one copy of the protective allele (T ) at C2/CFB
may reduce the risk contributed by CFH and LOC387715 risk genotypes. For example in the
unadjusted model (Figure 5.2C), individuals with the CT-GT and CT-GG two-locus genotypes at
CFH and LOC387715 and without the C2/CFB protective allele are classified as cases while those
with the protective allele are classified as controls. In the adjusted model (Figure 5.2D), however,
individuals with the CT-GT and CC-GG as well as TT-TT and CC-GT two-locus genotypes at
CFH and LOC387715, are classified as controls if they carry the C2/CFB protective allele but
cases otherwise. Note that the difference between the three-factor unadjusted and adjusted models
is not due to the smaller dataset used in the adjusted analysis. To make sure this was not the
case, we ran unadjusted analysis on the smaller dataset and arrived at the same model as in the
unadjusted analysis. The predictive models presented in Figure 5.2 seem sensible as the predicted
high-risk two- and three-locus genotypes group together. The predictive accuracy of the three-factor
model measured by sensitivity, specificity, and balanced accuracy is > 70% of both the unadjusted
and adjusted models (Table 5.5). In the unadjusted analysis all five cross-validations suggest that






























































































































































































Figure 5.2: A: Results of unadjusted GMDR analysis for the best two-factor model. B: Results of
adjusted GMDR analysis for the best two-factor model. C: Results of unadjusted GMDR analysis
for the three factor model. D: Results of adjusted GMDR analysis for the three-factor model. Dark
grey and light grey boxes correspond to the high- and low-risk genotype combinations, respectively.
The black and white bars within each box correspond to cases and controls, respectively. The top
number above each bar is number of individuals and the bottom number is the sum of scores for the
corresponding group of individuals (cases or controls with particular three-locus genotype). The
heights of the bars are proportional to the sum of scores in each group.
and in the adjusted analysis the classification is significantly better in all but one cross-validation
experiment (Table 5.5). Both models provide excellent fit to the whole data (P-values < 0.0001).
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In Table C2, we present the joint genotype and relative genotype frequencies in cases and controls,
which provides a complementary view of the same findings as in Figure 5.2.
5.4.2.3 Logistic regression vs. GMDR In both the logistic regression and GMDR analyses,
the best fitting one-factor model is the model with LOC387715 only (Tables 5.4-5.5); in the logistic
regression, the LOC387715 model has the lowest AIC of all one-factor models and, in the GMDR
results the LOC387715 model has the highest balanced accuracy (in both the unadjusted and
adjusted analyses). However, the difference between the CFH and LOC387715 one-factor models
is, very small, and, as the GMDR analyses show, the difference lies in the sensitivity and specificity
rather than the overall balanced accuracy measure (Table 5.5). The three-factor model of CFH,
LOC387715, and C2/CFB effects is implicated as the best model in both the regression and GMDR
analyses (Tables 5.4-5.5). The logistic regression analyses suggest that accounting for C2/CFB
effects significantly improves the two-factor model of CFH and LOC387715 only (P-value 0.002).
The GMDR analyses show that this improvement is due the increases sensitivity but the balanced
accuracy increases only from 71% to 72% (Table 5.5). The GMDR analyses also suggest that
adjusting for age, gender, and cigarette smoking does not dramatically improve the fit of the
models. In fact, all models (1-, 2-, and 3-factor) have approximately the same balanced accuracy
irrespective of whether adjustment is made (Table 5.5).
5.4.3 Results of gene-cigarette smoking interaction analysis
Cigarette smoking does not significantly interact with any of the three variants investigated in our
data. The p-values of LRTs are 0.24, 0.99, and 0.43 for Y402H in CFH, S69A in LOC387715, and
IVS10 in C2, respectively. For all three genes the most parsimonious models, according to AIC,
are the models with only the additive gene effect and no smoking effect (results not shown).
5.5 DISCUSSION
We have replicated the association of one C2 variant (rs547154 ) with ARM in both our case-control
and family datasets and we have shown that accounting for the effects of C2/CFB significantly
improves the fit of the logistic regression model in comparison to the two-factor model of joint
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Table 5.5: Results of GMDR analyses.
Unadjusted Adjusted
Balanced Balanced
Model P-value Sensitivity Specificity Accuracy P-value Sensitivity Specificity Accuracy
CFH, LOC387715, and C2
Testing 1 0.0079 0.76 0.62 0.69 0.0029 0.70 0.79 0.74
Testing 2 0.0140 0.55 0.79 0.67 0.0047 0.70 0.77 0.73
Testing 3 0.0027 0.73 0.71 0.72 0.0172 0.75 0.64 0.70
Testing 4 0.0001 0.65 0.93 0.79 0.0237 0.49 0.86 0.68
Testing 5 0.0298 0.71 0.61 0.66 0.0823 0.75 0.54 0.64
Average . . . 0.68 0.73 0.71 . . . 0.68 0.72 0.70
Whole data <0.0001 0.73 0.72 0.72 <0.0001 0.70 0.74 0.72
CFH and LOC387715
Testing 1 0.0079 0.63 0.76 0.69 0.0026 0.66 0.83 0.74
Testing 2 0.0140 0.55 0.79 0.67 0.0038 0.76 0.72 0.74
Testing 3 0.0087 0.77 0.61 0.69 0.0320 0.62 0.73 0.68
Testing 4 0.0003 0.67 0.86 0.76 0.0165 0.52 0.86 0.69
Testing 5 0.0117 0.66 0.71 0.69 0.2298 0.75 0.45 0.60
Average . . . 0.66 0.75 0.70 . . . 0.66 0.72 0.69
Whole data <0.0001 0.63 0.80 0.71 <0.0001 0.61 0.80 0.71
CFH
Testing 1 0.0317 0.89 0.38 0.64 0.0276 0.88 0.45 0.66
Testing 2 0.0341 0.78 0.52 0.65 0.0764 0.41 0.85 0.63
Testing 3 0.1653 0.85 0.32 0.59 0.1413 0.83 0.39 0.61
Testing 4 0.0011 0.83 0.64 0.74 0.1484 0.81 0.41 0.61
Testing 5 0.0794 0.89 0.32 0.61 0.0400 0.89 0.41 0.65
Average . . . 0.85 0.44 0.64 . . . 0.77 0.50 0.63
Whole data <0.0001 0.85 0.44 0.64 <0.0001 0.85 0.45 0.65
LOC387715
Testing 1 0.0132 0.67 0.69 0.68 0.0564 0.71 0.60 0.66
Testing 2 0.0447 0.67 0.62 0.65 0.0074 0.71 0.73 0.72
Testing 3 0.0012 0.73 0.75 0.74 0.1565 0.72 0.51 0.61
Testing 4 0.0305 0.74 0.57 0.66 0.0140 0.60 0.81 0.70
Testing 5 0.0224 0.73 0.61 0.67 0.1102 0.68 0.59 0.63
Average . . . 0.71 0.65 0.68 . . . 0.68 0.65 0.66
Whole data <0.0001 0.71 0.65 0.68 <0.0001 0.68 0.64 0.66
Each testing set corresponds to 1/5 of the data. The same individuals are in each testing set across models and within type
of analysis (unadjusted or adjusted). The individuals are not necessarily the same in the testing sets across type of analysis
because of the smaller number of individuals that were available in the adjusted analyses compared to the unadjusted analysis
(see the text for details). The average is the average over the five testing sets and the P-value corresponds to χ2 tests of fitting
the models to the testing sets or the whole data.
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additive effects of CFH and LOC387715 (Table 5.2 and 5.4). Interestingly, both of the non-
synonymous coding changes, E318D (rs9332739 ) in C2 and L9H (rs415667 ) in CFB, identified
by Gold et al. (Gold et al. 2006) are insignificant in both of our datasets. However, as these
variants (rs9332739 and rs415667 ) are quite rare, power to detect these variants is low. Even
so, our independent confirmation of the statistically significant effect of this locus in ARM in two
datasets, including family-based data, further supports the contribution of this locus to the genetic
susceptibility of ARM.
As mentioned above, accounting for the effect of the C2/CFB locus significantly improved
the fit of a logistic regression model of additive effects of CFH and LOC387715 variants. To further
understand this, we built predictive models of these three loci using the new generalized multifactor
dimensionality reduction method (GMDR), and found that addition of C2/CFB to the model
increased sensitivity (from 63% to 73%). However, the specificity is lowered (from 80% to 72%)
and so the balanced accuracy only increases from 71% for the two-factor CFH-LOC387715 model
to 72% for the three-factor CFH-LOC387715-C2 model in the unadjusted analysis (Table 5.5). If
it were considered more important to identify cases than controls correctly, while maintaining a
reasonable specificity, the three-factor model would be the better choice.
Since our associated variant (rs547154 ) in C2/CFB is rare, it is expected that accounting
for the effect of this locus, using rs547154 as a tag, would not markedly improve the overall
prediction accuracy of the genetic risk model with CFH and LOC387715 effects only, even though
the effect may be strong. Although, positive associations in the C2/CFB region have been found and
replicated primarily for rare variants (Gold et al. 2006; Maller et al. 2006; Spencer et al. 2007)
we cannot exclude the possibility that the true causal variant(s) in this region may be common,
especially since not all known common SNPs have been typed in C2/CFB studies (Figure S1).
Obviously, a genetic risk model of CFH, LOC387715, and C2/CFB effects could be quite different
from our model presented here if the C2/CFB causal variant(s) were common, as then the rare
rs547154 would be a bad proxy.
Another concern regarding correctness of the three-factor model is the small sample size for
the ’protective’ GT genotype at IVS10 (rs547154 ) in C2 (Figure 5.2 and Table ??), although it
is important to remember that cross-validation does guard against over-fitting due to small sample
sizes or a large number of parameters. The least stable classifications in Figure 5.2C are those
cells in which the height of the bars is similar or number of individuals is low. In such cases, the
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classification rule can change if only a few individuals were added to that cell. For example, if
we had only one additional control with a CC-GG-GG CFH-LOC387715-C2 genotype (upper left
most cell, left panel in Figure 5.2C), then individuals with this genotype combination would have
been classified as controls instead of cases. To construct our original unrelated data set, we picked
one case at random from each of the families. Figure S2 examines the sensitivity of our three-factor
analyses when we randomly re-pick one case from each family. We created 10 other combined
data-sets (overlap among cases from the families ranges from 57% to 66%) and ran the GMDR
method. The figure clearly shows that only classifications corresponding to the rare GT genotype
at IVS10 (rs547154 ) in C2 are changed across samples, while the classifications corresponding to
the common GG genotype are robust.
Accounting for covariates (age, gender, and cigarette smoking) failed to improve the predic-
tion accuracy of the genetic risk models (Table 5.5). In fact, for the one- and two-factor models,
the adjusted analyses arrived at the same high-risk (and low-risk) genotype combinations as the
unadjusted analyses. The difference in sensitivity, specificity, and balanced accuracy between the
two analyses is solely due to different number of individuals used in each set of analyses (because
of incomplete smoking information). In the three-factor model, genotypes were grouped differently
depending on whether unadjusted or adjusted analyses were performed (Figure 5.2) and, as men-
tioned in the results section, this difference is not solely due to different number of individuals used
in each set of analyses.
The one-factor models of CFH and LOC387715 did worse than the higher-factor models
(balanced accuracy 64% and 68%, respectively), although, when considering they only model ge-
netic effects at one locus, both models perform amazingly well. The GMDR method selected the
LOC387715 model as the best of all the one-factor models. However, depending on what the goals
of using a prediction model are, one could easily choose the CFH model as the best one-factor
model. For example, the sensitivity of the CFH model is much higher than of the LOC387715
model (85% vs. 71%), but this increased sensitivity comes at a cost of low specificity (44% vs.
65%).
In their original report on the C2/CFB locus in ARM, Gold et al. (Gold et al. 2006)
did not include LOC387715 variants and, using a genetic algorithm search approach, they arrived
at a genetic risk model of two CFH variants and three C2/CFB variants. The sensitivity and
specificity of their model were 74% and 56%, respectively (which results in balanced accuracy of
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65%). Interestingly, our three-factor model, which includes LOC387715 effects, provides a better
prediction accuracy (balanced accuracy 72%), similar specificity (73%), and better specificity (72%)
than their more complicated five-factor model. Furthermore, even our simpler two-factor model of
CFH and LOC387715 effects also provides better prediction accuracy (balanced accuracy 71%).
We believe that a word of caution must be provided with regard to the possible use of these
predictive models in clinical situations. It must be understood that the models presented in this
paper and by others are based on comparison of extreme phenotypes (those with advanced forms
of ARM and age-matched controls with minimal or no clinical findings). This does not address the
determination of ARM risk for individuals for whom mild to moderate retinal findings are present.
Secondly, odds ratios based on case-control association studies are not comparable to prospective,
population-based relative risk assessments that still need to be done for ARM. Finally, one must
always consider the composition of the population that may be subjected to molecular genetic
screening. If we are considering the general population for whom the risk of ARM-related vision
loss is less than 1% over their lifetime, then the current genetic models have inadequate levels of
specificity to avoid a high percentage of false positive results. However, for individuals from high-
risk cohorts for whom the prevalences of the high-risk variants are known, molecular diagnostic
testing may be sufficiently discriminating of relative risk, though it is unclear how such knowledge
would affect individual behavior or preventive treatments at this time.
In summary, we have confirmed the likely influence of the C2/CFB locus on ARM and shown
that accounting for the effects at this locus can likely further stratify individuals as being at high
or low risk of developing ARM. The important role the classical and/or alternative complement
pathways seem to have in the disease-pathology of ARM should now encourage investigators to
not only look at more complement pathway genes, but also to establish the biological mechanism
behind the influence of LOC387715 (or HTRA1 ) on the development of the disorder. Then, once
either LOC387715 or HTRA1 has been convincingly shown to be the true ARM susceptibility gene
on 10q26, it is likely that we will see similar trends in discoveries of genes involved in the same
pathway as either of those genes.
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6.0 INTERPRETATION OF GENETIC ASSOCIATION STUDIES: MARKERS
WITH REPLICATED HIGHLY SIGNIFICANT ODDS RATIOS MAY BE POOR
CLASSIFIERS
This section has been published in PLoS Genetics volume 2, issue 2, pages e1000337 (Jakobsdot-
tir et al. 2009). The copyright of the article belongs to the authors and the article is an open-access
article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and
source are credited. No changes have been made to the published version of the paper, except
that tables and figures have been renumbered, the citations are of different style and some minor
formatting has been made to keep this chapter coherent to the reminder of the thesis. My contri-
bution to this paper was in writing all components of the paper, data analysis, and script writing
for method implementation.
6.1 ABSTRACT
Recent successful discoveries of potentially causal single nucleotide polymorphisms (SNPs) for com-
plex diseases hold great promise, and commercialization of genomics in personalized medicine has
already begun. The hope is that genetic testing will benefit patients and their families, and en-
courage positive lifestyle changes and guide clinical decisions. However, for many complex diseases,
it is arguable whether the era of genomics in personalized medicine is here yet. We focus on the
clinical validity of genetic testing with an emphasis on two popular statistical methods for evalu-
ating markers. The two methods, logistic regression and receiver operating characteristic (ROC)
curve analysis, are applied to our age-related macular degeneration dataset. By using an additive
model of the CFH, LOC387715, and C2 variants, the odds ratios are 2.9, 3.4, and 0.4, with P
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values of 10−13, 10−13, and 10−3, respectively. The area under the ROC curve (AUC) is 0.79, but
assuming prevalences of 15%, 5.5%, and 1.5% (which are realistic for age groups 80 y, 65 y, and
40 y and older, respectively), only 30%, 12%, and 3% of the group classified as high risk are cases.
Additionally, we present examples for four other diseases for which strongly associated variants
have been discovered. In type 2 diabetes, our classification model of 12 SNPs has an AUC of only
0.64, and two SNPs achieve an AUC of only 0.56 for prostate cancer. Nine SNPs were not sufficient
to improve the discrimination power over that of nongenetic predictors for risk of cardiovascular
events. Finally, in Crohn’s disease, a model of five SNPs, one with a quite low odds ratio of 0.26,
has an AUC of only 0.66. Our analyses and examples show that strong association, although very
valuable for establishing etiological hypotheses, does not guarantee effective discrimination between
cases and controls. The scientific community should be cautious to avoid overstating the value of
association findings in terms of personalized medicine before their time.
6.2 INTRODUCTION
Recent successes in the discoveries of potentially causal single nucleotide polymorphisms (SNPs) for
complex diseases hold great promise, and commercialization of genomics in personalized medicine
has already begun. A number of companies now offer, for relatively modest fees, personalized
genomics services that provide individualized disease-risk estimates based on genome–wide SNP
genotyping. Most companies offering such profiling make it clear that they are not a clinical service
and that their calculations are not intended for diagnostic or prognostic purposes. They typically
advise their clients to consult their health care provider for more information. In most cases,
people would turn to their general physician (Mitka 1998). However, as noted by others (Feero
2008; Goetz 2007), few doctors currently have enough genetics training to actually make sense
of the risk calculations now commercially offered. Many physicians seem to feel the same way. In
surveys in five European countries, physicians ranked the disciplines in which they felt they needed
more training to overcome future challenges (Calefato et al. 2008; Julian-Reynier et al. 2008).
In all countries, the top ranked area was “genetics of common disease”, and ranked second was
“approaching genetic risk assessment in clinical practice”.
92
Not only are risk results likely to be often poorly understood by the tested individuals and
their physicians, but also these results are often based on risk models, such as logistic regression
models, that may not be good classification models (Pepe et al. 2004). Therefore, the disclaimer
made by the companies that their services are not intended as medical advice cannot be overem-
phasized. Current knowledge of the role of most genes in complex diseases is at the group level of
correlations of disease status with SNPs. Most of these SNPs were discovered via genetic associa-
tion studies aimed at finding variants correlated with disease risk. It is hoped that these discoveries
will provide insights into the pathogenesis and etiology, and ultimately lead to developments of
new treatments or preventive therapies. Assuming these SNPs will also be effective classifiers, they
are now being used in individual-level risk estimation, classification, and clinical decision-making.
However, for many complex diseases, such as the ones discussed here (age-related macular degen-
eration [AMD], type II diabetes, inflammatory bowel disease [Crohn’s disease], and cardiovascular
disease), it is arguable whether the era of genomics in personalized medicine is here yet. In this
article, we discuss and explore how useful highly associated SNPs might be for individual-level
risk estimation and prediction. Our focus will be on the classification accuracy of genetic testing,
with an emphasis on two popular statistical methods for evaluating biomarkers. We give realis-
tic real-data examples that illustrate that, currently, the genetic information is of limited value
for personalized medicine. We also discuss and apply risk-based and classification-based analysis
approaches to our AMD data.
6.3 TWO STATISTICAL METHODS
There are two basic statistical approaches for evaluating markers. The risk-based approach models
the risk as a function of marker(s), often with adjustment for covariates, and is commonly applied
in genetic studies. In case-control studies, this is done with logistic regression, and the markers
with the strongest effect on disease risk are those associated with the smallest p-values and most
extreme odds ratios (ORs). The other method, the classification-based approach, evaluates markers
based on how well they can discriminate between cases and controls. The performance is evaluated
by various measures, such as the proportion of positive test results among cases or the true positive
fraction (TPF, or sensitivity) and the proportion of positive test results among controls or the false
positive fraction (FPF, or 1−specificity). A perfect classifier will assign a positive test result to
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everyone with the condition (TPF = sensitivity = 1) and a negative test result to everyone without
the condition (FPF = 0, specificity = 1). Often more than one possible grouping into cases and
controls is possible based on a classifier. The receiver operating characteristic (ROC) curve is a
plot of all (FPF, TPF) pairs for each possible grouping. The area under the ROC curve (AUC) is
a popular measure of the discrimination power of a classifier. It is the probability that given two
random individuals, one who will develop the disease and the other who will not, the classifier will
assign the former a positive test result and the latter a negative result. Theoretically, the AUC can
take values between 0 and 1, but the practical lower bound is 0.5; a perfect classifier has an AUC of
1. Classifiers with an AUC significantly greater than 0.5 have at least some ability to discriminate
between cases and controls. However, for screening of individuals with an increased risk of disease,
it is suggested that the AUC be > 0.75, and for presymptomatic diagnosis of the general population,
the AUC should be > 0.99 (Janssens et al. 2007). When prognosis is the goal, one typically also
evaluates the classification model by two additional measures: (1) the proportion of individuals who
will develop the disease among those with a positive test result, or the positive predictive value
(PPV), and (2) the proportion of individuals who will not develop the disease among those with
negative test result, or the negative predictive value (NPV) (Box 1). We note in passing that there
are other methods that model classification performance and have been applied in genetic studies,
including, for example, genetic algorithms, generalized multifactor dimensionality reduction, and
random forests (Dunai et al. 2008; Gold et al. 2006; Jakobsdottir et al. 2008). However, to
keep our discussion focused, we do not discuss these other methods here.
Although the risk-based (logistic regression) and classification-based (ROC theory) methods
do not yield contradictory results in terms of directionality, they can and often will differ in terms
of size or importance. For example, a marker strongly related to risk may very well be a poor
classifier; and vice versa, a good classifier may only be weakly associated with risk (Pepe et al.
2004). Furthermore, neither method directly measures calibration, which is how well the predicted
risks agree with the underlying true risks (Cook 2007) (Box 2).
In a diagnostic setting in which discrimination between cases and controls is most important,
it only matters that the cases have higher estimated risk, accurate or not, than the controls.
However, when prognosis or risk stratification is the goal, both discrimination and calibration are
important. We then need a model that both discriminates well between future cases and those
who will remain controls, and also accurately estimates the exact risk of developing disease in the
future.
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6.4 THE ODDS RATIO, CLASSIFICATION, CALIBRATION, AND
PREDICTION
The OR is widely used to evaluate markers, and it is assumed the markers associated with the most
extreme OR are effective predictors. However, as we mentioned above, a marker strongly related
to risk may very well be a poor classifier, and vice versa, a good classifier may only be weakly
associated with risk (Pepe et al. 2004). In addition, a marker associated with risk may be well or
poorly calibrated, that is, the predicted risk may agree well or poorly with the true risk (Cook
2007).
For a strongly associated marker to be effective in classification, the associated OR must be
of an extreme magnitude rarely (if ever) seen in genetic association studies. As illustrated in fig.
6.1, if one wants to be able to detect 80% of cases with a binary marker, such as the presence or
absence of a risk allele, with ORs of 1.5, 10, or 50, then about 73%, 29%, and 7% of the controls
would be mislabeled as cases, and the AUC achieved by the binary marker would be 0.54, 0.76, and
0.86, respectively. Even a huge OR of 50 does not guarantee that a marker will have acceptable
prediction accuracy; for example, the TPF may be unacceptably low (TPF = 55%, FPF = 2.4%,
and AUC = 0.76) or the FPF unacceptably high (TPF = 97.6%, FPF = 45%, and AUC = 0.76)
(fig. 6.1).
Let us examine the achievable AUC as a function of risk allele frequency under an additive
genetic model in which the genotypes are coded 0, 1, and 2 (fig. 6.2 and table 6.1). In fig. 6.2,
we have plotted the AUC for fixed values of the OR, as a function of risk allele frequency in cases
(pca) under the assumption of Hardy-Weinberg equilibrium in both cases and controls. We clearly
see that markers with a reasonably high OR of 3 have a maximum possible AUC of less than 0.70,
and markers with an OR of 5 do not even reach an AUC of 0.80. For each OR, the risk allele
frequency in controls (pco) corresponding to the maximum possible AUC is given on the plot,
and not surprisingly, to reach the maximum possible AUC for each OR, the risk allele frequency
difference between cases and controls has to be quite large (table 6.1). For example, to reach an
AUC of 0.80 using a marker with an OR of 10, the allele frequencies in cases and controls would
be quite different (pca = 0.49 and pco = 0.09) (table 6.1).
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Figure 6.1: Accuracy curves for binary markers. The curves of accuracy points (FPF, TPF) for
binary markers with ORs 1.5, 10, and 50 are plotted. The black diamonds and horizontal dotted
line highlight the points (FPF, TPF)=(FPF, 80%) on the accuracy curves. The ORs are marked
on the curves.
6.5 THE ODDS RATIO, RELATIVE RISK, AND RISK
In retrospective studies, the relative risk or risk ratio (RR) cannot be estimated unless the preva-
lence is known, and therefore, the OR is used as a proxy. Theoretically, the OR will give a good
approximation for the RR if the prevalence is low, but otherwise it tends to overestimate the RR
(Davies et al. 1998; Deeks 1998). RRs, which are the ratio of two risks (probabilities), are correctly
interpreted as an estimate of how much more likely people sharing the same genotype combination
are to develop the condition of interest when compared to a group without this genotype com-
bination. The numerator of the RR is the risk of the condition given the genotype combination
of interest, but clearly, the RR (or the OR) itself is not an estimate of individual-level risk and
certainly not a diagnostic test or classifier.
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Figure 6.2: AUC for additive risk models of SNP markers as function of risk allele frequency in cases.
The AUC is estimated for all risk allele frequencies in controls assuming additive ORs 1.5, 3, 5, 10,
and 50 (the ORs are marked on the curves). The numbers in gray are the risk allele frequencies
in controls corresponding to the maximum AUC for each OR. The dotted horizontal line in gray
marks an AUC of 0.7 and 0.8. The black diamonds highlight the points (pca, AUC)=(pca, 0.80) for
markers with additive ORs 10 and 50 (see table 6.1).
Statisticians should easily understand this relationship between OR, RR, and risk, but a
person not trained in statistics (or science in general) may not make the same distinction as easily.
Numerous studies in the genetic counseling literature have investigated what people make of risk
estimates. For example, in a study of women’s perceived risk of breast cancer, 98% of women
overestimated their risk of dying from breast cancer in 10 y by half to 8-fold when asked to quantify
risk as a number out of 1,000. Interestingly, only 10% of those women thought they were at higher
risk than an average woman their age (Woloshin et al. 1999).
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Table 6.1: AUC, risk allele frequency in cases (pca) and controls (pco) for specific ORs in an additive
model (genotypes coded 0-1-2 according to number of risk alleles).
AUC = 0.80
OR Maximum AUC pca pco pca pco
1.5 0.58 0.55 0.45 NP NP
3 0.70 0.63 0.36 NP NP
5 0.77 0.69 0.31 NP NP
10 0.85 0.76 0.24 0.49 0.09
50 0.96 0.88 0.13 0.39 0.01
NP=Not possible
6.6 CLINICAL VALIDITY AND UTILITY OF PREDICTIVE GENETIC
TESTING
The clinical validity is measured by the discrimination ability of the marker, or its ability to classify
people as cases or controls. The AUC, though imperfect, is a popular and easily interpretable
measure of classification accuracy. It can be interpreted as the probability that predicted risk is
higher for a case than a control. Various TPF and FPF pairs and various values of the AUC can
correspond to the same OR (fig. 6.1). Thus, the OR by itself cannot give a meaningful indication
of the probability of being correctly classified as case (TPF) or of the probability of being wrongly
classified as a case (FPF), and alone its value is essentially useless to the individual.
The clinical utility of predictive genetic profiling for complex diseases rests on at least two
conditions: (1) preventive means with high efficacy in the general population are available, and
(2) these preventive means will also be effective in the genetically high-risk cohorts. Additionally,
it is worth noting that for many complex diseases, known preventive lifestyle changes are broadly
beneficial: weight loss, smoking cessation, blood pressure control, regular exercise, diets enriched
with fruits and vegetables, etc., so to many individuals, it might be wasteful to spend 1,000 to find
out they are genetically at increased risk for some condition only to have their doctor tell them all
they can do is to lose weight and stop smoking. On the other hand, if the person is more likely to
make lifestyle changes and stick to them, then the benefits can be great, both for the individual
and the population as whole. Of course, the flip side is what the actions will be if the genetic test
suggests lower than average risk for one or more specific conditions.
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6.7 RECLASSIFICATION
The AUC attempts to measure the ability of a model to discriminate between cases and controls for
a set of cutoff values that separate the two groups. However, on an individual basis, we also want
the model to provide the best possible estimation of that person’s risk. One way to compare the
accuracy of individual-level risk estimates of different risk models is to use the reclassification table
approach (Cook 2007; Pencina et al. 2008). In this approach, one measures how often subjects
are estimated to be in different risk strata when different risk models are applied and whether the
reclassification more accurately stratifies individuals into higher or lower risk strata. A marker that
has a modest or no effect on the AUC can improve risk classification (Cook 2007). For example,
suppose we are comparing two risk models that differ regarding a single individual’s membership
in the 20%–30% risk stratum versus the 10%–20% risk stratum. If both models achieve the best
discrimination by classifying everyone below the 40% risk threshold as controls and everyone above
as cases, then the TPF and FPF will not be altered due to this person’s reclassification, but one
model is more accurate than the other in terms of the true value of the individual’s risk estimate.
6.8 EXAMPLES
We now provide several examples, from the literature as well as from our own data, illustrating that
although a set of SNPs can be strongly associated with disease risk with extremely small p-values,
that same set of SNPs may not necessarily have high discrimination ability or may not dramati-
cally improve the discrimination ability of a classification model constructed using “conventional”
nongenetic risk factors without the SNPs.
6.8.1 Risk of Cardiovascular Events
In a recent replication study of nine SNPs associated with levels of either low-density lipoprotein
(LDL) or high-density lipoprotein (HDL) cholesterol, Kathiresan et al. (2008) created a genotype
score on the basis of the total number of unfavorable alleles at these risk SNPs, and investigated the
classification accuracy of the genotype score and the effect on reclassification beyond standard risk
factors for cardiovascular events. The authors found that accounting for the effect of the nine SNPs
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did not improve the classification accuracy of their model. The ROC curves with and without the
genotype score lined up almost perfectly, and both had an AUC of 0.80 despite the SNPs having P
values as low as 10−29, with six out of nine SNPs having P values < 10−6 (Appendix D and Table
D1). Adding the genotype score to the model did, however, modestly improve the reclassification.
Unfortunately for this dataset, the classification accuracy of the genotype score alone was not
estimated. Nevertheless, these data provide an example of highly associated variants that do not
markedly improve the discrimination ability of a model, yet at the same time, they give hope that
genetic variants may become valuable prognostic tools.
6.8.2 Risk of Type 2 Diabetes
In type 2 diabetes, 12 SNPs (Scott et al. 2007; Sladek et al. 2007; Weedon et al. 2006) with
P values as low as 10−34 (Appendix D and Table D2) reach an AUC of 0.64, suggesting only fair
discrimination power. We arrived at this AUC of 0.64 using only published allele frequencies; we
did this using the method of Lu and Elston (2008) (Appendix D, Estimating the AUC from
meta-data). Lu and Elston (2008) also applied their method to a model of the same 12 SNPs
and four additional environmental factors, and got a slightly improved AUC of 0.67.
6.8.3 Risk of Prostate Cancer
A genetic classification model of two prostate cancer risk SNPs in low linkage disequilibrium with
each other (Yeager et al. 2007) has an AUC of 0.56, based on the method of Lu and Elston
(2008). An AUC of this magnitude suggests that the model has a very poor discrimination power.
The SNPs have P values of 10−13 and 10−14, but the genotype–specific ORs are not extreme and
range from 1.3 to 2.2 (D and Table D3).
6.8.4 Risk of Inflammatory Bowel Disease
A genetic classification model of five well-replicated genetic associations (Cummings et al. 2007;
Cummings et al. 2007; Duerr et al. 2006; Parkes et al. 2007; Rioux et al. 2007) in inflammatory
bowel disease (Crohn’s disease) has an AUC of only 0.66. This suggests only fair discrimination
power for Crohn’s disease despite the variants being highly significant (P values range from 10−7
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to 10−14) and one SNP having quite an extreme OR of 0.26 ( 1/4). Again, the method of Lu and
Elston was used to estimate the AUC [20]. For more details, see Appendix D and Table D4.
6.8.5 Risk of Age-Related Macular Degeneration
Using our previous published AMD data (Jakobsdottir et al. 2008) on the CFH, LOC387715,
and C2 variants, we plotted the ROC curves and estimated the AUC and positive predictive values
of one-, two-, and three-factor models (detailed methods are in Appendix D). Fig. 6.3 displays
the ROC curves for the null model and for five genetic risk models: the three-factor model of
CFH, LOC387715, and C2 SNPs, the two-factor model of CFH and LOC387715, and all of the
one-factor models. We see that to correctly identify about 74% of the cases using the three-factor
model, we would wrongly classify 31% of the controls, and for the TPF to be around 80%, the FPF
needs to be unacceptably high (¿40%). The AUC for the three-factor model is quite high, 0.79,
and significantly different from 0.5 (95% confidence interval [CI] 0.74–0.83) (table 6.2). Table 6.2
also gives the results of logistic regression analysis: the ORs for additive inheritance of CFH and
LOC387715 risk alleles are about 3 with P values of around 10−13.
We also plotted the integrated predictiveness and classification plot, which combines infor-
mation from both the risk- and classification-based analysis approaches discussed above (Pepe
et al. 2008). In the integrated plot (fig. 6.4), there are two aligned plots: in the top plot, ordered
individual risks are plotted as function of the risk percentile, and in the bottom plot, the TPF and
FPF are plotted as a function of the risk percentile such that at each point, the TPF and FPF are
calculated for the risk threshold equal to the risk associated with the corresponding risk percentile.
If we now look at the integrated predictiveness and classification plot for the three-factor model,
we see that the TPF and FPF pair 74% and 31% corresponds to the 35% risk percentile (fig. 6.4,
bottom panel), which then corresponds to choosing an AMD risk of 4% as the cutoff point for
classifying individuals (fig. 6.4, top panel). Those with risk greater than 4% are assumed to be
at high risk and are classified as cases, and those with lower risk are classified as controls. To
illustrate this, suppose we have a population of size 1,000 and a prevalence of 5.5% (which is the
prevalence of advanced AMD in the U.S. in white individuals 65 y or older according to Friedman
et al. (2004) and the U.S. 2000 census data–see Appendix D for further details). If the prevalence is
5.5%, there would be 55 cases in our population. Of those 55 cases, 74%, or 41, would be correctly
considered to be at high risk of AMD, and 31%, or 293, of the true 945 controls would be wrongly
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Figure 6.3: ROC curves for AMD classification models. The black diamond highlights the point
(FPF, TPF) = (31%, 74%) on the ROC curve of the three-factor model of CFH, LOC387715, and
C2. The gray line for reference gives the “chance” classification rule: the farther the ROC curve is
from the chance line, the better the classification rule.
assumed to be at high risk. Therefore, out of the 334 (41+293) individuals in the high-risk group,
88% should actually be in the low-risk group, or in other words, the PPV would be only 12% (i.e.,
100%–88%). When designing a clinical trial to test preventive therapies in high-risk cohorts based
on genotyping alone, it may or may not be cost effective to have 12% (instead of 5.5%) of the study
cohort as true cases. However, as a clinical test, it may be considered unethical to needlessly alarm
88% of the high-risk cohort, especially when limited treatment and preventive options are available
(Young 2007).
To lower the proportion of controls in the high-risk cohort, a more stringent threshold for
calling someone high risk, say 25%, can be used instead of the 4% threshold used above. However,
using this higher risk threshold only lowers the proportion of controls in the high-risk group from
88% to 84%, as can be seen in this manner: the plot (fig. 6.4, top panel) shows that the risk
threshold of 25% corresponds to the 85% risk percentile. Looking at the classification curve (fig.
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Table 6.2: Results of logistic regression and ROC analysis.
Model Logistic regression ROC analysis
Factors OR P value AUC 95% CI
Model 1 0.79 0.74–0.83
CFH 2.89 9.1× 10−13
LOC387715 3.42 2.3× 10−13
C2 0.39 1.3× 10−3
Model 2 0.77 0.73–0.82
CFH 3.00 9.1× 10−14
LOC387715 3.38 2.5× 10−13
Model 3 0.69 0.64-0.73
CFH 2.77 2.1× 10−13
Model 4 0.69 0.65-0.74
LOC387715 3.11 6.2× 10−13
Model 5 0.56 0.53-0.60
C2 0.33 1.9× 10−5
The ORs for each variant is for an additive model
in which the genotypes are coded 0-1-2.
The confidence intervals (CIs) for the AUC are asymptotic
and derived using the DeLong’s estimator (Zhou et al. 2002)
for the variance
6.4, bottom panel), we see that the 85% risk percentile corresponds to a TPF of 17% and FPF of
5%. Again, to put these numbers in perspective, let us again assume we have a population of size
1,000. Nine (17%) out of 55 true cases would then be correctly classified as “high risk”, and 47 (5%)
out of 945 controls would be incorrectly classified as high risk. Therefore 84% (47/56 = 47/(9+47))
of those classified as “high risk” would actually be controls (PPV = 100%–84% = 16%).
When applied to case–control data, the integrated predictiveness and classification plot de-
pends on the assumed prevalence of the disease, which may not be known with precision or may,
as in the case of AMD, depend strongly on age. Note that as the prevalence changes, the bottom
plot does not change, only the top plot does: although it still will look essentially the same, the
risks will be more spread out between 0 and 1 as the prevalence gets higher and less spread out
otherwise.
Second, it is worth noting how the results of our AMD example change if different values
for the prevalence are used. The prevalence of AMD is highly age-dependent, and in table 6.3, we





































Figure 6.4: Integrated predictiveness and classification plot for the three-factor model. The light
gray lines show how the plots are used in the examples given in the text: the dashed lines are for the
first example with TPF = 74%, FPF = 31%, risk percentile = 35%, and AMD risk threshold = 4%;
and the dotted lines are for the second example with AMD risk threshold = 25%, risk percentile
=85%, TPF = 17% and FPF = 5%. On the top panel, the risks for cases are marked with a dot
in black while the risks for controls are marked with a vertical line segment in dark-gary.
the results are less disappointing (PPV increases) but are even worse if it decreases (table 6.3).
Clearly, the ability to discriminate between current cases and controls, based on genotype data
from CFH, LOC387715, and C2 alone, changes with age. A crude estimate of the lifetime risk at
age 80 y, given a genetically high-risk score based on the three variants, is 30% compared to 15%
baseline lifetime risk at age 80 (table 6.3).
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Table 6.3: Positive predictive values (PPV) for different values of the prevalence.
Prevalence Age group Risk threshold PPV
15% 80 y and older 10% 30%
5.5% 65 y and older 4% 12%
1.5% 40 y and older 1% 3%
The risk threshold corresponds to TPF = 74% and FPF = 31%.
(as in the first example in the text).
PPV = proportion of cases in the high-risk group.
1-PPV = proportion of controls in the high-risk group.
6.9 DISCUSSION OF THE AMD EXAMPLE
If the primary goal of genetic diagnostic tests for AMD were to identify those who are at high
risk before they show irreversible degenerative changes to maximize the effectiveness of long-term
preventive strategies, then we would want to test individuals 40–55 y old (or younger) to predict
whether they will develop AMD before age 80 y. Our case-control data presented here do not
fully measure the ability of genetic data to predict future disease status (prognosis) for several
reasons: (1) AMD prevalence increases with age, (2) females have higher prevalence in all age
groups compared to males, (3) females live longer, (4) the FPF derived from case-control data is
overestimated because some controls will develop AMD as the cohort ages, (5) the case/control
counts are unbalanced, so our sample may not be optimal for estimating the classification accuracy
of the markers (Janes and Pepe 2006), and (6) the estimates of the ORs, and estimates from
most other AMD case-control studies, are based on the comparison of extreme phenotypes: a
group of individuals with advanced AMD are contrasted with a control group of individuals with
no or very minimal clinical findings. Therefore, they very likely overestimate the RR and the
discrimination power for individuals with intermediate clinical findings. Even accounting for all
these issues in an optimistic manner, the overall conclusions of our analysis are unlikely to change
dramatically. Proper analyses of longitudinal cohort data using survival analysis techniques could
lead to a more precise assessment of the potential value of genetic data in predicting lifetime AMD
status (Moskowitz and Pepe 2004; Pepe et al. 2008).
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The major achievements that have been made in understanding the genetics of AMD are
well known, and the AMD discoveries (Edwards et al. 2005; Hageman et al. 2005; Haines et al.
2005; Jakobsdottir et al. 2005; Klein et al. 2005; Rivera et al. 2005) are widely mentioned as
the first “proof” that genome-wide association analysis works (although the majority of the AMD
studies were not genome-wide association studies, but rather targeted searches following up regions
of linkage). The results have been so exciting that perhaps all of us who study AMD are guilty of
overstating our results. Here are just a few examples:
“Nevertheless, with all the genetic findings, it may soon be possible to provide pre-symptomatic
diagnosis with reasonable accuracy, leading to better disease management strategies for high-risk
individuals.”—Swaroop et al. (2007)
“The continued support for these genes in ARM susceptibility will hopefully bring us closer to being
able to utilize the information in these genes to identify at risk individuals and provide a rational
basis for future clinical trials to test preventive therapies in high-risk cohorts.”—Conley et al. (2006)
“Expressed another way, these genotypes apparently identify individuals whose lifetime risk of AMD
ranges from less than 1% to more than 50%; however, longitudinal studies are needed to define
the true risk attributable to these loci and the ways in which these might interact with the known
environmental and lifestyle risk factors.”—Maller et al. (2006)
All these statements are scientifically valid, they are carefully worded, and it is clear the
investigators are talking about “potential”, “future”, and “hope”. Nevertheless, they can and have
been overinterpreted. For example, a recent review (Ross et al. 2007) cites Maller et al. (2006)
and states:
“SNPs in complement factor H (CFH) and PLEKHA1/ARMS2/HtrA1 capture a substantial fraction
of AMD risk and permit the identification of individuals at high risk of developing AMD.”
Even Nature Genetics appears to also overstate the potential impact of AMD genetics. In
the December 2007 issue (Editorial 2007), the editors discuss the new hype about personalized
genomics and ask: With the possible exception of age-related macular degeneration, how much can
we say with confidence about the spectrum of risk? However, as we have shown here, we cannot
yet make an exception for AMD. We should, however, not let this discourage us. The discoveries
of the AMD risk genes are truly amazing, and they should of course encourage and guide future
research. In fact, the discovery of the likely involvement of the CFH gene gave firmer footing to the
hypothesis that the abnormal function of complement pathway can cause AMD and has resulted
in discoveries of other AMD genes in this pathway (Gold et al. 2006; Dinu et al. 2007; Maller
et al. 2007; Yates et al. 2007).
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6.10 CONCLUSIONS
Genetic association studies have identified many susceptibility variants for complex diseases and, in
many cases, added to the understanding of the etiology of the diseases. However, as we discuss here
using real data and theoretical examples, strong association does not necessarily guarantee good
classification or discrimination ability. Before using association results for classification and risk
estimation purposes, we need to establish their effectiveness formally using appropriate measures
and, ideally, appropriate study designs. Additionally, when evaluating the improvement in the
predictive value by adding a marker to a prediction model, we may need to use additional measures
besides the AUC, such as reclassification tables.
In our examples, we saw that the addition of nine highly significant risk SNPs to the risk
model could not improve the discrimination power for cardiovascular events beyond standard risk
factors. For type 2 diabetes, the classification rule based on 12 SNPs gave an AUC of only 0.64, a
value that is well below the guidelines of 0.75 and 0.99 cutoffs for screening and prognosis purposes,
respectively. For Crohn’s disease, a classification model based on five SNPs gave an AUC of only
0.66, and for prostate cancer, a model of two SNPs achieves an AUC of only 0.56. Both values
are well below the 0.75 and 0.99 cutoffs. For AMD, the AUC of a model with three SNPs was
0.80, but the proportion of positive test results among affected individuals was only 30%, 12%,
and 3%, depending on assumed prevalence (15%, 5.5%, and 1.5%, respectively). The results of
these four examples, although somewhat disappointing, are not surprising given the theoretical
results of Janssens et al. (2007, Janssens et al. (2006) that indicate that achieving a high AUC
requires a much larger number of genetic variants than we have to date. For example, Janssens et
al. demonstrated that for genetic profiling, on average 80 common variants with ORs of 1.25 each
were needed to develop a model useful for identification of high-risk individuals (AUC¿0.80).
Even though our examples illustrate that highly associated SNPs may not be effective as
classifiers, it should not be concluded that the association findings are not important nor that
association studies are not valuable. In many cases, the association discoveries have and will
continue to result in new etiological hypotheses previously not considered. For example, in the
case of AMD, the CFH discovery (Edwards et al. 2005; Hageman et al. 2005; Haines et al.
2005; Klein et al. 2005) resulted in a new focus on the complement pathway and subsequent
identification of additional novel disease genes in that pathway (Gold et al. 2006; Dinu et al.
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2007; Maller et al. 2007; Yates et al. 2007). The scientific community should be very cautious to
avoid overhyping association findings in terms of their “personalized medicine” value before their
time, lest we lose the goodwill and support of the general public.
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7.0 SCORE STATISTICS FOR X-LINKED QTLS
This part of the dissertation focuses on linkage mapping methods for X-linked QTLs. In the next
sections I explain issues specific to X-linked inheritance and give an overview of linkage methods
for QTLs and.
7.1 X-LINKED INHERITANCE
As mentioned previously the genetic material in humans is stored in 23 pairs of chromosomes and
most human cells contain 46 chromosomes. Two of these are the sex chromosomes, two paired X’s
in females and an X and a Y in males. The remaining 22 pairs are the homologous pairs called
autosomes. One chromosome of each homologous pair is maternally transmitted via an egg and
the other is paternally transmitted via a sperm. The eggs contain 22 autosomes and an X but the
sperm contain 22 autosomes and an X or a Y.
Most female cells contain two X chromosome but a simple dosage model (such as an additive
model) may not be realistic for all X-linked loci. In each female cell 75% of loci are believed to be
expressed only from one of the X chromosomes while the other chromosome is inactivated. About
15% of loci are estimated to escape inactivation (or have incomplete inactivation) and 10% of loci
exhibit rates of inactivation that vary widely among individual females (Carrel and Willard
2005). Typically either the whole maternally or the whole paternally derived X chromosome is
inactivated (randomly) during mitosis so that in one cell all the genes are expressed from the same
chromosome. However, between cells it varies which chromosome is inactivated. In humans the
timing of inactivation occurs early on in the development of the embryo. During the very early
stages in the development of the placenta and other organs that support the embryo, inactivation
is imprinted such that paternally derived X chromosome is always inactivated. Therefore, in both
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female and male embryos the placenta only expresses genes from the mother’s X chromosome.
Later in the development this is reversed and random inactivation occurs in all cells that form
other tissues. Since all the daughter cells have the same chromosome inactivated and after a
certain time-point the inactivation cannot be reversed, cell patches are formed such that all the
cells in any particular patch have the same X chromosome inactivated.
The pseudoautosomal regions, PAR1 and PAR2, are homologous sequences on the X and
Y chromosomes. The regions are called pseudoautosomal because any genes located within them
are inherited similarly to the autosomal genes. Males have two copies of these genes, one in the
pseudoautosomal region on Y and the other on the corresponding region on the X chromosome.
Females also have two copies of the pseudoautosomal genes, as each of their two X chromosomes
contains a pseudoautosomal region. The pseudoautosomal regions allow the X and Y chromosomes
to pair and properly segregate during meiosis in males. Crossing over can occur between the
pseudoautosomal regions on the X and Y chromosomes in males. Therefore, females can inherit an
allele originally from their father’s Y chromosome and likewise males can inherit an allele originally
from their father’s X chromosome. Most mapping studies support at least one obligatory crossover
in the PAR1 and it has been suggested that sons have 50% chance of receiving the Y PAR1
haplotype from their fathers as a whole without recombination (Flaquer et al. 2008).
7.2 OVERVIEW: QTL LINKAGE METHODS
An early method for investigation of linkage of QTLs is the Haseman-Elston Regression (HE-
regression) (Haseman and Elston 1972). In HE-regression the squared trait differences of sib
pairs yD are regressed on the estimated proportion of alleles at a locus shared identical by descent.
Various extensions have been made to improve the original HE-regression and an X-linked version
has also been developed (Wiener et al. 2003). An important extension of the HE-regression
was based on the observation that the squared trait sum adds independent information to the
regression model (Drigalenko 1998). Thus, the method has been improved by changing the
dependent variable from the squared difference to the mean-corrected product of the sib-pair trait
values (Elston et al. 2000).
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Later, variance components (VC) methods were developed. The basic idea of the VC model
is to fit a multivariate normal model to the trait values of relatives with a variance-covariance
matrix that expresses the covariance between relatives as function of the IBD sharing at a marker
locus (Amos 1994; Goldgar 1990; Schork 1993). The VC model led to development of powerful
statistics for both linkage and association analyses. The major strengths of the model are that the
framework allows models to be easily extended to incorporate household effects, individual-specific
covariates, and interactions (Blangero and Almasy 1997). Since the power of the method is
proportional to the heritability, power can often be increased by reducing the residual variance by
adjusting for covariates (Zeegers et al. 2004). Naive incorporation of covariates can, however,
inflate the type I error (Zeegers et al. 2004; Purcell and Sham 2002). The main disadvantage
of the VC model is its sensitivity to violations of normality. This is of particular importance as
the assumption of normality is often violated under the alternative. The VC models have been
extended for X-linked traits; Ekstrøm (2004) assumed an additive model, ignoring the possibility
of X-inactivation in females, while Lange and Sobel (2006) and Kent et al. (2005) allowed for
X-inactivation.
The latest statistics for QTL mapping are regression-based score statistics (or score tests)
proposed by numerous authors (Lebrec et al. 2004; Tang and Siegmund 2001; Putter et al.
2002; Wang and Huang 2002b; Wang and Huang 2002a; Wang 2002). The statistics attempt
to achieve the power of the VC models while being less sensitive to non-normality and selected
samples. The score test is a locally most powerful test and can be computationally fast, and
much faster than the VC methods on large pedigrees. Score tests are simply the partial derivative
of the likelihood with respect to the linkage parameter(s) evaluated under the null hypothesis
of no linkage and standardized (by the information or an estimate of the standard error). The
theoretical background of score tests for autosomal QTL mapping is more or less complete and
recently investigation of appropriate methods to estimate the standardization factor was published
(Bhattacharjee et al. 2008). The choice of an appropriate standardization factor directly affects
power and so is very important. To my knowledge the score statistics have not been extended for
X-linked traits, which is the goal of this part of the dissertation.
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7.3 MODEL
In order to develop score statistics for X-linked traits, we assume the quantitative phenotypic value
yi of individual i is influenced by a X-linked locus in the following manner:
yi = µis + g
i
kl + ei (7.3.1)
where µs is the sex-specific mean (s = m, f), gkl represents the genotypic value of the X-linked QTL
for genotype k/l in females or k in males, and e represents the residuals, i.e., the environmental effect
that is unique to each individual, and which is assumed to be uncorrelated between individuals.







where σ2g is the variance attributed to the X-linked QTL and σ
2
e the random noise.
For an additive model in females we define gkl = αk + αl + δkl and for males we define
gkl = gk = βk. We interpret αk as the effect of allele k in females and βk is the effect in males
and δkl is the dominance deviation from an additive model. The inactivation of one of the X
chromosomes in females suggests that dosage compensation needs to be modeled. However, we
start by assuming that all loci escape inactivation and use the additive model. The main reason
to start with this simplifying assumption is the fact that the same X chromosome needs not to be
inactivated in all cells. Therefore, to model inactivation the most appropriate model is probably a
model where the contribution of each allele is weighted by 0.5 in females. Hence, the derivation of
the score statistics would be essentially the same as for an additive model in females. We denote
the population allele frequency as pk and assume Hardy-Weinberg equilibrium and equal allele
frequencies in females and males.
7.4 ALLELIC AND GENOTYPIC EFFECTS
No generality is lost if all the trait values are standardized so that E[y] = 0 and E[e] = 0. In this
section we therefore work with the model yi = gikl+ei. Note, that the means µ
i
s we have subtracted
from each side may be different for males and females. However, the global mean remains zero as
112
this sex-specific standardization gives
E[y] = E[y|female]P [female] + E[y|male]P [male]
= 0P [female] + 0P [male] = 0
In reality, the strictly additive model in females may not fit perfectly and so the allelic effects
αk and the dominance deviation δkl are are estimated such that |δkl| = |gkl−αk−αl| are minimized.




kl, where pk is the
population allele frequency of allele k. Now under our assumption of standardized trait values
E[y] = 0 we get
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∑


















k,l pkplδkl = 0 and 2
∑
k pkαk = −
∑
k,l pkplδkl = 0 and we have E[α] =
∑
k pkαk = 0
and E[g] = 0. The effect of allele k in males is βk = gk and so E[β] = E[g] = E[y|male] = 0. Hence
we can assume that E[g] = 0, which will simplify our derivations in later sections.
7.5 VARIANCES-COVARIANCES
7.5.1 X-linked kinship coefficient and variances-covariances
Genetic identity coefficients are powerful tools for genetic analysis. Here we define the kinship
coefficient and condensed identity coefficients for non-inbred individuals.
The kinship coefficient φij is a simple measurement of relationship between two relatives i
and j. Namely φij is the probability that allele selected randomly from i and an allele selected
randomly from the same autosomal locus of j are IBD. Thus the kinship coefficient takes into
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account the common ancestry of i and j as defined by the pedigree structure but ignoring their
genotypes (Lange 2003; Malcot 1948).
The IBD relation partitions the four alleles of ordered genotypes, afi |ami and afj |amj , of in-
dividuals i and j into equivalent classes or identity states; superscript f and m denote the allele
inherited from the mother and father, respectively. The detailed identity states keep track of the
IBD status according to the ordered genotypes (Jacquard 1966). The condensed identity states,
however, keep track of how many alleles are IBD within and between individuals. At an autosomal
locus there are a total of 15 detailed identity states and 9 condensed identity states. The condensed
identity coefficient ∆c is the probability of the condensed identity state Sc (Figure 7.1) .
For two non-inbred individuals, the (autosomal) kinship coefficient and the (autosomal)















4∆8,X for female-female pair
P1 for male-male pair
1
2Λ3 for female-male pair
where ∆c,X , Pc, and Λc are the sex-specific condensed identity coefficients for female-female, male-
male, and female-male relative pairs, respectively (Figure 7.2). Note that ∆c,X will generally be
different from ∆c.
In next section we will derive the covariance formula for all three types of relative pairs
(female–female pairs, male–male pairs and female–male pairs). For comparison the covariance for
autosomal loci is





where σ2a is the variance component accounted for by the additive genetic effect of autosomal loci










































S1 S2 S3 S4 S5
S6 S7 S8 S9
Figure 7.1: Detailed identity states on the left and condensed states on the right. The autosomal
and female-female sex-specific states are the same. ∆c is the probability of state Sc at autosomal
loci and ∆c,X the probability at X-linked loci. Alleles have lines drawn between them if they are
IBD. Therefore condensed states S1, S2, S3, S4, S5 and S6 all have probability zero in non-inbred
individuals. S1 = S∗1 , S3 = S∗2∪S∗3 , S5 = S∗4∪S∗5 , S7 = S∗9∪S∗12, and S8 = S∗10∪S∗11∪S∗13∪S∗14. The
graphical presentation of identity states is adapted from Jacquard (Jacquard 1974) and Lange
(Lange 2003).








Figure 7.2: The condensed identity states for X-linked loci of female-male and male-male pairs. The
probability of each state is given in the figure. For non-inbred individuals Λ1 = Λ2 = 0. Adapted
after Pan et al. (2007), Jacquard (1974), and Lange (2003).
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7.5.2 Female-Female relative pairs
In this section we derive the covariance between two non-inbred females by conditioning on various
identity states (Figure 7.2) and using the facts
∑
k pk = 1, E[α] =
∑
k pkαk = 0,
∑
j pjδkj = 0, and
αk =
∑
j pjgkj . Since the trait values y have been standardized, we have
Cov(yi, yj) = Cov(gikl, g
j
kl) trait values standardized
= E[giklg
j
uv]− E[gikl]E[gjuv] general covariance formula
= E[giklg
j












k,l(αk + αl + δkl)
2pkpl k = u; l = v if both alleles IBD
+∆ij8,X
∑
k,l,v(αk + αl + δkl)(αk + αv + δkv)pkplpv k = u if one allele IBD
+∆ij9,X
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8,X ]2V ar[α] + ∆
ij
7,XV ar[δ] E[α] = E[δ] = 0






a,f ≡ 2V ar[α];σ2d,f ≡ V ar[δ]
Note, that this derivation is essentially identical to derivations for covariances of traits due to an
autosomal QTL (Lange 2003)- the kinship coefficient φij is replaced by its X-linked version ψij
and the condensed identity coefficients ∆c are similarly replaced by its X-linked version ∆c,X .
7.5.3 Male-Male relative pairs
We derive the covariance between two non-inbred males by conditioning on various identity states
(Figure 7.2) and using the facts
∑
k pk = 1 and E[β] =
∑
k pkβk = 0. Since the trait values are
standardized, we have
Cov(yi, yj) = Cov(gik, g
j
u) trait values standardized
= E[gikg
j
u]− E[gik]E[gju] general covariance formula
= E[gikg
j
u] E[g] = 0
= E[gikg
j














k pkβk = 0
= P1E[β2]
= P1V ar[β] E[β] = 0
= P1σ2X,m σ
2
X,m ≡ V ar[β]
= ψijσ2X,m
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7.5.4 Female-Male relative pairs
We derive the covariance between non-inbred females and males by conditioning on various identity
states (Figure 7.2) and using the facts
∑
k pk = 1, E[α] =
∑
k pkαk = 0, αk =
∑
j pjgkj , and
E[β] =
∑
k pkβk = 0. Since the trait values are standardized, we have
Cov(yi, yj) = Cov(gikl, g
j
u) trait values standardized
= E[giklg
j
u]− E[gikl]E[gju] general covariance formula
= E[giklg
j
u] E[g] = 0
= E[giklg
j
u|1 allele IBD]Λ3 + E[giklgju|0 alleles IBD]Λ4 condition on IBD status
= Λ3
∑
k,l(αk + αl + δkl)βkpkpl + Λ4
∑
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√






The scaling of the covariance by
√
2 is the one chosen by Bulmer (1985), Kent et al. (2005),





X,m. The constraint is a result of the Cauchy–Schwarz inequality:
σ2X,fm = 2E[αβ]







From the derivations in sections 7.5.2, 7.5.3, and 7.5.4 we have the covariances due to an












d,f i 6= j female-female
σ2X,m + σ
2
e i = j male
ψijσ
2
X,m i 6= j male-male√
2ψijσX,fm i 6= j female-male
(7.5.2)
7.5.5 Marker loci
Now consider a candidate marker locus. If either the marker is at the trait locus or there is
no recombination between them then we derive the covariance between two related individuals
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conditional on number alleles shared IBD at the marker locus. Let IBD(i, j) denote number of
alleles individuals i and j share IBD. From sections 7.5.2, 7.5.3, and 7.5.4 we can quite easily see
Cov(yi, yj |IBD(i, j) = τ) =









Now if we add and subtract Cov(yi, yj) from the right hand side and the substitute the
second part according to formula 7.5.2
Cov(yi, yj |IBD(i, j) = τ)
=

Cov(yi, yj) + (1{τ=1}/2 + 1{τ=2} − 2ψij)σ2a,f + (1{τ=2} −∆ij7,X)σ2d,f female-female
Cov(yi, yj) + (1{τ=1} − ψij)σ2X,m male-male




These expressions have the well-known desirable form which separates the segregation pa-






X,fm) in the remaining terms
(Tang and Siegmund 2001; Wang 2002). This means that the partial derivatives of Cov(yi, yj)
w.r.t the linkage parameters equals zero. Furthermore the covariance matrix is linear with respect
to the linkage parameters. We like to point out that this separation of segregation and linkage
parameters is not quite right, under our model, since the variance components due to the trait
contribute to Cov(yi, yj) as can be seen in equation 7.5.2. However allowing the partial derivative
of Cov(yi, yj) = 0 w.r.t to linkage parameters can be defended in at least three ways:
1. Cov(yi, yj) can be estimated from the observations yi themselves without any assumption of
linkage or inheritance. If the underlying model is good and the ascertainment and sample size
are such that the estimators are consistent then this is reasonable to do. This is the reason
behind similar derivations in the autosomal case (Tang and Siegmund 2001; Wang 2002)
2. Generally a number of QTLs, each with relatively small effect on the trait, contribute to the trait
variance and so Cov(yi, yj) will be approximately constant w.r.t to the trait linkage parameters.
Hence the derivative should be approximately zero. Note, that for simplicity we have, as Tang
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and Siegmund (2001) did, assumed only one major QTL in their derivations. Wang (2002),
on the other hand, modeled multiple QTLs.
3. The test statistic resulting from assuming that the partial derivative of Cov(yi, yj) = 0 w.r.t
to linkage parameters is intuitively sensible as then we are looking at how far the IBD sharing
deviates from its expected values.
7.6 SCORE FUNCTIONS AND LIKELIHOOD
The genetic similarity among individuals is characterized by their IBD configurations. Let γn be
the probability of the nth IBD configuration in a pedigree. Assume that conditional on the nth
IBD configuration among the pedigree members, the phenotype y follows a multivariate normal
distribution with mean vector µs of sex-specific global means and variance-covariance matrix Σn;
the elements of Σn are the conditional covariances in formula 7.5.4. Additionally assume random
(or unselected) sampling. The density is
φ(y;µs,Σn) ∝ |Σn|−1/2exp{−12(y − µs)
TΣ−1n (y − µs)}









In the next subsections we derive the scores of the log-likelihood for each parameter.
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7.6.1 Score for σ2a,f
The partial derivative of
∑


























exp{− 12 (y − µs)TΣ−1n (y − µs)}
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− 12 |Σn|−3/2|Σn|tr(Σ−1n ∂Σn∂σ2a,f ) exp{−
1
2 (y − µs)TΣ−1n (y − µs)} (∗)
− 12 |Σn|−1/2 exp{− 12 (y − µs)TΣ−1n (y − µs)}(y − µs)T (−Σ−1n ∂Σn∂σ2a,f Σ
−1








2 |Σn|−1/2 exp{− 12 (y − µs)TΣ−1n (y − µs)}
{
(∗ ∗ ∗)













{− tr(Σ−1n ∂Σn∂σ2a,f ) + (y − µs)T (Σ−1n ∂Σn∂σ2a,f Σ−1n )(y − µs)}}γn (∗ ∗ ∗∗)
In the above derivation we used




for matrix A = Σn and scalar x = σ2a,f
(∗∗) Here we used ∂∂xvTA−1v = vT ∂A
−1
∂x v if v independent of x, and
∂A−1
∂x = −A−1 ∂A∂xA−1 for matrix
A = Σn, vector v = y − µs, and scalar x = σ2a,f
(∗ ∗ ∗) Here we factorize 12 |Σn|−1/2 exp{−12(y − µs)TΣ−1n (y − µs)} out
(∗ ∗ ∗∗) Here we have φ(y;µs,Σn) ≡ 12 |Σn|−1/2 exp{−12(y − µs)TΣ−1n (y − µs)}







































{− tr(Σ−1n ∂Σn∂σ2a,f ) + (y − µs)T (Σ−1n ∂Σn∂σ2a,f Σ−1n )(y − µs)}}γn∑
n φ(y;µs,Σn)γn
(7.6.1)




X,m, σX,fm). If we evaluate each partial derivative at θ = 0 then we note
that all the terms φ(y;µs,Σn)γn are equal Σn|θ=0 ≡ Σ(0). Therefore we factorize φ(y;µs,Σn)γn
out of the sums in the numerator and denominator in equation 7.6.1 and use
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Now define matrix Π, a symmetric matrix whose elements pii,j = pi
(1)
ij /2 + pi
(2)
ij , where pi
(k)
ij is
the probability of individuals i and j sharing k alleles IBD at the marker locus. Note, that pii,j can
be interpreted as the averaged number of alleles shared IBD. We then split the matrix up according
to the sexes of the relative pairs: Π = Πf + Πm + Πfm, where Πf are the same as Π except that
the elements corresponding to non-female-female pairs are zero. The other matrices are similarly
defined. We also define matrix Ω, a symmetric matrix whose diagonal elements (ωi,i) are all zero
and the ijth off-diagonal element is ωi,j = pii,j . We then split the matrix up according to the sexes
of the relative pairs: Ω = Ωf + Ωm + Ωfm, where Ωf are the same as Ω except that the elements
corresponding to non-female-female pairs are zero. The other matrices are similarly defined.





|θ=0γn. We assume that the partial derivatives






1{τ=1}/2 + 1{τ=2} − 2ψij
0
if i = j female (diagonal element)








IBD(i,j)=τ γn, piij = pi
(1)
ij /2 + pi
(2)







(1{τ=1}/2 + 1{τ=2} − 2ψij)γn
= pi(1)ij /2 + pi
(2)
ij − 2ψij
= piij − E[piij ]
0
if i = j female (diagonal element)







|θ=0γn = Ωf − E[Ωf ]
Since y ∝ φ(y;µs,Σn) then under the null hypothesis of no linkage y ∝ φ(y;µs,Σ(0)) and


























































(pii,j − E[pii,j ])(wiwj − E[wiwj ]) (7.6.2)
where we take the last step by using ωi,i = 0 for all i and ωi,j = pii,j for all i 6= j, as well as the fact
that the Π matrices are symmetric (pii,j = pij,i).
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7.6.2 Score for σ2d,f





0 if i = j female (diagonal element)
pi
(2)














(pi(2)i,j − E[pi(2)i,j ])(wiwj − E[wiwj ]) (7.6.3)
7.6.3 Score for σ2X,m





0 if i = j male (diagonal element)














(pii,j − E[pii,j ])(wiwj − E[wiwj ]) (7.6.4)
7.6.4 Score for σX,fm



















(pii,j − E[pii,j ])(wiwj − E[wiwj ]) (7.6.5)
7.7 SUMMARY OF SCORES
Remember that w = Σ(0)−1(y − µs) and that Π(2) is the probability of two females sharing two
alleles IBD and the other Π’s are the proportion of alleles shared IBD between relatives. Now we
can write the scores (see equations 7.6.2, 7.6.3, 7.6.4, and 7.6.5) in matrix format
ba,f = vec(wTw − E[wTw])T vec(Πf − E[Πf ])
bd,f = vec(wTw − E[wTw])T vec(Π(2) − E[Π(2)])
bX,m = vec(wTw − E[wTw])T vec(Πm − E[Πm])
bX,fm = vec(wTw − E[wTw])T vec(Πfm − E[Πfm])
where we let vec be an operator that vectorizes the lower diagonal elements in column-wise order.
In the derivations above we used a sample size of one family. If we had larger data set of K




























vec(wTk wk − E[wTk wk])T vec(Πfmk − E[Πfmk ])
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7.8 VARIANCE OF THE SCORES
We estimate the Fisher information from our data set of K pedigrees as
I =

V ar(ba,f ) Cov(ba,f , bd,f ) Cov(ba,f , bX,m) Cov(ba,f , bX,fm)
Cov(ba,f , bd,f ) V ar(bd,f ) Cov(bd,f , bX,m) Cov(bd,f , bX,fm)
Cov(ba,f , bX,m) Cov(bd,f , bX,m) V ar(bX,m) Cov(bX,m, bX,fm)
Cov(ba,f , bX,fm) Cov(bd,f , bX,fm) Cov(bX,m, bX,fm) V ar(bX,fm)

where conditional on the IBD sharing, the variances and the covariances have the following form
V ar(ba,f ) =
∑
k




vec(Πfk − E[Πfk ]))T var(vec(wTk w)T )vec(Πfk − E[Πfk ]))
Cov(ba,f , bd,f ) =
∑
k




vec(Πfk − E[Πfk ]))T var(vec(wTk wk)T )vec(Π(2)k − E[Π(2)k ])
and similarly for the remaining scores.
We note that the covariances between scores for parameters corresponding to different types of
sex-sex pairs are always zero, that is Cov(ba,f , bX,m) = Cov(ba,f , bX,fm) = Cov(bd,f , bX,m) =




V ar(ba,f ) Cov(ba,f , bd,f ) 0 0
Cov(ba,f , bd,f ) V ar(bd,f ) 0 0
0 0 V ar(bX,m) 0
0 0 0 V ar(bX,fm)

The variances may be estimated empirically. Generally, in the autosomal case, the empirical
variance is preferred over theoretical variance (Bhattacharjee et al. 2008) and I suspect this is
also the case in the X-linked case, though extensive simulations studies are required to confirm
that.
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7.9 SCORE STATISTICS AND ASYMPTOTIC DISTRIBUTIONS
Depending on our hypothesis of interest, we can define a number of score statistics. One obvious
choice is a ‘global’ null hypothesis of no female or male linkage




X,m = σX,fm = 0
versus
HA : σ2a,f > 0 or σ
2
d,f > 0 or σ
2
X,m > 0 or |σX,fm| > 0









X,m all four parameters are tested at the boundary of the parameter










X,m, 0) is a boundary point only




X,m = 0. Deriving the statistic in a closed from and
its distribution for testing this general hypothesis in general pedigrees is quite challenging (if not
impossible). We follow similar procedure as Wang (2002), however the constraint |σX,fm| ≤√
σ2a,fσ
2
X,m causes problems. Briefly, the Wang procedure forms a standard likelihood ratio test
which is then written as a score tests by applying theorem 16.7 of van der Vaar (1998). This
theorem states that under normality or the quadratic approximation of the log–likelihood the
likelihood ratio and scores tests are equivalent.
We write the Fisher information matrix per pedigree as
I0 ≡

I11 I12 I13 I14
I21 I22 I23 I24
I31 I32 I33 I34
I41 I42 I43 I44
 =

I11 I12 0 0
I12 I22 0 0
0 0 I33 0






V ar(ba,f ) Cov(ba,f , bd,f ) 0 0
Cov(ba,f , bd,f ) V ar(bd,f ) 0 0
0 0 V ar(bX,m) 0
0 0 0 V ar(bX,fm)

From asymptotic theory (Pawitan 2001) we have for a random vector a
K−1/2S(θ) = K−1/2(ba,f , bd,f , bX,m, bX,fm)T
d−→ a ∼ N(0, I0)
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T and we let ΘA = {θ : θ ∈ HA} be the set of parameters that





















(I0 + IT0 )θ
= a− I0θ
If we set a− I0θ = 0 and solve for θ then we get the unrestricted solution θ∗ = I−10 a, which may
return parameter estimates that are out of bounds, hence we refer to it as the unrestricted solution
and the formula of the corresponding statistic as the unrestricted statistic, which is






Ta− (I−10 a)T I0I−10 a
= 2aT (I−10 )
Ta− aT (I−10 )Ta














0 0 1I33 0
0 0 0 1I44

Now we need to derive the composite statistic, that is the form of the statistic in all situations, as















































where xi = ai/
√
Iii and r = I12/
√
I11I22.
If all conditions hold and no parameter estimates are out of bounds then the statistic has
the form aT I−10 a, which we may formulate as
Λ = aT I−10 a =
x21 − 2rx1x2 + x22





if all the following conditions hold
















I11(1−r2) ≥ 0 or x2 ≥ x1r
3. θ∗3 = x3
1√
I33
≥ 0 or x3 ≥ 0








7.9.1 Derivation of the statistic when parameter estimates are out of bounds
Now look at how the statistic given in equation 7.9.1 looks when the each condition fails, that is
when the unrestricted formula returns parameter estimates that are out of bounds.





I22(1−r2) < 0 then θ
∗
1 = 0 and θ
∗
4 = 0 due to condition |θ4| ≤
√
θ1θ3. Then we optimize the
likelihood ratio statistic Λ2,3 = 2 supθ∈Θ1∩Θ2,3(θ












3 if x2 ≥ 0 and x3 ≥ 0, where the subscripts 2, 3 indicate sub-matrix
(with rows and columns 2 and 3), vector (a2,3 = (a2, a3)T ), and set (Θ2,3 = {θ : θ1 = θ4 = 0}).
7.9.1.2 Condition σ2X,m ≥ 0 fails The third condition σ2X,m ≥ 0 fails when θ∗3 < 0 then
θ∗3 = 0 and θ∗4 = 0 due to condition |θ4| ≤
√
θ1θ3. We get the optimized likelihood ratio statistic
Λ2,4 = x22 + x
2
4 if x2 ≥ 0 and x4 ≥ 0.
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7.9.1.3 Both σ2a,f ≥ 0 and σ2X,m ≥ 0 fail If both θ∗1 < 0 and θ∗3 < 0 then θ∗4 = 0 due to
condition |θ4| ≤
√
θ1θ3. We get the optimized likelihood ratio statistic Λ2 = x22 if x2 ≥ 0.
7.9.1.4 Condition σ2d,f ≥ 0 fails If θ∗2 < 0 then θ∗2 = 0 and so Λ1,3,4 = x21 + x23 + x24 if x1 ≥ 0,














= θ1a1 + θ2a2 + θ3a3 + θ4a4 − 12(θ
2
















which needs to be maximized. By taking the partial derivatives w.r.t to each parameter, we quickly
see that the solutions, as function of only the xi, and Iij , will be quite challenging to write out in a
simple formula. However, the solution exists (and can be found with the help of Mathematica) and
so we can get a legitimate score statistic when the fourth condition fails. However, the closed form
solution is too long and cumbersome to write down and not usable in practice. In appendix E we
show which equations need to be solved numerically and we give the Hessian matrices necessary the
solutions corresponding to the maxima. In section 7.9.3 we show how we can arrive at a statistic
described by a simple formula if we assume that the allelic effects are the same in females and
males, i.e. αk = βk for all alleles k.
Let Z1 = ba,f/
√
V ar(ba,f ), Z2 = bd,f/
√
V ar(bd,f ), Z3 = bX,m/
√
V ar(bX,m), and Z4 =
bX,fm/
√
V ar(bX,fm), i.e. the scores are standardized by their respective variances. We replace the










4 if Z1 ≥ Z2r, Z2 ≥ Z1r, Z3 ≥ 0,
|Z4 1√I44 | ≤
√











4 if Z2 < Z1r, Z1 ≥ 0, Z3 ≥ 0,










3 if Z1 < Z2r, Z2 ≥ 0, Z3 ≥ 0,
|Z4 1√I44 | ≤
√









4 if Z2 ≥ 0, Z4 ≥ 0
Z22 if Z2 ≥ 0
W if |Z4 1√I44 | >
√









where W is evaluated by numerical methods (see appendix E).
7.9.2 Distribution of the statistic
In developing the distribution of the test statistic from variance component models for the null
hypothesis of no female or male linkage assuming that the female dominance is zero (i.e. H0 :
σ2a,f = σ
2X,m = σX,fm = 0) Ekstrøm (2004) notes that the variance terms are being tested at
the boundary of their parameter space (σ2a,f ≥ 0, σ2X,m ≥ 0) while the covariance (σX,fm) is being





also being tested at the boundary of its parameters space. This suggests that Ekstrøm (2004) is
using the wrong case from Self and Liang to arrive at the distribution of the test statistic. However,
even if Ekstrøm (2004) had noticed this he would not be able to use the theoretical results of Self
and Liang (2007) to derive the distribution. Self and Liang (2007) showed that the asymptotic
distribution of the likelihood ratio test in multi-parameter cases is a mixture of χ2 distributions,
but in all the cases considered the parameter space could be described, in the case of p parameters,
as a simple product space: Ω = Ω1 × . . .Ωp, where the Ωi’s are either closed, half-open, or open
intervals in R. Our parameter space cannot be approximated by such a simple space and therefore
it is most appropriate to establish the distribution of the test statistic using simulations under the
null hypothesis.
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7.9.3 Simpler model: Assuming equal allelic effects in both sexes
If instead of allowing the allelic effects in the sexes to be different (i.e. αk in females and βk in
males) we can assume that they are equal, which is perfectly reasonable to do. If we go through
the derivations in sections 7.5.2, 7.5.3, and 7.5.4 assuming αk = βk for all alleles k we see that
σ2 ≡ σ2a,f = σ2X,m = σX,fm and we can write
Cov(yi, yj) =

σ2 + σ2d,f + σ
2





d,f i 6= j female-female
σ2 + σ2e i = j male
ψijσ
2 i 6= j male-male
√
2ψijσ2 i 6= j female-male
and
Cov(yi, yj |IBD(i, j) = τ)
=

Cov(yi, yj) + (1{τ=1}/2 + 1{τ=2} − 2ψij)σ2 + (1{τ=2} −∆ij7,X)σ2d,f female-female
Cov(yi, yj) + (1{τ=1} − ψij)σ2 male-male
Cov(yi, yj) + (1{τ=1} −
√
(2)ψij)σ2 female-male




X,m is no longer a problem and we can go through all the




1−r2 if Z1 ≥ Z2r, Z2 ≥ Z1r
Z21 if Z2 < Z1r, Z1 ≥ 0
Z22 if Z1 < Z2r, Z2 ≥ 0
0 o.w.













which should be verified by simulations under the null hypothesis. Interestingly, this statistic has
the same form as the autosomal statistic S2n developed by Wang (2002), they only differ in the
way the Π’s are estimated based on either the rules for autosomal or X-linked inheritance.
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7.9.3.1 No dominance in females If we assume that the dominance in females is negligible
(i.e. σ2d,f = 0) then our test statistic becomes Z
2
1 ∼ 12χ20 + 12χ21, which is of the same form as the
statistic S1n developed by Wang (2002).
7.10 DISCUSSION AND FUTURE WORK
7.10.1 Selected sampling, small samples, and choice of variance
An extensive simulation study has investigated the optimal choice of variance under various con-
ditions in the autosomal case (Bhattacharjee et al. 2008). When the theoretical basis for the
X-linked score statistics is complete a similar study should be performed. I suspect that similar
results will hold for the X-linked case: the estimators for the scores themselves are same whether
samples are small or ascertainment is selective (i.e., sampling based on phenotype) (Lebrec et al.
2004) but the correct estimators for the variances of the scores are not the same (Bhattacharjee
et al. 2008). In the above derivations we have used the “conditional on IBD” approach to decompose
the unconditional variance; but we could easily replace the variance estimators by the unconditional
and fully empirical estimators. However, the unconditional variance can also be decomposed by
conditioning on the trait values (i.e., “conditional on trait” variance formula). Conditioning on the
trait is done as a surrogate for conditioning on the ascertainment scheme, which may not be very
well documented or overly complicated, and results in more robust variance estimators than the
“conditional on IBD” approach. The choice of variance directly affects power of the statistics and
so very important theoretical work remains to be done (Bhattacharjee et al. 2008).
7.10.2 Inactivation in females and the pseudoautosomal regions
While it should be relatively straightforward to change the above derivation to appropriately model
X-inactivation in females, the work remains to be done. Additionally, the model needs to be
extended to appropriately model the pseudoautosomal regions.
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7.10.3 Other genetic and environmental effects
I suspect that for a complex trait with considerable genetic contribution one major gene on the
X chromosome is unlikely to account for all the genetic variation in the complex trait. Therefore,
it may be important to extend the model to incorporate effects of autosomal genes, which may
or may not show sex-specific effects and may or may not interact with the X-linked genes. One
of the advantages of the variance component model, underlying our derivations, is how easily
extendable it is. For example to add the effect of a major autosomal QTL and household (i.e.
shared environmental) effects to the model of X-linked QTL effect, we assume that the autosomal
and X-linked QTLs are in linkage equilibrium and write
y = µs + g + a+ h+ e
where g is the effect of the X-linked gene, a the effect of the major autosomal gene, h the household
effect and e the residuals. Then the covariance matrix may be written as












where H is a matrix whose elements are 1 if the relative pair shares the environmental exposure but
0 otherwise, I is the identity matrix, Ψf is a matrix of X-linked kinship coefficients whose elements
corresponding to non-female-female pairs are 0 (the other Ψ’s are similarly defined).
7.10.4 Asymptotic and empirical distributions
I mentioned that the asymptotic distribution of the test statistics may be impossible to derive,
especially in the general case when allowing for unequal allelic effects in females and males. However,
for the theoretical derivations, above, to be useful in practice, the distributions of the test statistics
need to empirically evaluated.
7.10.5 Score statistics for X-linked association analysis
It remains part of my future goals to build on this work and develop score statistics for family-based
association analysis of X-linked markers.
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7.10.6 General properties of score statistics
Generally score statistics have many good properties such as being locally most powerful and robust
to non-normality of the dependent variable. They are asymptotically equivalent to the likelihood
ratio test but simpler and faster to compute, especially when explicit expressions are known. We
were able to derive explicit formulas under the simplifying, but perfectly reasonable, assumption of
equal allelic effects in females and males. Before we can assume that the general properties of score
statistics hold in the more general case that allows for unequal effects, more work and extensive
simulations need to be done. The complexity of the parameter space in the general case makes
intuitive guesses about the properties of the statistic harder to make.
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8.0 CONCLUSIONS
8.1 SYNTHESIS OF THE ARM WORK
When I started working on ARM, about 5 years ago, the project had been ongoing for over 10
years. At that time, there was strong epidemiologic evidence that implicated heredity in the ARM
pathogenesis. However, there was considerable doubt that common genetic variants influencing
ARM could be identified and that they even existed. After all, ARM is a late onset disorder,
typically affecting people over 65 years of age. Clearly, that alone leaves plenty of opportunities
and time for environmental exposures to influence the phenotype. Add to that the complexity of
the phenotype itself, for example the two advanced forms of ARM, the dry (GA) and the wet (CNV)
forms seem to manifest themselves quite differently even though the end result is, in both cases, loss
of central vision and damaged macula. There is, however, no clear evidence or examples that the
phenotypic variations of advanced ARM reflect genetic heterogeneity and many individuals have
both forms of the disease, even in the same eye. We have focused on establishing which individuals
are truly affected with ARM and collectively analyzed all individuals, rather than focussing on
subtype-specific analysis.
Three microsatellite linkage studies had already been published when I joined the team
(Weeks et al. 2000; Weeks et al. 2001; Weeks et al. 2004). The initial linkage study using our
data, which at that time included over 200 families and 386 markers, identified susceptibility regions
on chromosomes 5, 9, 10, and 12. After adding over 100 families and typing 18 additional markers
in those regions, only the signals on chromosome 5 and 10 remained. However, no signal reached
the genome-wide significance level of a LOD score of 3 or greater, the LOD scores observed were
in the 1–1.5 range (Weeks et al. 2000). The second study, was an expanded collaborative study
of almost 400 families, that identified four regions, 1q31, 9p13, 10q26, and 17q25, with LOD scores
over 2 and some over 3 (Weeks et al. 2001). The third study, also an expanded collaborative study
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of over 500 families, found continued evidence of LOD scores close to 3 within the 1q31, 10q26, and
17q25 susceptibility regions (Weeks et al. 2004).
In 2004–2005, high-density focused SNP genotyping in those regions (1q31, 10q26, and 17q25)
was done on an expanded data-set of 594 ARM-affected families and 179 unrelated controls. The
analysis successfully replicated the discovery of the CFH gene under the 1q31 linkage peak, which
was independently published by three groups shortly after we received our genotype data. Using
those data, we were the first to report a locus of three closely linked genes (PLEKHA1, LOC387715,
and HTRA1 ) under the 10q26 linkage peak (see chapter 3). Those studies particularly pinpointed
the nonsynonymous SNP rs1061170 (Y402H ) in CFH and the nonsynonymous SNPs rs1045216
(A320T ) and rs10490924 (S69A) in PLEKAH1 and LOC387715, respectively (Jakobsdottir
et al. 2005).
The CFH region harbors number of other genes in the same biological pathway, the alterna-
tive complement pathway. Regulation plays of this pathway plays a central role in innate immunity
and inflammation. While it is outside of the scope of this thesis to discuss the pathway in detail,
it is interesting and important to note that the widely replicated Y402H variant is not the only
variant in the CFH gene, nor in the whole region, showing strong replicable association with ARM.
Following the CFH discovery, there has been a considerable amount of work done in order to un-
derstand the genetic contribution of the gene, and the surrounding complement related genes, to
the etiology of ARM. Those follow-up studies have identified number of haplotypes, spanning the
region, and other variants in CFH and nearby genes. Conditional analysis have shown that there
are at least two LD blocks with variants and haplotypes contributing susceptibility (Li et al. 2006).
The LD in the LOC387715 region appears to be much more extensive than in the CFH
region. However, we were able to perform conditional analysis in two independent cohorts where
the LD between A320T in PLEKHA1 and S69A in LOC387715 is much lower than in our own
cohort. In both cohorts we demonstrated that the association of this region with ARM is more
likely attributed to the LOC387715 SNP than the PLEKHA1 SNP, and that A320T does not
explain significant amount of the variation after accounting for S69A (Conley et al. 2006). These
findings, do not exclude the possibility that there is another variant in strong LD with S69A, that
is the true disease causing variant, nor do they imply that there are no other variants in the region
contributing significantly, beyond S69A, to the susceptibility. In fact, another SNP in the promoter
region of HTRA1 has been discovered (DeWan et al. 2006; Yang et al. 2006). This variant
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is, however, in almost complete LD with S69A. While the putative role HTRA1 in extracellular
matrix homeostasis makes it the obvious causal candidate within the locus (DeWan et al. 2007),
no study convincingly suggests either the HTRA1 gene or the LOC387715 gene to be a better
ARM candidate gene than the other, and two studies even suggest that LOC387715 and the S69A
variant specifically is more likely to be the causal gene in this locus. Nevertheless, the strong
LD across the two genes (LOC387715 and HTRA1 ) makes statistical methods alone insufficient
to distinguish between them; comprehensive analysis and characterization of the molecular and
functional relevance of the variants in the region is warranted.
The CFH discovery has been quite fruitful. A few complement pathway based candidate
genes studies have been done for ARM and resulted in the discoveries of two novel loci, one harboring
the closely linked C2 and CFB genes (Gold et al. 2006) and the other the C3 gene (Yates et al.
2007). We have published our replication effort of the C2/CFB locus (see chapter 5) but not the
C3 locus. However, we have data on that locus now and our not yet published analysis show that
we also replicate the C3 association signal. We also showed that the C2/CFB locus significantly
confers susceptibility after accounting for the effect of the CFH and LOC387715 genes. Neither of
those association signals were observed in any of the family-based linkage studies.
It is interesting to note that linkage and association studies are thought to be optimally
powered under different conditions: linkage being more powerful than association to detect rare
variants with strong effect on disease risk and association being more powerful than linkage to detect
common variants of smaller effect. However, even though only the rarer variants of C2/CFB seem
to be associated with ARM, no linkage signals have been observed near this locus. This apparent
lack of correspondence between linkage and association, for rarer variants, can perhaps be explained
by the observations that the most strongly associated SNPs could be protective and would therefore
not be detected in family studies based mostly on affected sib pairs (Gorin 2007). In fact, the
original report on the C2/CFB locus stated that the variants were protective (Gold et al. 2006);
although it is impossible to establish the direction of potential causality from descriptive frequency
data alone.
The LOC387715 gene is an interesting candidate gene. Unlike the CFH gene, there is little
known about molecular function of the LOC387715 gene and the biological properties of its putative
protein explaining its role in the pathobiology of ARM. Studying the molecular function of the gene
specific to the ARM will undoubtedly prove challenging for number of reasons, including: 1) the
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gene is an evolutionary recent gene with conservation restricted to the primate lineage (Rivera
et al. 2005), 2) even though ARM in the rhesus monkeys is also associated with LOC387715/HTRA1
variants, the LD appears to be just as strong (Francis et al. 2008), and 3) the typical experimental
animals, mice, do not have a macula (Rakoczy et al. 2006).
In the past couple of years many novel potentially causal SNPs and genes for common
complex disease have been discovered in genetic association studies. For ARM the CFH and
LOC387715 findings are particularly remarkable and it is only natural to ask how powerful these
might be in discriminating between those with and without the disease and those who will and will
not develop the disease in the future (see chapter 6). While association statistics, such as odds
ratios and P values, used during the discovery phase measure these properties indirectly, they are
not the most appropriate for evaluating the predictive value of genetic profiles and can exaggerate
the potential predictive power of the genetic data. Other measures, such as sensitivity, specificity,
positive predictive values, negative predictive values, and area under the ROC curves, are more
useful if the goal is to identify a genetic profile for classification or risk prediction. We argue, in
our study, that the “scientific community should be very cautious to avoid overhyping association
findings in terms of their personalized medicine value” and while robust statistical associations are
important to establish etiological hypothesis, which in turn may enhance our understanding of the
causes of the disease and ultimately lead to development of new therapeutic targets for treatment
and prevention, they do not, alone, guarantee the clinical validity for the use of genetic profiles in
medical or public health practice.
Among ARM geneticists, there seems to be consensus that there are more genes than CFH,
LOC387715, and the other complement related genes predisposing individuals to ARM. I agree.
Given that environmental risk factors also play significant role in ARM and that the effect of CFH
and LOC387715 appears strong, it will be challenging to find novel genes. It seems intuitively
unlikely that many common variants remain to be discovered, there are perhaps some undiscovered
variants of very weak effects or in regions poorly covered by genome-wide SNP panels. In the current
phase of the study, we have attempted to increase our chances of finding novel disease genes via
an association study using a candidate gene approach. The candidate genes were selected based
on extensive literature search of biological targets and pathways and then subjected to a selection
process based on prior statistical evidence regarding which regions are most likely to contain ARM
related loci. However, even though we have reduced the burden of multiple testing by performing
a candidate gene study our study is still limited regarding the number of unaffected controls, so
138
that the weaker effects and rarer variants will not necessarily reach statistical significance.
It is easy to say that now that the genome-wide association studies have found ‘all’ the
common variants we should begin to focus on rarer variants. First, the studies to date may have
found all the common variants of strong enough effect to be possibly found with the sample sizes
available. Second, to find the rarer variants it may be most powerful to use family data, but for
many diseases, like ARM, linkage studies using family data have already been done. For ARM,
fine-mapping under the linkage peaks led to the discoveries of CFH and LOC387715. Using the
same family data again will unlikely results in new peaks, even if a genome-wide SNP linkage panel
is used instead of a microsatellite panel, as was used in the past. To find new replicable linkage
signals more powerful larger data sets are needed. I am very hopeful that the approach we have
taken with our ARM families will result in new findings; the goal is to extend the genome-wide
linkage analyses of our ARM families by extending the pedigrees downward to include the next
generation. The majority of our families have consisted of a single generation of siblings but the
third generation children are now reaching the age to have presymptomatic findings for ARM and
a small percentage will also develop advanced disease during the study.
All the ARM genes discovered to date were found by investigating individuals with advanced
disease. Association has also been observed for milder disease and some early onset clinical features.
I think it could improve the understanding of the biophysiology of ARM by not only demonstrating
an association with early onset clinical features but also to prospectively evaluate the effect of a
combination of CFH and LOC387715 genotypes and specific early onset clinical features on the
incidence and the progression to ARM. I think the evidence for the potential causal effect those
genes have on ARM are strong enough to warrant such a study, albeit expensive. In fact, the
third generation children ascertained in the next phase of our study will contribute to such an
investigation.
8.2 MY FUTURE AIMS
I have worked quite extensively on ARM. I am excited to continue working on dissecting the
genetics of complex diseases and hope to do so in the future. However, for the next couple of
years, I plan on focusing on strengthening my methodology development skills and use both my
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theoretical background, from my steps taken in developing score statistics and as a mathematician,
and my applied and invaluable data analysis experience from working on the ARM for almost 5
years, to tackle theoretical problems in complex disease and population genetics. I think there is
room for basic methodology development in genetics, for example for association analysis of X-
linked and mitochondrial markers, especially when using family data. Genetics is more than just
SNP genotypes and so I am also interested in methodology development for analyzing genetic data




The supplementary material published online as a part of the paper (Jakobsdottir et al. 2005)
presented in chapter 3 is given here.
Table A1: Allele labeling
SNP and Allele Label Amino Acid CIDR controls Local controls HWE P-value.
rs6658788 0.580
A 1 0.511 0.483
G 2 0.489 0.517
rs1538687 0.410
A 1 0.693 0.658
G 2 0.307 0.342
rs1416962 0.440
T 1 0.648 0.607
C 2 0.352 0.393
rs946755 0.700
T 1 0.656 0.62
C 2 0.344 0.38
rs6428352 1.000
T 1 0.997 0.996
C 2 0.003 0.004
rs800292 0.820
T 1 0.232 0.269
C 2 0.768 0.731
rs1061170 Tyr402His 0.260
T 1 = Tyr . . . 0.69
C 2 = His . . . 0.31
rs10922093 0.660
G 1 . . . 0.295
A 2 . . . 0.705
rs70620 0.280
Continued on next page
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T 1 0.173 0.15
C 2 0.827 0.85
rs1853883 0.450
G 1 0.511 0.568
C 2 0.489 0.432
rs1360558 0.700
A 1 0.397 0.389
G 2 0.603 0.611
rs955927 0.850
T 1 0.609 0.615
A 2 0.391 0.385
rs4350226 0.340
A 1 0.905 0.897
G 2 0.095 0.103
rs4752266 0.180
A 1 0.777 0.774
G 2 0.223 0.226
rs915394 1.000
T 1 0.813 0.791
A 2 0.187 0.209
rs1268947 0.650
G 1 0.883 0.885
C 2 0.117 0.115
rs1537576 0.350
G 1 0.567 0.581
C 2 0.433 0.419
rs2039488 0.010
T 1 0.885 0.885
C 2 0.115 0.115
rs1467813 0.660
T 1 0.293 0.295
C 2 0.707 0.705
rs927427 0.100
A 1 0.464 0.487
G 2 0.536 0.513
rs4146894 1.000
A 1 0.466 0.474
G 2 0.534 0.526
rs12258692 Pro233Arg . . .
C 1 = Pro . . . 1
G 2 = Arg . . . 0
rs4405249 1.000
T 1 . . . 0.158
C 2 . . . 0.842
rs1045216 Ala320Thr 0.460
G 1 = Ala . . . 0.573
A 2 = Thr . . . 0.427
Continued on next page
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rs1882907 0.760
A 1 0.813 0.816
G 2 0.187 0.184
rs10490923 His3Arg 0.390
G 1 = Arg . . . 0.859
A 2 = His . . . 0.141
rs2736911 Arg38Ter 1.000
C 1 = Arg . . . 0.881
T 2 = Ter . . . 0.119
rs10490924 Ser69Ala 0.210
G 1 = Ala . . . 0.807
T 2 = Ser . . . 0.193
rs11538141 Gly54Glu 1.000
A 1 = Glu . . . 0.995
G 2 = Gly . . . 0.005
rs760336 0.580
T 1 0.52 0.526
C 2 0.48 0.474
rs763720 0.790
A 1 0.212 0.226
G 2 0.788 0.774
rs1803403 Cys384Gly 1.000
T 1 = Cys . . . 0.03
G 2 = Gly . . . 0.97
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Table A2: Primers, Annealing Conditions, and Restriction Endonucleases Used for Genotype Data Collection
Primer Sequences Annealing Restriction
Variant Forward Reverse Temperature (◦C) Enzyme
rs11538141 CAG AGT CGC CAT GCA GAT CC CCC GAA GGG CAC CAC GCA CT 58 MnlI
rs2736911 GCA CCT TTG TCA CCA CAT TA GCC TGA TCA TCT GCA TTT CT 54 DraIII
rs10490923 GCA CCT TTG TCA CCA CAT TA GCC TGA TCA TCT GCA TTT CT 54 HhaI
rs10490924 GCA CCT TTG TCA CCA CAT TA GCC TGA TCA TCT GCA TTT CT 54 PvuII
rs1803403 TGC TGT CCC TTT GTT GTC TC AGA CAC AGA CAC GCA TCC TG 55 NA
rs12258692
(and rs4405249 ) GCC AGG AAA AGG AAC CTC GCC AGG CAT CAA GTC AGA 54 NA
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Table A3: Results of Fitting Two-Locus Models by Logistic Regression














































Table A4: ORs, ARs, and Simulated P Values from χ2 Test with 10,000 Replicates
Dominant Heterozygotes Recessive Homzygotes
([RR+RN] vs. NN) (RN vs. NN) (RR vs [RN+NN]) RR vs. NN
SNP (allele) Gene Subtype OR 95% CI AR P OR AR OR 95% CI AR P OR AR
rs6658788 (2) CNV 0.84 .56-1.25 -13.41 0.36706 1.21 6.19 1.11 .73-1.68 2.5 0.68123 0.95 -2.26
rs6658788 (2) GA 0.88 .55-1.4 -9.92 0.63064 1.07 2.18 1.01 .62-1.66 0.35 1.0 0.92 -3.97
rs1538687 (2) CNV 0.71 .5-1.02 -17.04 0.07499 0.54 -10.68 0.47 .25-.9 -5.97 0.0202 0.42 -11.38
rs1538687 (2) GA 0.62 .41-.94 -23.86 0.0317 0.56 -10.14 0.45 .2-1.01 -6.25 0.07239 0.38 -12.32
rs1416962 (2) CNV 0.88 .61-1.25 -7.7 0.41676 1.02 0.46 0.95 .56-1.62 -.62 0.89111 0.89 -2.63
rs1416962 (2) GA 0.77 .51-1.17 -15.12 0.24708 0.69 -7.53 0.62 .31-1.24 -5.07 0.22948 0.57 -11.11
rs946755 (2) CNV 0.84 .59-1.2 -9.81 0.37326 1.14 2.86 1.03 .6-1.78 0.37 1.0 0.94 -1.39
rs946755 (2) GA 0.73 .48-1.11 -18.18 0.17258 0.79 -4.46 0.69 .34-1.38 -3.8 0.37606 0.6 -9.26
rs6428352 (2) CNV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs6428352 (2) GA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs800292 (1) CFH CNV 0.48 .33-.7 -26.97 0.0002 0.53 -21.4 0.21 .07-.64 -4.59 0.0053 0.18 -7.64
rs800292 (1) CFH GA 0.39 .25-.62 -33.02 0.0002 0.44 -26.29 0.09 .01-.75 -5.33 0.0113 0.08 -8.66
rs1061170 (2) CFH CNV 5.25 3.22-8.55 68.0 < 0.0001 2.37 24.74 4.11 2.2-7.69 27.24 < 0.0001 9.35 61.82
rs1061170 (2) CFH GA 5.76 3.17-10.47 70.42 < 0.0001 3.31 35.78 5.66 2.9-11.04 35.95 < 0.0001 12.26 68.61
rs10922093 (1) CFH CNV 0.56 .37-.85 -28.05 0.0083 0.61 -20.84 0.4 .18-.91 -5.96 0.0327 0.33 -11.72
rs10922093 (1) CFH GA 0.51 .31-.84 -32.2 0.0089 0.58 -23.06 0.26 .08-.85 -7.43 0.032 0.21 -14.08
rs70620 (1) CFH CNV 0.77 .52-1.14 -7.45 0.23338 0.8 -5.9 0.63 .24-1.69 -1.46 0.42256 0.6 -2.2
rs70620 (1) CFH GA 0.72 .45-1.15 -9.48 0.18978 0.78 -6.4 0.28 .06-1.36 -2.9 0.17068 0.26 -4.1
rs1853883 (2) CNV 2.52 1.64-3.89 52.14 0.0002 1.5 15.44 1.88 1.28-2.78 18.84 0.0014 3.2 51.28
rs1853883 (2) GA 3.54 1.97-6.36 64.51 < 0.0001 1.95 25.93 2.57 1.65-4 29.15 0.0003 5.12 66.42
rs1360558 (1) CNV 1.1 .76-1.59 5.96 0.64364 1.04 2.29 1.24 .78-1.98 3.75 0.41376 1.27 7.61
rs1360558 (1) GA 1.16 .75-1.79 9.09 0.57904 1.13 6.6 1.17 .68-2.02 2.67 0.67873 1.25 7.14
rs955927 (2) CNV 1.12 .78-1.63 7.31 0.51105 1.32 7.01 1.34 .83-2.17 4.9 0.20048 1.38 9.84
rs955927 (2) GA 1.08 .7-1.67 5.0 0.74163 1.18 4.02 1.2 .68-2.1 2.86 0.57564 1.22 6.06
rs4350226 (2) CNV 0.55 .34-.91 -8.65 0.0209 . . . . . . . . . . . . . . . . . . . . . . . .
rs4350226 (2) GA 0.52 .28-.96 -9.46 0.0462 . . . . . . . . . . . . . . . . . . . . . . . .
rs4752266 (2) GRK5 CNV 0.93 .65-1.34 -2.87 0.71243 3.13 10.08 2.82 .96-8.24 3.9 0.06229 2.63 5.74
rs4752266 (2) GRK5 GA 0.78 .51-1.19 -10.33 0.27667 3.67 12.31 2.88 .9-9.23 4.04 0.06909 2.51 5.33
rs915394 (2) GRK5 CNV 1.39 .96-2.01 11.91 0.08469 1.28 2.23 1.56 .57-4.3 1.54 0.48645 1.74 2.96
rs915394 (2) GRK5 GA 1.09 .7-1.67 2.88 0.74493 1.38 2.94 1.42 .44-4.58 1.17 0.57824 1.45 1.81
rs1268947 (2) GRK5 CNV 1.15 .75-1.75 3.15 0.52415 1.23 1.72 1.35 .36-5.05 0.58 0.76382 1.39 0.8
rs1268947 (2) GRK5 GA 0.78 .46-1.32 -5.0 0.42146 1.24 1.82 1.0 .2-5.02 0.0 1.0 0.95 -.1
rs1537576 (2) GRK5 CNV 1.57 1.07-2.3 27.1 0.0211 0.88 -4.02 1.06 .69-1.63 1.3 0.83192 1.44 14.26
Continued on next page
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rs1537576 (2) GRK5 GA 1.84 1.15-2.94 35.48 0.0143 1.17 5.17 1.44 .89-2.34 8.51 0.17778 2.04 28.32
rs2039488 (2) CNV 0.76 .48-1.2 -5.05 0.28877 0.2 -12.5 0.18 .03-.91 -2.36 0.0318 0.17 -2.88
rs2039488 (2) GA 0.62 .35-1.09 -8.3 0.11599 0.27 -11.29 0.2 .02-1.7 -2.3 0.21758 0.19 -2.83
rs1467813 (1) RGS10 CNV 0.95 .67-1.36 -2.31 0.85551 0.98 -.68 0.83 .45-1.54 -1.61 0.63004 0.83 -2.79
rs1467813 (1) RGS10 GA 0.85 .56-1.29 -7.69 0.52905 0.88 -5.73 0.81 .39-1.69 -1.85 0.70453 0.76 -3.85
rs927427 (1) CNV 1.08 .72-1.63 5.82 0.75722 0.91 -6.99 1.76 1.13-2.74 11.97 0.0107 1.65 21.15
rs927427 (1) GA 1.1 .68-1.78 6.67 0.81152 0.98 -1.63 1.5 .9-2.5 8.16 0.15618 1.47 16.43
rs4146894 (1) PLEKHA1 CNV 2.53 1.64-3.91 52.45 < 0.0001 1.94 37.72 2.46 1.63-3.71 23.64 < 0.0001 3.95 56.0
rs4146894 (1) PLEKHA1 GA 2.09 1.24-3.51 44.0 0.0069 1.77 33.08 1.92 1.2-3.08 16.31 0.0084 2.87 44.63
rs12258692 (2) PLEKHA1 CNV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs12258692 (1) PLEKHA1 GA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs4405249 (1) PLEKHA1 CNV 0.53 .27-1.02 -16.43 0.06989 0.51 -16.36 0.97 .11-8.85 -.05 1.0 0.83 -.41
rs4405249 (1) PLEKHA1 GA 0.63 .3-1.33 -12.27 0.17898 0.64 -11.43 0.57 .04-9.31 -.76 1.0 0.51 -1.2
rs1045216 (2) PLEKHA1 CNV 0.5 .32-.78 -48.35 0.0026 0.4 -22.18 0.31 .17-.58 -15.72 0.0002 0.25 -38.01
rs1045216 (2) PLEKHA1 GA 0.44 .26-.72 -58.72 0.001 0.45 -19.85 0.32 .15-.7 -15.46 0.0017 0.24 -38.67
rs1882907 (2) CNV 0.52 .35-.77 -19.38 0.0024 0.7 -3.08 0.44 .14-1.38 -1.91 0.20808 0.38 -3.11
rs1882907 (2) GA 0.6 .38-.95 -15.9 0.035 0.22 -8.27 0.16 .02-1.37 -2.89 0.12039 0.14 -4.32
rs10490923 (2) LOC387715 CNV 0.48 .28-.85 -14.84 0.0114 0.17 -11.63 0.1 .01-.98 -2.89 0.0413 0.09 -3.78
rs10490923 (2) LOC387715 GA 0.74 .39-1.38 -7.07 0.41496 0.58 -5.49 0.48 .08-2.91 -1.66 0.65244 0.45 -2.24
rs2736911 (2) LOC387715 CNV 0.71 .41-1.22 -7.12 0.24548 1.22 0.96 0.92 .09-8.92 -.08 1.0 0.86 -.18
rs2736911 (2) LOC387715 GA 0.62 .32-1.19 -9.43 0.13179 2.2 4.96 1.43 .13-15.97 0.42 1.0 1.3 0.38
rs10490924 (2) LOC387715 CNV 5.64 3.52-9.06 60.52 < 0.0001 2.81 23.7 6.18 2.62-14.59 22.67 < 0.0001 12.11 46.39
rs10490924 (2) LOC387715 GA 3.43 2.02-5.84 44.55 < 0.0001 2.63 21.83 4.74 1.9-11.84 17.47 0.0003 7.05 32.05
rs11538141 (2) PRSS11 CNV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs11538141 (2) PRSS11 GA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rs760336 (2) PRSS11 CNV 0.63 .43-.92 -37.33 0.0178 0.71 -10.35 0.61 .39-.95 -10.03 0.0348 0.49 -30.78
rs760336 (2) PRSS11 GA 0.63 .4-.98 -36.73 0.0322 0.84 -5.52 0.71 .42-1.19 -7.3 0.23778 0.56 -25.69
rs763720 (1) PRSS11 CNV 1.77 1.24-2.54 23.25 0.0031 1.69 20.43 2.1 .85-5.18 3.55 0.12829 2.64 7.87
rs763720 (1) PRSS11 GA 1.74 1.14-2.65 22.5 0.0107 1.4 12.86 4.71 1.88-11.79 11.06 0.0001 5.41 18.69
rs1803403 (1) PRSS11 CNV 3.33 1.39-8.02 12.17 0.0055 3.33 12.17 . . . . . . . . . . . . . . . . . .
rs1803403 (1) PRSS11 GA 3.85 1.53-9.72 14.49 0.0039 3.85 14.49 . . . . . . . . . . . . . . . . . .
Note.—Type A-affected individuals are compared with controls. Allele denotes the risk allele (minor allele in controls). RR = homozygotes for the risk allele; RN
= heterozygotes for the risk allele; NN = homozygotes for the normal allele. Locally typed SNPs are in bold italics. Blank spaces separate the three chromosomal regions
corresponding to SNPs in and around CFH, GRK5/RGS10, and PLEKHA1/LOC687715/PRSS11.
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Figure A1: LD patterns on chromosome 10 based on analysis of 196 CIDR SNPs and 179 unrelated controls. A, The false peak at 135
cM (see fig. 3.3); the SNP with the largest Sall in the peak is highlighted in green. B, The false peak at 142 cM (see fig. 3.3); the SNP
with the largest Sall in the peak is highlighted in green. C, Linkage peak. Significant SNPs, from CCREL (table 5), that overlie the five
genes (GRK5, RGS10, PLEKHA1, LOC387715, and PRSS11 ) are highlighted in green. Squares shaded pink or red indicate significant
LD between SNP pairs (bright red indicates pairwise D′ = 1), white squares indicate no evidence of significant LD, and blue squares
indicate pairwise D′ = 1 without statistical significance. LD is measured using D′, and the values within the squares give pairwise LD
in D′/100.
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Figure A2: LD patterns on chromosome 1 based on analysis of 679 CIDR SNPs and 179 unrelated controls. A, The false peak at 188
cM (see fig. 3.4); the SNP with the largest Sall in the peak is highlighted in green. B, The false peak at 202 cM (see fig. 3.4); the SNP
with the largest Sall in the peak is highlighted in green. C, Linkage peak. Significant SNPs, from CCREL (table 5), that overlie CFH
are highlighted in green. Squares shaded pink or red indicate significant LD between SNP pairs (bright red indicates pairwise D′ = 1),
white squares indicate no evidence of significant LD, and blue squares indicate pairwise D′ = 1 without statistical significance. LD is
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B.1 DISTINGUISHING BETWEEN PLEKHA1 AND LOC387715
We employed the haplotype method (Valdes and Thomson 1997) to identify which one of the two
loci, A320T in PLEKHA1 or S69A in LOC387715, is more likely the actual disease predisposing
variant in the 10q26 region. If all predisposing variants are included on a haplotype, then the neutral
variants are expected to be in the same ratio on a particular disease predisposing haplotype, in cases
and controls, although the actual frequencies may differ. On the other hand, if not all predisposing
variants have been identified, equality in the ratios of haplotype frequencies of non-predisposing
variants is not expected.
The expected ratios for the A320T-S69A haplotypes are formulated below, assuming one
variant is ARM-predisposing and the other is a neutral variant. We assume that A320T and
S69A are all the ARM predisposing variants in the PLEKHA1 –LOC387715 haplotype block on
chromosome 10q26. Four possible A320T-S69A haplotypes exist: G–G, A–G, G–T, and A–T. If

















































where f denotes frequencies of a particular haplotype in controls or cases.
The hypotheses of interest are:
H0P : The A320T variant in PLEKHA1 fully accounts for the ARM predisposition to the PLEKHA1 –
LOC387715 haplotype block.
H0L : The S69A variant in LOC387715 fully accounts for the ARM predisposition to the PLEKHA1 –
LOC387715 haplotype block.
Rejecting either of these hypotheses means that the tested variant is not sufficient to account
for the ARM predisposition to the PLEKHA1 –LOC387715 haplotype block, alone. Four 2× 2 ta-
bles can be derived from equations 1a, 1b, 2a, and 2b:
Table 1a Unexposed Exposed
Controls f(G−G) f(G− T )
Cases f(G−G) f(G− T )
Table 1b Unexposed Exposed
Controls f(A−G) f(A− T )
Cases f(A−G) f(A− T )
Table 2a Unexposed Exposed
Controls f(G−G) f(A−G)
Cases f(G−G) f(A−G)
Table 2b Unexposed Exposed
Controls f(G− T ) f(A− T )
Cases f(G− T ) f(A− T )
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Under H0P we expect homogeneity in contingency tables 1a and 1b, and under H0L we expect
homogeneity in contingency tables 2c and 2d. Regular χ2 statistic may be calculated from each
contingency table to generate a combined statistic. For H0P the statistic is the maximum χ
2 from
tables 1a and 1b, and for H0L the statistic is the maximum χ
2 from tables 2a and 2b. However,
due to dependency of the statistics derived from each set of contingency talbes, the distribution of
the combined statistics is not clear. The lack of independence arises from (1) combining measure-
ments corresponding to various alleles at predisposing loci, and (2) linkage disequilibrium between
predisposing and non-predisposing loci. Both of these conditions are inevitable, (1) because variant
always has more than one allele, and (2) because, if the variants are in complete linkage equilibrium,
there is no need to distinguish between their independent association signals.
As a result of the dependency in the data a permutation testing needs to be done condi-
tionally on the allele at the predisposing locus (under the null hypotheses). We start by grouping
the haplotypes (two for each person) according to the allele at the predisposing locus. Then the
case-control labels are permuted within each group and a combined statistic is calculated for each
pair of replicate. This permutation procedure is similar to the procedure proposed by (Li 2001).
B.1.1 Distinguishing between PLEKHA1 and LOC387715–Results
Haplotype frequencies were estimated separately in controls and cases. The program SNPHAP
(Clayton ) was used to estimated the haplotype frequencies and phased haplotypes at each sub-
ject. The estimated haplotype frequencies are:
A320T–S69A AREDS CHS
haplotype Controls Cases Controls Cases
G−G 0.3928 0.2802 0.3909 0.3188
G− T 0.1790 0.4149 0.1924 0.3294
A−G 0.4186 0.2792 0.3894 0.3337
A− T 0.0096 0.0257 0.0272 0.0180
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We calculate the ratio of haplotypes under H0P and compare the value estimated from

























































































and H0P is rejected (P=0.0002) in the CHS data.
Now we calculate the ratio of haplotypes under H0L and compare the value estimated from

























































































and H0L is not rejected (P=0.45) in the CHS data.
In conclusion, H0P is rejected both when the hypothesis is tested using the AREDS and
CHS data. Therefore, it is unlikely that A320T in PLEKHA1 is sufficient to account for the
ARM predisposition to the PLEKHA1 –LOC387715 haplotype block on chromosome 10q26. On
the other hand we fail to reject similar hypothesis for S69A in LOC387715. Our results of applying
the haplotype method support LOC387715 as a major susceptibility gene for ARM.
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B.2 HAPMAP POPULATIONS
Individuals recruited into the CEPH population (CEU) of the International HapMap project (The
International HapMap Consortium 2003; The International HapMap Consortium
2005) were residents of Utah with ancestry from northern and western Europe. Individuals recruited
from Ibadan in Yoruba, Nigeria (YRI), were individuals who identified themselves as having four
Yoruba grandparents. 90 individuals (30 parent-offspring trios) were sampled from each population.
The following table compares the genotype frequencies in different populations without
ARM. In addition to the 1051 white CHS controls and 126 white CHS ARM cases, a total of
180 African American CHS controls were genotyped for Y402H in CFH, M299V in ELOVL4,
A320T in PLEKHA1, and S69A in LOC387715. Genotype frequencies for each of the two HapMap
populations (CEU and YRI) are estimated from 60 individuals. Note that the HapMap populations
have not been genotyped for Y402H.
Gene (Variant) AREDS CHS HapMap CHS HapMap
and Genotypes Whites Whites CEU Blacks YRI P a
CFH (Y402H )
TT 0.434 0.448 . . . 0.367 . . .
CT 0.416 0.450 . . . 0.528 . . . 0.14
CC 0.150 0.103 . . . 0.106 . . .
ELOVL4 (M299V )
AA 0.711 0.802 0.717 0.695 0.533
AG 0.259 0.174 0.233 0.264 0.333 0.01
GG 0.030 0.030 0.050 0.040 0.133
PLEKHA1 (A320T )
GG 0.339 0.346 0.317 0.633 0.729
AG 0.464 0.476 0.467 0.311 0.254 <0.01
AA 0.196 0.178 0.217 0.057 0.017
LOC387715 (S69A)
GG 0.645 0.604 0.583 0.561 0.467
GT 0.331 0.353 0.400 0.368 0.450 0.25
TT 0.023 0.043 0.017 0.070 0.083
a P value from 2 df Pearson’s χ2 test of difference in genotype frequencies between CHS
Whites (non-Hispanic whites) and CHS Blacks (African Americans)
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Table B1: Genotype distrbutions in AREDS and CHS cohorts, by ARM status
AREDS CHS
Controls Cases (n = 701)
Gene Grade 4 (n = 266) Grade 5(n = 399)
(Variant) Grade 1 Grade 2 Grade 3 GA CNV GA CNV Controls Cases
Genotype (n = 175) (n = 63) (n = 96) All only only All only only (n = 1051) (n = 126)
CFH
(Y402H)
TT 75 19 21 46 13 27 52 12 25 406 29
CT 72 35 39 118 21 72 147 40 52 408 53
CC 26 9 36 101 25 49 139 36 52 93 28
All 173 63 96 265 59 148 338 88 129 907 110
ELOVL4
(M299V)
AA 118 55 75 204 47 115 249 70 97 826 92
AG 43 7 17 50 10 30 65 14 23 179 31
GG 5 0 1 6 2 3 9 2 0 25 1
All 166 62 93 260 59 148 323 86 120 1030 124
PLEKHA1
(A320T)
GG 57 24 42 111 25 65 169 34 73 355 51
AG 78 31 45 114 25 61 142 43 46 489 57
AA 33 7 6 34 7 21 17 6 6 183 16
All 168 62 93 259 57 147 328 83 125 1027 124
LOC387715
(S69A)
GG 111 40 35 105 22 59 77 30 26 601 53
GT 57 19 44 126 31 74 171 44 70 351 49
TT 4 3 15 31 6 14 89 13 33 43 18
All 172 62 94 262 59 147 337 87 129 995 120
Note.—Genotypes are ordered: NN - RN - RR, where N is the normal allele and R is the risk
allele. The risk allele is defined as the least frequent allele in controls. GA = geographic atrophy.
CNV = choroidal neovascular membranes.
a Grade 2 AREDS subjects were not included in the analysis.
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Table B2: Estimated crude ORs, corresponding 95% CIs, and PARs, unadjusted for age and gender
ORdom (95% CI) PAR ORrec (95% CI) PAR ORhet (95% CI) PAR ORhom (95% CI) PAR
CFH (Y402H)
1 vs. 345      3.73 (2.60, 5.34) 0.60      3.69 (2.37, 5.75) 0.22      2.66 (1.81, 3.92) 0.43     6.69  (4.08, 10.98) 0.37
1 vs. 45      3.94 (2.72, 5.71) 0.62      3.74 (2.39, 5.85) 0.22      2.82 (1.89, 4.19) 0.45     7.06  (4.27, 11.70) 0.38
1 vs. 3      2.73 (1.55, 4.83) 0.49      3.39 (1.89, 6.10) 0.20      1.93 (1.04, 3.60) 0.30     4.95  (2.46, 9.95) 0.29
1 vs. 4      3.64 (2.35, 5.64) 0.59      3.48 (2.14, 5.66) 0.20      2.67 (1.67, 4.27) 0.43     6.33  (3.60, 11.16) 0.35
1 vs. 5      4.21 (2.76, 6.42) 0.64      3.95 (2.47, 6.32) 0.23      2.94 (1.87, 4.63) 0.47     7.71  (4.46, 13.34) 0.41
1 vs. 45 (GA)      3.73 (2.21, 6.31) 0.60      4.01 (2.36, 6.82) 0.24      2.54 (1.44, 4.48) 0.41     7.04  (3.69, 13.41) 0.38
1 vs. 4 (GA)      2.71 (1.36, 5.37) 0.49      4.16 (2.14, 8.07) 0.24      1.68 (0.78, 3.61) 0.23     5.55  (2.48, 12.41) 0.32
1 vs. 5 (GA)      4.85 (2.46, 9.56) 0.68      3.91 (2.16, 7.10) 0.23      3.47 (1.69, 7.14) 0.53     8.65  (3.92, 19.09) 0.44
1 vs. 45 (CNV)      3.31 (2.16, 5.07) 0.56      3.24 (2.00, 5.26) 0.19      2.48 (1.57, 3.93) 0.40     5.60  (3.21, 9.78) 0.32
1 vs. 4 (CNV)      3.43 (2.05, 5.74) 0.57      2.80 (1.63, 4.80) 0.16      2.78 (1.61, 4.80) 0.44     5.24  (2.74, 10.01) 0.30
1 vs. 5 (CNV)      3.18 (1.87, 5.41) 0.55      3.82 (2.21, 6.59) 0.22      2.17 (1.22, 3.86) 0.34     6.00  (3.12, 11.53) 0.34
CHS      2.26 (1.45, 3.53) 0.41      2.99 (1.85, 4.83) 0.17      1.82 (1.13, 2.92) 0.27     4.22  (2.39, 7.42) 0.25
ELOVL4 (M299V)
1 vs. 345      0.69 (0.47, 1.01) -0.07      0.78 (0.28, 2.16) -0.01      0.69 (0.46, 1.02) -0.06     0.72  (0.26, 1.99) -0.01
1 vs. 45      0.71 (0.48, 1.04) -0.06      0.85 (0.30, 2.38) 0.00      0.70 (0.46, 1.04) -0.06     0.78  (0.28, 2.19) -0.01
1 vs. 3      0.59 (0.32, 1.09) -0.09      0.35 (0.04, 3.04) -0.02      0.62 (0.33, 1.17) -0.07     0.31  (0.04, 2.75) -0.02
1 vs. 4      0.67 (0.43, 1.06) -0.07      0.76 (0.23, 2.53) -0.01      0.67 (0.42, 1.07) -0.06     0.69  (0.21, 2.32) -0.01
1 vs. 5      0.73 (0.48, 1.12) -0.06      0.92 (0.30, 2.80) 0.00      0.72 (0.46, 1.12) -0.05     0.85  (0.28, 2.60) 0.00
1 vs. 45 (GA)      0.59 (0.35, 1.00) -0.09      0.91 (0.24, 3.47) 0.00      0.56 (0.32, 0.99) -0.08     0.81  (0.21, 3.08) 0.00
1 vs. 4 (GA)      0.63 (0.31, 1.29) -0.08      1.13 (0.21, 5.99) 0.00      0.58 (0.27, 1.26) -0.08     1.00  (0.19, 5.36) 0.00
1 vs. 5 (GA)      0.56 (0.30, 1.06) -0.10      0.77 (0.15, 4.04) -0.01      0.55 (0.28, 1.07) -0.09     0.67  (0.13, 3.57) -0.01
1 vs. 45 (CNV)      0.65 (0.42, 1.01) -0.07      0.36 (0.09, 1.55) -0.02      0.69 (0.43, 1.09) -0.06     0.33  (0.08, 1.42) -0.02
1 vs. 4 (CNV)      0.71 (0.42, 1.18) -0.06      0.67 (0.16, 2.84) -0.01      0.72 (0.42, 1.22) -0.05     0.62  (0.14, 2.64) -0.01
1 vs. 5 (CNV)      0.58 (0.33, 1.03) -0.09 … …      0.65 (0.37, 1.15) -0.06 … …
CHS      1.41 (0.92, 2.17) 0.07      0.33 (0.04, 2.43) -0.02      1.55 (1.00, 2.41) 0.09     0.36  (0.05, 2.68) -0.02
PLEKHA1 (A320T)
1 vs. 345      0.57 (0.40, 0.81) -0.39      0.37 (0.23, 0.60) -0.13      0.68 (0.47, 0.99) -0.18     0.31  (0.18, 0.51) -0.14
1 vs. 45      0.56 (0.39, 0.81) -0.40      0.39 (0.24, 0.63) -0.12      0.67 (0.46, 0.98) -0.19     0.31  (0.19, 0.53) -0.14
1 vs. 3      0.62 (0.37, 1.05) -0.33      0.28 (0.11, 0.70) -0.15      0.78 (0.46, 1.35) -0.12     0.25  (0.09, 0.64) -0.16
1 vs. 4      0.68 (0.46, 1.02) -0.26      0.62 (0.37, 1.04) -0.07      0.75 (0.49, 1.15) -0.13     0.53  (0.30, 0.94) -0.09
1 vs. 5      0.48 (0.33, 0.71) -0.51      0.22 (0.12, 0.42) -0.16      0.61 (0.41, 0.92) -0.23     0.17  (0.09, 0.34) -0.17
1 vs. 45 (GA)      0.70 (0.44, 1.12) -0.24      0.42 (0.21, 0.83) -0.12      0.84 (0.52, 1.37) -0.08     0.38  (0.18, 0.80) -0.12
1 vs. 4 (GA)      0.66 (0.36, 1.21) -0.29      0.57 (0.24, 1.38) -0.08      0.73 (0.38, 1.40) -0.15     0.48  (0.19, 1.24) -0.10
1 vs. 5 (GA)      0.74 (0.43, 1.27) -0.20      0.32 (0.13, 0.79) -0.14      0.92 (0.53, 1.63) -0.04     0.30  (0.12, 0.80) -0.14
1 vs. 45 (CNV)      0.50 (0.33, 0.74) -0.49      0.45 (0.26, 0.78) -0.11      0.57 (0.37, 0.87) -0.26     0.34  (0.19, 0.61) -0.13
1 vs. 4 (CNV)      0.65 (0.41, 1.02) -0.30      0.68 (0.37, 1.24) -0.06      0.69 (0.42, 1.12) -0.18     0.56  (0.29, 1.07) -0.09
1 vs. 5 (CNV)      0.37 (0.23, 0.59) -0.71      0.21 (0.08, 0.51) -0.16      0.46 (0.28, 0.76) -0.35     0.14  (0.06, 0.36) -0.18
CHS      0.76 (0.52, 1.11) -0.19      0.68 (0.39, 1.18) -0.06      0.81 (0.54, 1.21) -0.10     0.61  (0.34, 1.10) -0.07
LOC387715 (S69A)
1 vs. 345      3.99 (2.81, 5.67) 0.54    10.16 (3.70, 27.88) 0.28      3.06 (2.13, 4.39) 0.42   17.26  (6.22, 47.89) 0.41
1 vs. 45      4.17 (2.92, 5.96) 0.56    10.52 (3.83, 28.93) 0.29      3.18 (2.20, 4.60) 0.43   18.30  (6.57, 50.93) 0.43
1 vs. 3      3.07 (1.82, 5.17) 0.45      7.97 (2.56, 24.81) 0.23      2.45 (1.42, 4.23) 0.34   11.89  (3.70, 38.19) 0.32
1 vs. 4      2.72 (1.83, 4.05) 0.41      5.64 (1.95, 16.27) 0.17      2.34 (1.55, 3.53) 0.32     8.19  (2.80, 24.00) 0.24
1 vs. 5      6.14 (4.11, 9.19) 0.67    15.07 (5.43, 41.82) 0.38      4.32 (2.85, 6.57) 0.54   32.07  (11.30, 91.01) 0.57
1 vs. 45 (GA)      3.29 (2.07, 5.21) 0.48      6.28 (2.09, 18.93) 0.19      2.81 (1.74, 4.52) 0.39   10.14  (3.28, 31.31) 0.28
1 vs. 4 (GA)      3.06 (1.66, 5.65) 0.45      4.75 (1.29, 17.49) 0.14      2.74 (1.46, 5.17) 0.38     7.57  (1.97, 29.06) 0.22
1 vs. 5 (GA)      3.46 (2.01, 5.94) 0.49      7.38 (2.33, 23.38) 0.22      2.86 (1.63, 5.02) 0.40   12.02  (3.65, 39.57) 0.32
1 vs. 45 (CNV)      4.09 (2.73, 6.12) 0.55      8.62 (3.05, 24.39) 0.25      3.30 (2.17, 5.01) 0.45   15.34  (5.32, 44.25) 0.38
1 vs. 4 (CNV)      2.71 (1.72, 4.27) 0.40      4.42 (1.42, 13.74) 0.13      2.44 (1.53, 3.90) 0.34     6.58  (2.07, 20.90) 0.19
1 vs. 5 (CNV)      7.21 (4.24, 12.27) 0.71    14.44 (4.96, 41.99) 0.37      5.24 (3.02, 9.10) 0.60   35.22  (11.47, 108.17) 0.60
CHS      1.93 (1.32, 2.83) 0.27      3.91 (2.17, 7.03) 0.11      1.58 (1.05, 2.39) 0.17     4.75  (2.56, 8.80) 0.14
NOTE - N denotes the normal allele and R denotes the risk allele. The risk allele is defined as the least frequent allele in controls.The OR for dominance effects compares 
those who carry one risk allele (RN and RR genotypes) to individuals homozygote for the normal allele (NN), the OR for recessice effects compares individuals with RR 
genotype to those who carry one normal allele (NN and RN genotypes). Hetero- and homozygote ORs compare individuals with one (RN) and two (RR) risk alleles to 
individuals with NN genotype, respectively.  GA = geographic atrophy.  CNV = choroidal neovascular membranes.




in AREDS or 
CHS
DOMINANCE      
(RN+RR vs. NN)
RECESSIVE                   
(RR vs. RN+NN)
HETEROZYGOTES        
(RN vs. NN)
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Table B3: Estimated ORs, corresponding 95% CIs, and PARs, adjusted for age and gender
ORdom (95% CI) PAR ORrec (95% CI) PAR ORhet (95% CI) PAR ORhom (95% CI) PAR
CFH (Y402H)
1 vs. 345      3.73 (2.60, 5.34) 0.60      3.69 (2.37, 5.75) 0.22      2.66 (1.81, 3.92) 0.43     6.69  (4.08, 10.98) 0.37
1 vs. 45      3.94 (2.72, 5.71) 0.62      3.74 (2.39, 5.85) 0.22      2.82 (1.89, 4.19) 0.45     7.06  (4.27, 11.70) 0.38
1 vs. 3      2.73 (1.55, 4.83) 0.49      3.39 (1.89, 6.10) 0.20      1.93 (1.04, 3.60) 0.30     4.95  (2.46, 9.95) 0.29
1 vs. 4      3.64 (2.35, 5.64) 0.59      3.48 (2.14, 5.66) 0.20      2.67 (1.67, 4.27) 0.43     6.33  (3.60, 11.16) 0.35
1 vs. 5      4.21 (2.76, 6.42) 0.64      3.95 (2.47, 6.32) 0.23      2.94 (1.87, 4.63) 0.47     7.71  (4.46, 13.34) 0.41
1 vs. 45 (GA)      3.73 (2.21, 6.31) 0.60      4.01 (2.36, 6.82) 0.24      2.54 (1.44, 4.48) 0.41     7.04  (3.69, 13.41) 0.38
1 vs. 4 (GA)      2.71 (1.36, 5.37) 0.49      4.16 (2.14, 8.07) 0.24      1.68 (0.78, 3.61) 0.23     5.55  (2.48, 12.41) 0.32
1 vs. 5 (GA)      4.85 (2.46, 9.56) 0.68      3.91 (2.16, 7.10) 0.23      3.47 (1.69, 7.14) 0.53     8.65  (3.92, 19.09) 0.44
1 vs. 45 (CNV)      3.31 (2.16, 5.07) 0.56      3.24 (2.00, 5.26) 0.19      2.48 (1.57, 3.93) 0.40     5.60  (3.21, 9.78) 0.32
1 vs. 4 (CNV)      3.43 (2.05, 5.74) 0.57      2.80 (1.63, 4.80) 0.16      2.78 (1.61, 4.80) 0.44     5.24  (2.74, 10.01) 0.30
1 vs. 5 (CNV)      3.18 (1.87, 5.41) 0.55      3.82 (2.21, 6.59) 0.22      2.17 (1.22, 3.86) 0.34     6.00  (3.12, 11.53) 0.34
CHS      2.26 (1.45, 3.53) 0.41      2.99 (1.85, 4.83) 0.17      1.82 (1.13, 2.92) 0.27     4.22  (2.39, 7.42) 0.25
ELOVL4 (M299V)
1 vs. 345      0.69 (0.47, 1.01) -0.07      0.78 (0.28, 2.16) -0.01      0.69 (0.46, 1.02) -0.06     0.72  (0.26, 1.99) -0.01
1 vs. 45      0.71 (0.48, 1.04) -0.06      0.85 (0.30, 2.38) 0.00      0.70 (0.46, 1.04) -0.06     0.78  (0.28, 2.19) -0.01
1 vs. 3      0.59 (0.32, 1.09) -0.09      0.35 (0.04, 3.04) -0.02      0.62 (0.33, 1.17) -0.07     0.31  (0.04, 2.75) -0.02
1 vs. 4      0.67 (0.43, 1.06) -0.07      0.76 (0.23, 2.53) -0.01      0.67 (0.42, 1.07) -0.06     0.69  (0.21, 2.32) -0.01
1 vs. 5      0.73 (0.48, 1.12) -0.06      0.92 (0.30, 2.80) 0.00      0.72 (0.46, 1.12) -0.05     0.85  (0.28, 2.60) 0.00
1 vs. 45 (GA)      0.59 (0.35, 1.00) -0.09      0.91 (0.24, 3.47) 0.00      0.56 (0.32, 0.99) -0.08     0.81  (0.21, 3.08) 0.00
1 vs. 4 (GA)      0.63 (0.31, 1.29) -0.08      1.13 (0.21, 5.99) 0.00      0.58 (0.27, 1.26) -0.08     1.00  (0.19, 5.36) 0.00
1 vs. 5 (GA)      0.56 (0.30, 1.06) -0.10      0.77 (0.15, 4.04) -0.01      0.55 (0.28, 1.07) -0.09     0.67  (0.13, 3.57) -0.01
1 vs. 45 (CNV)      0.65 (0.42, 1.01) -0.07      0.36 (0.09, 1.55) -0.02      0.69 (0.43, 1.09) -0.06     0.33  (0.08, 1.42) -0.02
1 vs. 4 (CNV)      0.71 (0.42, 1.18) -0.06      0.67 (0.16, 2.84) -0.01      0.72 (0.42, 1.22) -0.05     0.62  (0.14, 2.64) -0.01
1 vs. 5 (CNV)      0.58 (0.33, 1.03) -0.09 … …      0.65 (0.37, 1.15) -0.06 … …
CHS      1.41 (0.92, 2.17) 0.07      0.33 (0.04, 2.43) -0.02      1.55 (1.00, 2.41) 0.09     0.36  (0.05, 2.68) -0.02
PLEKHA1 (A320T)
1 vs. 345      0.57 (0.40, 0.81) -0.39      0.37 (0.23, 0.60) -0.13      0.68 (0.47, 0.99) -0.18     0.31  (0.18, 0.51) -0.14
1 vs. 45      0.56 (0.39, 0.81) -0.40      0.39 (0.24, 0.63) -0.12      0.67 (0.46, 0.98) -0.19     0.31  (0.19, 0.53) -0.14
1 vs. 3      0.62 (0.37, 1.05) -0.33      0.28 (0.11, 0.70) -0.15      0.78 (0.46, 1.35) -0.12     0.25  (0.09, 0.64) -0.16
1 vs. 4      0.68 (0.46, 1.02) -0.26      0.62 (0.37, 1.04) -0.07      0.75 (0.49, 1.15) -0.13     0.53  (0.30, 0.94) -0.09
1 vs. 5      0.48 (0.33, 0.71) -0.51      0.22 (0.12, 0.42) -0.16      0.61 (0.41, 0.92) -0.23     0.17  (0.09, 0.34) -0.17
1 vs. 45 (GA)      0.70 (0.44, 1.12) -0.24      0.42 (0.21, 0.83) -0.12      0.84 (0.52, 1.37) -0.08     0.38  (0.18, 0.80) -0.12
1 vs. 4 (GA)      0.66 (0.36, 1.21) -0.29      0.57 (0.24, 1.38) -0.08      0.73 (0.38, 1.40) -0.15     0.48  (0.19, 1.24) -0.10
1 vs. 5 (GA)      0.74 (0.43, 1.27) -0.20      0.32 (0.13, 0.79) -0.14      0.92 (0.53, 1.63) -0.04     0.30  (0.12, 0.80) -0.14
1 vs. 45 (CNV)      0.50 (0.33, 0.74) -0.49      0.45 (0.26, 0.78) -0.11      0.57 (0.37, 0.87) -0.26     0.34  (0.19, 0.61) -0.13
1 vs. 4 (CNV)      0.65 (0.41, 1.02) -0.30      0.68 (0.37, 1.24) -0.06      0.69 (0.42, 1.12) -0.18     0.56  (0.29, 1.07) -0.09
1 vs. 5 (CNV)      0.37 (0.23, 0.59) -0.71      0.21 (0.08, 0.51) -0.16      0.46 (0.28, 0.76) -0.35     0.14  (0.06, 0.36) -0.18
CHS      0.76 (0.52, 1.11) -0.19      0.68 (0.39, 1.18) -0.06      0.81 (0.54, 1.21) -0.10     0.61  (0.34, 1.10) -0.07
LOC387715 (S69A)
1 vs. 345      3.99 (2.81, 5.67) 0.54    10.16 (3.70, 27.88) 0.28      3.06 (2.13, 4.39) 0.42   17.26  (6.22, 47.89) 0.41
1 vs. 45      4.17 (2.92, 5.96) 0.56    10.52 (3.83, 28.93) 0.29      3.18 (2.20, 4.60) 0.43   18.30  (6.57, 50.93) 0.43
1 vs. 3      3.07 (1.82, 5.17) 0.45      7.97 (2.56, 24.81) 0.23      2.45 (1.42, 4.23) 0.34   11.89  (3.70, 38.19) 0.32
1 vs. 4      2.72 (1.83, 4.05) 0.41      5.64 (1.95, 16.27) 0.17      2.34 (1.55, 3.53) 0.32     8.19  (2.80, 24.00) 0.24
1 vs. 5      6.14 (4.11, 9.19) 0.67    15.07 (5.43, 41.82) 0.38      4.32 (2.85, 6.57) 0.54   32.07  (11.30, 91.01) 0.57
1 vs. 45 (GA)      3.29 (2.07, 5.21) 0.48      6.28 (2.09, 18.93) 0.19      2.81 (1.74, 4.52) 0.39   10.14  (3.28, 31.31) 0.28
1 vs. 4 (GA)      3.06 (1.66, 5.65) 0.45      4.75 (1.29, 17.49) 0.14      2.74 (1.46, 5.17) 0.38     7.57  (1.97, 29.06) 0.22
1 vs. 5 (GA)      3.46 (2.01, 5.94) 0.49      7.38 (2.33, 23.38) 0.22      2.86 (1.63, 5.02) 0.40   12.02  (3.65, 39.57) 0.32
1 vs. 45 (CNV)      4.09 (2.73, 6.12) 0.55      8.62 (3.05, 24.39) 0.25      3.30 (2.17, 5.01) 0.45   15.34  (5.32, 44.25) 0.38
1 vs. 4 (CNV)      2.71 (1.72, 4.27) 0.40      4.42 (1.42, 13.74) 0.13      2.44 (1.53, 3.90) 0.34     6.58  (2.07, 20.90) 0.19
1 vs. 5 (CNV)      7.21 (4.24, 12.27) 0.71    14.44 (4.96, 41.99) 0.37      5.24 (3.02, 9.10) 0.60   35.22  (11.47, 108.17) 0.60
CHS      1.93 (1.32, 2.83) 0.27      3.91 (2.17, 7.03) 0.11      1.58 (1.05, 2.39) 0.17     4.75  (2.56, 8.80) 0.14
NOTE - N denotes the normal allele and R denotes the risk allele. The risk allele is defined as the least frequent allele in controls.The OR for dominance effects compares 
those who carry one risk allele (RN and RR genotypes) to individuals homozygote for the normal allele (NN), the OR for recessice effects compares individuals with RR 
genotype to those who carry one normal allele (NN and RN genotypes). Hetero- and homozygote ORs compare individuals with one (RN) and two (RR) risk alleles to 
individuals with NN genotype, respectively.  GA = geographic atrophy.  CNV = choroidal neovascular membranes.




in AREDS or 
CHS
DOMINANCE      
(RN+RR vs. NN)
RECESSIVE                   
(RR vs. RN+NN)
HETEROZYGOTES        
(RN vs. NN)
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Table B4: Joint ORs and 95% CIs at Y402H in CFH and S69A in LOC387715
S69A TT CT CC
AREDS
ncontrols = 171
ncases = 693 ORY402H 1.00 (Ref) 2.70 (1.83, 3.98)  6.64 (4.04, 10.91)
GG        1.00 (Ref) 1.00 (Ref) 2.82 (1.59, 5.03) …
GT 3.17 (1.68, 5.96) 7.16 (3.80, 13.49) …
TT … … 15.79 (8.74, 28.54)a
CHS
ncontrols = 871 ORY402H 1.00 (Ref) 1.81 (1.12, 2.93)  4.12 (2.32, 7.33)
ncases = 106
GG        1.00 (Ref) 1.00 (Ref) 1.31 (0.64, 2.69) …
GT 1.22 (0.53, 2.83) 2.90 (1.47, 5.73) …
TT … …  4.82 (2.52, 9.23)a
a OR for individuals homozygous at least at one of the loci.
NOTE - ncontrols = number of controls fully typed at both loci, ncases = number of cases fully typed at both loci. ORY402H = 
OR for Y402H averaged across S69A genotypes, ORS69A = OR for S69A averaged across Y402H genotypes.
 3.03 (2.11, 4.36)
17.11 (6.17, 47.47)
 4.86 (2.55, 9.26)
Joint effectsORS69A







OR (95% CI) for
Y402H
158
Table B5: Joint genotype distribution at Y402H in CFH and S69A in LOC387715 in the AREDS
cohort
Genotype Genotype at Y402H in CFH
at S69A in Controls (n = 171) Cases (n = 693)
LOC387715 TT CT CC TT CT CC
GG 42 (0.246) 46 (0.269) 22 (0.129) 32 (0.046) 99 (0.143) 86 (0.124)
GT 29 (0.170) 24 (0.140) 4 (0.023) 70 (0.101) 131 (0.189) 140 (0.202)
TT 3 (0.018) 1 (0.006) 0 (0.000) 15 (0.022) 73 (0.105) 47 (0.068)
Table B6: Joint genotype distribution at Y402H in CFH and S69A in LOC387715 in the CHS
cohort
Genotype Genotype at Y402H in CFH
at S69A in Controls (n = 871) Cases (n = 106)
LOC387715 TT CT CC TT CT CC
GG 231 (0.265) 227 (0.261) 57 (0.065) 14 (0.132) 18 (0.170) 13 (0.123)
GT 135 (0.155) 148 (0.170) 33 (0.038) 10 (0.094) 26 (0.245) 8 (0.075)
TT 23 (0.026) 16 (0.018) 1 (0.001) 4 (0.038) 7 (0.066) 6 (0.057)
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ncontrols = 170 ORsmk    1.00 (Ref) 1.59 (1.13, 2.23)
ncases = 682
TT    1.00 (Ref) 1.65 (0.91, 2.98)
CT 2.53 (1.43, 4.48) 4.77 (2.66, 8.54)
CC 8.65 (4.03, 18.55) 10.55 (5.14, 21.66)
LOC387715 (S69A)
ncontrols = 169 ORsmk    1.00 (Ref) 1.57 (1.12, 2.20)
ncases = 676
GG    1.00 (Ref) 1.77 (1.11, 2.83)
GT 3.19 (1.87, 5,41) 5.06 (2.99, 8.55)
TT  21.15 (4.96, 90.22)   25.74 (6.06, 109.34)
Never Ever
CFH (Y402H)
ncontrols = 907 ORsmk    1.00 (Ref) 0.89 (0.60, 1.32)
ncases = 110
TT    1.00 (Ref) 0.62 (0.29, 1.33)
CT 1.52 (0.80, 2.91) 1.33 (0.69, 2.58)
CC 2.52 (1.10, 5.79) 4.16 (1.95, 8.86)
LOC387715 (S69A)
ncontrols = 995 ORsmk    1.00 (Ref) 0.89 (0.61, 1.30)
ncases = 120
GG    1.00 (Ref) 0.96 (0.55, 1.68)
GT 1.86 (1.04, 3.31) 1.28 (0.70, 2.34)
TT 3.37 (1.32, 8.63)   6.09 (2.63, 14.14)
Joint effects
2.65 (1.79, 3.90)












Gene (Variant) and 
Genotypes Main effects
Smoking history
    1.00 (Ref)
    1.00 (Ref)
    1.00 (Ref)
 7.27 (4.37, 12.09)




    1.00 (Ref)
Main effects





Table B8: Genotype distribution at Y402H in CFH and S69A in LOC387715 in the AREDS
cohort, by smoking history (ever vs. never smoked)
Gene (Variant) Smoking history and ARM status
and Genotypes Never Ever Never Ever
CFH (Y402H ) Controls (n = 170) Cases (n = 682)
TT 36 (0.212) 38 (0.224) 42 (0.062) 73 (0.107)
CT 40 (0.235) 32 (0.188) 118 (0.173) 178 (0.261)
CC 11 (0.065) 13 (0.076) 111 (0.163) 160 (0.235)
LOC387715 (S69A) Controls (n = 169) Cases (n = 676)
GG 55 (0.325) 53 (0.314) 78 (0.115) 133 (0.197)
GT 29 (0.172) 28 (0.166) 131 (0.194) 201 (0.297)
TT 2 (0.012) 2 (0.012) 60 (0.089) 73 (0.108)
Table B9: Genotype distribution at Y402H in CFH and S69A in LOC387715 in the CHS cohort,
by smoking history (ever vs. never smoked)
Gene (Variant) Smoking history and ARM status
and Genotypes Never Ever Never Ever
CFH (Y402H ) Controls (n = 907) Cases (n = 110)
TT 176 (0.194) 230 (0.254) 16 (0.145) 13 (0.118)
CT 202 (0.223) 206 (0.227) 28 (0.255) 25 (0.227)
CC 48 (0.053) 45 (0.050) 11 (0.100) 17 (0.155)
LOC387715 (S69A) Controls (n = 995) Cases (n = 120)
GG 277 (0.278) 324 (0.326) 25 (0.208) 28 (0.223)
GT 161 (0.162) 190 (0.191) 27 (0.225) 22 (0.183)
TT 23 (0.023) 20 (0.020) 7 (0.058) 11 (0.092)
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Table B10: Characteristics of studies included in meta-analysis of Y402H in CFH
Edwards et al.d
Discovery sample
Controls 131 67.6 (7.6) 42 0.99 0.340
Cases 225   72.7 (10.1) 58 0.42 0.553
Replication sample
Controls 59 68.1 (9.0) 35 0.28 0.390
Cases 170 78.2 (7.9) 65 0.64 0.544
Haines et al.e
Controls 185 ≥ 55 … … …
Cases 495 ≥ 55 … … …
Zareparsi et al.
Controls 275 ≥ 68 … 0.11 0.338
Cases 616 … … 0.15 0.608
Hageman et al.f
Columbia sample
Controls 272 68.8 (8.6) … 0.23 0.344
Cases 549 71.3 (8.9) … 0.86 0.538
Iowa sample
Controls 131 78.4 (7.4) … 0.70 0.336
Cases 403 79.5 (7.8) … 0.22 0.589
Jakobsdottir et al.
Controls 108 72.6 (8.9) 47 0.26 0.310
Cases 434 68.9 (8.8) 39 0.42 0.613
Rivera et al.g
Original sample
Controls 611 76.2 (5.3) 38 <0.01 0.382
Cases 793 76.3 (6.9) 36 0.30 0.595
Replication sample
Controls 335 68.3 (8.1) 45 0.48 0.358
Cases 373 75.0 (7.5) 35 0.13 0.617
Souied et al.
Controls 91 74.6 (6.3) 42 0.21 0.302
Cases 141 74.3 (8.0) 38 0.30 0.564
Sepp et al.
Controls 262 75.8 (7.8) 42 0.14 0.363
Cases 443 80.3 (6.9) 45 0.49 0.607
AREDS (1 vs. 345)
Controls 173 76.5 (4.4) 49 0.25 0.358
Cases 699 79.5 (5.2) 42 0.03 0.612
CHS
Controls 907 70.3 (3.9) 43 0.55 0.327
Cases 110 73.2 (4.8) 44 0.71 0.495









the C alleleStudy and sample
a Sample sizes based on total number of genotyped persons when genotype counts are available 
other wise on total sample size, not accounting for missing data.
g The two data sets of Rivera et al. paper are combined in the meta-analysis. HWE  P-values for 
the combined controls and cases are 0.03 and 0.09, respectively.
e Results form Haines et al. paper are included in meta-analysis of ORs for hetero- and 
homozygous individuals. Sample sizes are based on total number of individuals, not accounting 
for missing genotype data at Y402H in CFH.
d The two data sets of Edwards et al. paper are combined in the meta-analysis. HWE  P-values 
for the combined controls and cases are 0.53 and 0.36, respectively.
c When genotype counts are avaible P-value, derived from the exct test (implemented in R 
Genetics package), given.
f The two data sets of Hageman et al. paper are not combined, following the orignial paper.
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Table B11: Results of meta-analysis of Y402H in CFH. ORs (95% CIs) estimated from individual
studies and all studies pooled. Results of leave-one-out sensitivity analysis are shown
ORdom (95% CI) ORrec (95% CI) ORhet (95% CI) ORhom (95% CI)
Individual study
Edwards et al. 2.71 (1.86, 3.94) 2.89 (1.82, 4.60) 2.14 (1.44, 3.18)    4.54 (2.70, 7.65)
Haines et al. … … 2.45 (1.41, 4.25)    3.33 (1.79, 6.20)
Zareparsi et al. 4.36 (3.13, 6.08) 5.52 (3.54, 8.59) 3.03 (2.15, 4.28)  11.61 (7.05, 19.14)
Hageman et al. (Columbia) 2.97 (2.17, 4.07) 2.61 (1.76, 3.87) 2.48 (1.77, 3.47)    4.47 (2.89, 6.93)
Hageman et al. (Iowa) 3.64 (2.38, 5.58) 4.08 (2.33, 7.16) 2.61 (1.66, 4.10)    7.28 (3.92, 13.51)
Jakobsdottir et al. 5.29 (3.35, 8.35) 4.57 (2.48, 8.42) 3.78 (2.32, 6.17)  10.05 (5.16, 19.59)
Rivera et al. 2.92 (2.39, 3.57) 4.29 (3.42, 5.39) 1.99 (1.61, 2.46)    6.72 (5.14, 8.79)
Souied et al. 3.95 (2.22, 7.03) 3.75 (1.83, 7.71) 2.99 (1.61, 5.57)    6.84 (3.07, 15.21)
Sepp et al. 3.85 (2.71, 5.47) 3.36 (2.28, 4.95) 2.88 (1.98, 4.20)    6.49 (4.12, 10.23)
AREDS (1 vs. 345) 3.73 (2.60, 5.34) 3.69 (2.37, 5.75) 2.66 (1.81, 3.92)    6.69 (4.08, 10.98)
CHS 2.26 (1.45, 3.53) 2.99 (1.85, 4.83) 1.82 (1.13, 2.92)    4.22 (2.39, 7.42)
All studies pooled Pa Pa Pa Pa
Fixed effects 3.33 (2.99, 3.71) 0.11 3.75 (3.29, 4.27) 0.32 2.43 (2.17, 2.72) 0.32    6.22 (5.38, 7.19) 0.05
Random effects 3.40 (2.88, 4.00) … 3.70 (3.09, 4.42) … 2.49 (2.14, 2.89) …    6.15 (4.86, 7.79) …
∆b ∆b ∆b ∆b
Edwards et al. 3.39 (3.03, 3.80) -0.06 3.83 (3.35, 4.39) -0.08 2.46 (2.19, 2.77) -0.03    6.39 (5.49, 7.42) -0.17
Haines et al. … … … … 2.43 (2.17, 2.73) 0.00    6.45 (5.56, 7.48) -0.23
Zareparsi et al. 3.22 (2.87, 3.61) 0.11 3.62 (3.16, 4.14) 0.13 2.37 (2.10, 2.67) 0.06    5.88 (5.05, 6.83) 0.35
Hageman et al. (Columbia) 3.38 (3.01, 3.79) -0.05 3.92 (3.42, 4.50) -0.17 2.43 (2.15, 2.74) 0.01    6.48 (5.56, 7.55) -0.26
Hageman et al. (Iowa) 3.31 (2.96, 3.70) 0.02 3.73 (3.27, 4.26) 0.02 2.42 (2.16, 2.72) 0.01    6.16 (5.31, 7.15) 0.06
Jakobsdottir et al. 3.24 (2.89, 3.62) 0.09 3.72 (3.25, 4.24) 0.03 2.37 (2.11, 2.67) 0.06    6.08 (5.24, 7.05) 0.15
Rivera et al. 3.51 (3.09, 3.99) -0.18 3.52 (3.00, 4.12) 0.23 2.63 (2.30, 3.00) -0.20    6.03 (5.08, 7.16) 0.19
Souied et al. 3.31 (2.96, 3.69) 0.02 3.75 (3.29, 4.28) 0.00 2.42 (2.15, 2.71) 0.02    6.20 (5.35, 7.18) 0.02
Sepp et al. 3.28 (2.92, 3.67) 0.05 3.80 (3.31, 4.36) -0.05 2.39 (2.13, 2.69) 0.04    6.19 (5.32, 7.21) 0.03
AREDS (1 vs. 345) 3.29 (2.94, 3.68) 0.04 3.76 (3.28, 4.30) -0.01 2.41 (2.14, 2.72) 0.02    6.18 (5.31, 7.19) 0.04
CHS 3.41 (3.05, 3.81) -0.08 3.82 (3.34, 4.37) -0.07 2.48 (2.20, 2.78) -0.04    6.39 (5.50, 7.42) -0.17
a P-value for test of homogeneity of ORs across studies.
b Difference (∆) of pooled point estimate when a study is excluded from the pooled estimate of all studies (under fixed effects model)
Study excluded           
(Fixed effects)
RECESSIVE                   
(CC vs. CT+TT)
HETEROZYGOTES        
(CT vs. TT)
HOMOZYGOTES         
(CC vs. TT)
OR for
DOMINANCE      
(CT+CC vs. TT)
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Table B12: Characteristics of studies included in meta-analysis of S69A in LOC387715
Jakobsdottir et al.
Controls 106 72.6 (8.9) 47 0.21 0.193
Cases 456 68.9 (8.8) 39 0.06 0.485
Rivera et al.d
Original sample
Controls 594 76.2 (5.3) 38 0.30 0.196
Cases 759 76.3 (6.9) 36 0.14 0.417
Replication sample
Controls 328 68.3 (8.1) 45 0.75 0.215
Cases 361 75.0 (7.5) 35 0.01 0.460
Schmidt et al.e
Controls 186 66.7 (8.1) 43 0.55 0.247
Cases 758 76.8 (7.7) 35 <0.01 0.427
AREDS (1 vs. 345)
Controls 172 76.5 (4.4) 49 0.45 0.189
Cases 693 79.5 (5.2) 42 0.99 0.441
CHS
Controls 995 70.3 (3.9) 43 0.41 0.220




d The two data sets of Rivera et al. paper are combined in the meta-analysis. HWE  P-values for 
the combined controls and cases are 0.31 and 0.01, respectively.
e In the meta-analysis only grade 1 subjects are classified as controls (grade 2 subjects are 
dropped).  The original study by Schmidt et al. classified grade 2 individudals as controls. The 
mean age and % males of controls is taken from the paper and based on both grade 1 and 2.
Study and sample
a Sample sizes based on total number of genotyped persons.
b Mean age and corresponding standard deviation, or other summary statistic available from the 
orginal paper.









Table B13: Results of meta-analysis of S69A in LOC387715. ORs (95% CIs) estimated from
individual studies and all studies pooled. Results of leave-one-out sensitivity analysis are shown
ORdom (95% CI) ORrec (95% CI) ORhet (95% CI) ORhom (95% CI)
Jakobsdottir et al. 5.03 (3.20, 7.91)  5.75 (2.46, 13.46) 3.89 (2.40, 6.31) 10.57 (4.43, 25.22)
Rivera et al. 3.41 (2.84, 4.09) 5.28 (3.76, 7.41) 2.69 (2.22, 3.27)  8.21 (5.79, 11.65)
Schmidt et al. (1 vs. 345) 2.42 (1.75, 3.35) 3.59 (1.99, 6.47) 1.94 (1.37, 2.74) 4.87 (2.65, 8.95)
AREDS (1 vs. 345) 3.99 (2.81, 5.67) 10.16 (3.70, 27.88) 3.06 (2.13, 4.39) 17.26 (6.22, 47.89)
CHS 1.93 (1.32, 2.83) 3.91 (2.17, 7.03) 1.58 (1.05, 2.39) 4.75 (2.56, 8.80)
All studies pooled Pa Pa Pa Pa
Fixed effects 3.19 (2.80, 3.63) <0.01 4.91 (3.85, 6.27) 0.41 2.53 (2.20, 2.90) 0.02 7.32 (5.69, 9.42) 0.11
Random effects 3.15 (2.02, 4.90) … 4.91 (3.48, 6.94) … 2.48 (1.67, 3.70) …  7.33 (4.33, 12.42) …
∆b ∆b ∆b ∆b
Jakobsdottir et al. 3.06 (2.67, 3.51) 0.13 4.84 (3.76, 6.24) 0.07 2.43 (2.11, 2.81) 0.09 7.08 (5.44, 9.21) 0.24
Rivera et al. 2.98 (2.48, 3.58) 0.21 4.54 (3.20, 6.45) 0.37 2.37 (1.95, 2.88) 0.16 6.48 (4.51, 9.31) 0.84
Schmidt et al. (1 vs. 345) 3.36 (2.92, 3.87) -0.17 5.24 (4.01, 6.85) -0.33 2.66 (2.29, 3.08) -0.13  7.97 (6.04, 10.51) -0.65
AREDS (1 vs. 345) 3.08 (2.68, 3.54) 0.11 4.70 (3.65, 6.04) 0.22 2.45 (2.11, 2.84) 0.08 6.93 (5.34, 8.98) 0.40
CHS 3.41 (2.97, 3.91) -0.22 5.15 (3.94, 6.73) -0.24 2.68 (2.32, 3.10) -0.15  7.99 (6.06, 10.52) -0.66
a P-value for test of homogeneity of ORs across studies.
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ORhom and 95% CI
Figure B1: Estimated ORs and 95% CIs for CFH. A: ORdom for evaluation of dominance effects
(CT+CC vs. TT). B: ORhet for evaluation of the risk for heterozygotes (CT vs. TT). C: ORrec
for evaluation of recessive effects (CC vs. CT+TT). D: ORhom for evaluation of the risk for
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ORhom and 95% CI
Figure B2: Estimated ORs and 95% CIs for ELOVL4. A: ORdom for evaluation of dominance
effects (AG+GG vs. AA). B: ORhet for evaluation of the risk for heterozygotes (AG vs. AA). C:
ORrec for evaluation of recessive effects (GG vs. AG+AA). D: ORhom for evaluation of the risk for
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ORhom and 95% CI
Figure B3: Estimated ORs and 95% CIs for PLEKHA1. A: ORdom for evaluation of dominance
effects (AG+AA vs. GG). B: ORhet for evaluation of the risk for heterozygotes (AG vs. GG). C:
ORrec for evaluation of recessive effects (AA vs. AG+GG). D: ORhom for evaluation of the risk for
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ORhom and 95% CI
Figure B4: Estimated ORs and 95% CIs for LOC387715. A: ORdom for evaluation of dominance
effects (GT+TT vs. GG). B: ORhet for evaluation of the risk for heterozygotes (GT vs. GG). C:
ORrec for evaluation of recessive effects (TT vs. GT+GG). D: ORhom for evaluation of the risk for
homozygotes (TT vs. GG). The dotted vertical line marks the null value of OR of 1.
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Figure B5: A: Genotype frequencies (%) in unrelated ARM cases, across cohorts included in meta-
analysis of Y402H in CFH. B: Genotype frequencies (%) in unrelated controls without ARM, across
studies included in meta-analysis of Y402H in CFH. ‘Hage-C’ and ‘Hage-I’ denote estimates derived
from the Columbia and Iowa cohorts of Hageman et al., respectively, and ‘Jakobs’ denotes estimates
from the Jakobsdottir et al. paper. Frequencies were not available from Haines et al.
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Figure B6: A: Genotype frequencies (%) in unrelated ARM cases, across cohorts included in meta-
analysis of S69A in LOC387715. B: Genotype frequencies (%) in unrelated controls without ARM,
across studies included in meta-analysis of S69A in LOC387715. ‘Jakobs’ denotes estimates from




Here the supplementary material published online as a part of the paper (Jakobsdottir et al.
2008) presented in chapter 5 is given.
C.1 LOGISTIC REGRESSION ANALYSES
C.1.1 Coding in two-factor models
A series of logistic regression models were fitted to the data in order to find a parsimonious model for
the joint effects of each pair of loci. Models allowing for additive effects (ADD1, ADD2, and ADD-
BOTH), models incorporating dominance effects (DOM1, DOM2, and DOM-BOTH), and three
interaction models (ADD-INT, ADD-DOM, and DOM-INT) were fitted. In the additive models
the genotypes, RR, RN , and NN (or PP , PN , and NN), are coded −1, 0, and 1, respectively;
where R denotes the assumed risk allele at CFH or LOC387715, P the assumed protective allele at
C2, and N the assumed normal allele. The dominance models incorporate a variable to the additive
models coded as −0.5 for RR (or PP ) and NN and 0.5 for RN (or PN). We let x1 and x2 denote
the genotype variables in the additive models, and z1 and z2 the additional variables incorporated
into the dominance models. Then the ADD1, ADD2, and ADD-BOTH models include terms
(x1), (x2), and (x1 and x2), respectively, and the DOM1, DOM2, DOM-BOTH models incorporate
terms (z1), (z2), and (z1 and z2) to the ADD1, ADD2, and ADD-BOTH models, respectively.
Three further interaction models are fitted: ADD-INT incorporates the product term (x1x2) to
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the ADD-BOTH model, ADD-DOM incorporates the product terms (x1x2, x1z2, and z1x2), and
DOM-INT incorporates the product terms (x1x2, x1z2, z1x2, and z1x2) to the DOM-BOTH model.
C.1.2 Coding in three-factor models
Since, for each pair of loci, the two-factor analyses implicated additive models as the most parsimo-
nious and to keep the number of parameters as small as possible we only fit three-factor additive
models without interaction. The models are ADD1, ADD2, ADD3, ADD12, ADD13, ADD23, and
ADD123 and include terms (x1), (x2), (x3), (x1 and x2), (x1 and x3), (x2 and x3), and (x1, x2,
and x3), respectively, where x1, x2, and x3, are coded as in the additive two-factor models above.
C.2 ASSOCIATION ANALYSES–CFH AND LOC387715
In our prior studies, we tested the associations of Y402H in CFH (Conley et al. 2005) and S69A in
LOC387715 (Jakobsdottir et al. 2005) in a smaller subset of our data, than we have typed now.
In our larger dataset both variants are highly associated with ARM (allelic and genotypic P -values
< 0.00001 in both the case-control and family data, table 5.2) providing further confirmation for
the likely involvement of these genes in ARM pathogenesis. The ORs for individuals heterozygous
and homozygous for the risk allele at Y402H are 4.11 (95% CI 2.28 to 7.40) and 8.96 (95% CI 4.49
to 17.88), and the corresponding PARs are 56% (95% CI 34% to 71%) and 53% (95% CI 31% to
69%), respectively. The ORs for individuals heterozygous and homozygous the S69A risk allele are
3.63 (95% CI 2.19 to 6.03) and 8.24 (95% CI 3.81 to 17.81), and the corresponding PARs are 42%
(95% CI 26% to 54%) and 32% (95% CI 17% to 44%), respectively.
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Table C1: Genotype counts for C2/CFB variants, Y402H in CFH, and S69A in LOC387715
Allele Genotype counts in
labeling Cases Controls
SNP Gene Chr Bpa Locationa 1 2 11 12 22 11 12 22
rs9332739 C2 6 32011783 E318D C G 0 10 172 1 9 156
rs547154 C2 6 32018917 IVS10 G T 170 9 0 130 31 0
rs4151667 CFB 6 32022003 L9H A T 0 10 168 1 10 156
rs2072633 CFB 6 32027557 IVS17 A G 21 74 81 20 88 55
rs1061170 CFH 1 194925860 Y402H T C 21 80 60 69 64 22
rs10490924 LOC387715 10 124204438 S69A G T 50 74 40 103 42 10
Chr = chromosome
Bp = base pairs
a Bp and location within the genes are from NCBI build 127 (human genome build 36.2)
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Table C2: Joint and relative genotype frequencies
GG GT TT GG GT TT GG GT TT
CC 0.1338 0.0141 0.0070 0.1056 0.0070 0.0070 0.0282 0.0070 0.0000
CT 0.2465 0.1197 0.0423 0.2113 0.0915 0.0423 0.0352 0.0282 0.0000
TT 0.2676 0.1479 0.0211 0.2113 0.1127 0.0141 0.0563 0.0352 0.0070
CC 0.1188 0.1891 0.0797 0.1109 0.1812 0.0781 0.0078 0.0078 0.0016
CT 0.1391 0.2219 0.1000 0.1297 0.2047 0.0906 0.0094 0.0172 0.0094
TT 0.0344 0.0750 0.0422 0.0281 0.0688 0.0328 0.0062 0.0062 0.0094
CC 1.13 0.07 0.09 0.95 0.04 0.09 3.62 0.90 0.00
CT 1.77 0.54 0.42 1.63 0.45 0.47 3.74 1.64 0.00
















The genotype frequencies are for the subset of our data used in the GMDR unadjusted analyses. This inlcudes individuals typed at all three loci (CFH, LOC387715, and C2). The cases include the unrelated cases 
and those randomly picked from the families (see the main text for details). The Control/Case Ratios are the ratios of the joint allele frequencies in controls versus cases. The gray-highlighted cells corrspond to 
































































































































































































































































Figure C1: Minor allele frequency (MAF) of SNPs typed for the HapMap CEU population cite-
hapmap in the C2/CFB region. Locations of the SNPs within the genes are shown. Red lines/boxes
show the locations of exons in C2 and green lines/boxes the locations of exons in CFB. White sym-
bols represent SNPs not yet typed in any C2/CFB study citegold,maller,spencer (including the
present study), black filled symbols represent SNPs typed by Gold et al. citegold and grey filled
symbols represent SNPs typed in C2/CFB study citespencer other than the Gold et al. study
citegold. Grey lines and circles correspond to SNPs in C2 and black lines and dimonds correspond
to SNPs in CFB.
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Figure C2: GMDR sensitivity analyses for the three-factor unadjusted model. The classification
rules are shown for 10 data-sets, additional to the one used in the main paper (given at top). Each
of those 10 data-sets has one case picked at random from each family. Black cells = cases, gray




Here the supplementary material published online as a part of the paper (Jakobsdottir et al.
2009) presented in chapter 6 is given.
D.1 APPLICATION OF CLASSIFICATION-BASED METHODS TO AMD
DATA
AMD is a complex, late-onset degenerative disease that is characterized by the disruption of the
integrity of the retina, retinal pigment epithelium and choroid that can lead to the loss of central
vision and significant visual disability. In recent years, three loci have been found strongly associated
with AMD: functional SNPs at CFH (Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005)
and LOC387715 (or at the closely linked PLEKAH1 [MIM 607772] or HTRA1 [MIM 602194])
(Jakobsdottir et al. 2005; Rivera et al. 2005) are thought to increase the risk of AMD while
variants at CFB (MIM 138470) or C2 (MIM 217000) (Gold et al. 2006) are thought to decrease
risk. These findings appear robust and have been widely replicated (Gorin 2007). A number
of studies have attempted to use variants at these genes to build predictive models for AMD. To
our knowledge, none has applied ROC theory to evaluate the classification performance of these
variants individually or jointly.
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D.1.1 AMD data
For illustration we use part of our AMD data, which includes 640 cases and 142 controls fully typed
at three SNPs at all three loci: rs1061170 (Y402H ) in CFH, rs10490924 (S69A) in LOC387715, and
rs547154 (IVS10 ) in C2. For recruitment and phenotyping we refer to our previous publications
[8,9] and for genotyping see Jakobsdottir et al. (2008).
D.1.2 Methods
To combine information from the three SNPs for classification using ROC, we use a generalized
linear model proposed by Ma and Huang [11]: P (Y = 1|X) = G(βTX), where Y is the disease status
(Y = 1 for cases and Y = 0 for controls), X is the matrix of genotype columnsXi = (X1,i, . . . , Xd,i)T
for the ith subject, β = (β1, . . . , βd)T is a d-dimensional vector of unknown regression parameters,
and G is an unknown increasing link function. Since G is assumed to be increasing, a classification
rule can be constructed based on the risk score, βTX, only. We use the rule: if βTX > c, we
classify this individual as a case, otherwise we classify the individual as a control. This is a sensible
approach as decision criteria based on risk are statistically optimal [12]. The overall performance
of the classifier is then measured by the AUC of the ROC curve, which is a two-dimensional
plot of ((FPF (c), TPF (c)) : c ∈ R), where FPF (c), and TFP (c) are the FPF and TPF of the
classification rule if βTX > c. To get all points on the ROC curve the FPF and TPF are estimated
for all possible values of c. The empirical AUC is maximized as a function of β. For each β, the
AUC is estimated using a nonparametric trapezoidal estimator [13]. Note that this ROC model is
a more general model than the logistic model, as G needs not to be known. Since many previous
studies have found an additive model to be best fitting in both single and multi locus models of
CFH, LOC387715, and C2 variants, we let X1,i be the number of risk alleles at Y402H at CFH,
X2,i be the number of risk alleles at S69A at LOC387715, and X3,i be the number of protective
alleles at IV S10 at C2. For comparison, we also present the results of logistic regression analyses
where the genotypes are coded the same way. In addition to performing ROC and logistic regression
analyses, we draw an integrated predictiveness and classification plot [14]. In the integrated plot,
there are two aligned plots: In the top plot, ordered individual risks are plotted as function of the
risk percentile and, in the bottom plot, the TPF and FPF are plotted as a function of the risk
percentile such that at each point the TPF and FPF are calculated for the risk threshold, c, equal
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to the risk associated with the corresponding risk percentile. As we are working with case-control
data, we can only calculate individual-level risks from the logistic model (setting the G function to
be the logit function) if the prevalence is known. To be able to draw the plot we therefore need to
assume a specific value for the prevalence. Since our data are elderly white individuals (mean age
72.9 and standard deviation [sd] 9.9 in controls) and our cases are all of advanced phenotype, we use
a prevalence estimate for advanced AMD in white individuals 65 years and older (approximately 1
sd from the mean) of 5.5%; the US 2000 census data (Table 4: Annual Estimates of the White Alone
Population by Age and Sex for the United States: April 1, 2000 to July 1, 2006 [NC-EST2006-04-
WA]) were used to project the sex-specific 5-year age interval estimates of Friedman et al. [15] to
estimate the AMD prevalence for 65 years and older.
D.1.3 Accounting for covariates
We also ran the above analysis while adjusted for age, sex, and smoking. The AUC of the genetic
model without the covariates was 0.78 and improved to 0.82 when the covariates were added to the
model. The AUC of model with only the covariates had an AUC of 0.66. Note that the effective
sample size for these new analyses is smaller due to missing covariate information. The AUC of
the unadjusted model in the main text (0.79) is therefore, not exactly equal to the AUC of the
unadjusted model here (0.78).
D.2 ESTIMATING THE AUC FROM META-DATA
As science progresses, there is a need for methods to continuously update previous classification
models. Lu and Elston (2008) developed a method to do this when only meta-data and summary
statistics are available. This is especially useful if not all markers have been typed in the same
samples. Then, if we assume homogeneity across samples, we can combine estimates to form a
new classification rule. To compare the AUC of the new classification rule with the old rule, the
information we need are 1) allele frequencies in case and control populations or 2) allele frequencies
in the general population, risk ratios, and prevalence.
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D.3 DETAILS ON DATA IN OTHER REAL DATA EXAMPLES
D.3.1 Cardiovascular events
Kathiresan et al. (2008) investigated whether genetic variants could improve classification ac-
curacy for cardiovascular events beyond standard risk factors. First they tested for single SNP
associations of 11 SNPs with low-density lipoprotein (LDL) and high-density lipoprotein (HDL)
levels and then identified a set of 9 SNPs that were independently associated with lipid levels.
Using these 9 SNPs, they created a simple genotype score based on the total number of unfavorable
alleles in all 9 genotypes of the individual, and then evaluated the classification accuracy of the
genotype score for the 10-year incidence of cardiovascular events. The P values for the 9 SNPs
ranged from 0.003 to 10−29 (table D1) and the adjusted hazard ratio of the genotype score was
1.15 (95% CI 1.07–1.24).
The AUC for prediction of 10-year incidence of cardiovascular events was estimated using
model with 14 clinical covariates and no genotype information and found to be 0.80. When the
genotype score, which included several highly associated SNPs, was included in the model, the
AUC was not improved and also equaled 0.80 even though accounting for the genotype score sig-
nificantly improved the regression model (P value 0.0002, Table S3 of Kathiresan et al. (2008)).
The authors additionally looked at whether accounting for the genotype score improved the clinical
reclassification and found modest improvement such that the estimated risk correctly increased for
individuals who subsequently experienced cardiovascular event and correctly decreased for individ-
uals who remained free of cardiovascular events at 10-year follow-up (P value 0.01).
D.3.2 Type 2 diabetes
The 12 SNPs used to generate a classification rule for type 2 diabetes with the Lu and Elston
method (Lu and Elston 2008) come from three studies (table D2) [18-20].
D.3.3 Prostate cancer
We used the Lu and Elston method (Lu and Elston 2008) to investigate the classification accuracy
of a genetic risk model of two prostate cancer risk SNPs [21] (table D3). We used the information
from the combined cohort from the study of Yeager et al. (2007).
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Table D1: Association results of 9 SNPs associated with LDL and HDL cholesterol. Information













Table D2: Association results of 12 type 2 diabetes SNPs.
Allele frequency in
SNP Cases Controls P value OR Study
rs5219 0.384 0.354 0.0001 1.14 Weedon et al. (2006)
rs1801282 0.099 0.123 4× 10−5 1.29 Weedon et al. (2006)
rs7903146 0.406 0.293 2× 10−34 Het 1.65, Hom 2.77 Sladek et al. (2007)
rs13266634 0.254 0.301 6× 10−8 Het 1.18, Hom 1.53 Sladek et al. (2007)
rs1111875 0.358 0.402 3× 10−6 Het 1.19, Hom 1.44 Sladek et al. (2007)
rs740010 0.336 0.301 1× 10−4 Het 1.14, Hom 1.40 Sladek et al. (2007)
rs3740878 0.240 0.272 1× 10−4 Het 1.26, Hom 1.46 Sladek et al. (2007)
rs4402960 0.341 0.304 8× 10−4 1.18 Scott et al. (2007)
rs7754840 0.387 0.360 0.0095 1.12 Scott et al. (2007)
rs10811661 0.872 0.850 0.0022 1.20 Scott et al. (2007)
rs9300039 0.924 0.892 7× 10−8 1.49 Scott et al. (2007)
rs8050136 0.406 0.381 0.017 1.11 Scott et al. (2007)
Information from the combined cohort of stage 2 used from the Scott et al. study.
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Table D3: Association results of two prostate cancer disease SNPs.
Allele frequency in
SNP Cases Controls P value ORhet ORhom
rs1447295 0.15 0.11 2× 10−14 1.43 2.23
rs6983267 0.56 0.50 9× 10−13 1.26 1.58
D.3.4 Inflammatory bowel diseases
We used the Lu and Elston method (Lu and Elston 2008) to investigate the classification accuracy
of genetic risk model of five SNPs. Two SNPs are in IL23R and are thought to be uncorrelated, one
in ATG16CL, one in NOD2/CARD15, and one in IRGM ; all are associated with Crohns disease
(which is a form of inflammatory bowel disease) (table D4).
Table D4: Association results of five Crohns disease SNPs.
Allele frequency in
SNP Cases Controls P value OR Study
rs11209026 0.019 0.070 5× 10−9 0.26 Duerr et al. (2006)
rs751784 0.345 0.448 5× 10−9 0.89 Cummings et al. (2007)
rs2241800 0.61 0.52 2× 10−7 1.45 Cummings et al. (2007)
rs2076756 0.358 0.244 7× 10−14 NA Rioux et al. (2007)




Here we show how we evalute W in our statistic 7.9.2. For simplicity we first look at the case when
female dominance is not modeled
f(θ) = θTa− 1
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We take the partial first and second derivatives
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Then the Hessian matrix is
H =












We can solve the set of equations ∂f∂θ1 = 0 and
∂f
∂θ3
= 0 explicitely as shown with Mathematic
but the solutions are too long to write down. Therefore we solve those equations with numerical
methods instead. We then use the Hessian to find which solutions correspond to a local maxima
by using the second derivative test. If θ∗ is the solution that gives the maxima the value of the
score statistic when the condition fails becomes W = f(θ∗).













and take the partial derivatives as before (which define the Hessian matrix)
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